Inleiding

Inleiding
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Redactie WZC-Formularium. Methodologie bij het opstellen van het RVT-Formularium.
Geneesmiddelenbrief 2006;13:1-8. http://www.farmaka.be/nl/geneesmiddelenbrief/
2006_02_geneesmiddelenbrief.pdf.
Scottish Intercollegiate Guidelines Network. www.sign.ac.uk.
National Institute for Health and Clinical Excellence. http://www.nice.org.uk/.
PRODIGY (vroeger Clinical Knowledge Summaries (CKS))http://prodigy.clarity.co.uk/
home.
Agence Nationale d'Accréditation et d'Evaluation en Santé. http://www.anaes.fr.
Nederlands Huisartsen Genootschap. NHG Standaarden. http://nhg.artsennet.nl.
Domus Medica. Aanbevelingen voor goede praktijkvoering. http://www.domusmedi
ca.be
Société Scientifique de Médecine Générale. Recommandations de bonne pratique.
http://www.ssmg.be
Belgian Antibiotic Policy Coordination Committee. Richtlijnen voor het goed gebruik
van antibiotica - editie 2008. http://www.health.fgov.be/antibiotics.
Clinical Evidence. http://clinicalevidence.bmj.com.
Belgisch Centrum voor Farmacotherapeutische Informatie (BCFI). Transparantiefiches.
http://www.bcfi.be.
Minerva. Tijdschrift voor Evidence Based Medicine. http://www.minerva-ebm.be.
Evidence-Based Medicine. http://ebm.bmj.com/.
Evidence-Based Mental Health. http://ebmh.bmj.com/.
ACP Journal Club. http://acpjc.acponline.org/.
Journal Watch. http://www.jwatch.org/.
The Cochrane Collaboration. http://www.cochrane.org/.
British Medical Journal. http://www.bmj.com/.
Annals of Internal Medicine. http://www.annals.org.
The New England Journal of Medicine. http://www.nejm.org/.
Lancet. http://www.thelancet.com.
The Journal of the American Medical Association. http://jama.ama-assn.org.
Archives of Internal Medicine. http://archinte.ama-assn.org.
Journal of the American Geriatrics Society. http://www.wiley.com/bw/jour
nal.aspref=0002-8614.
International Society of Drug Bulletins. http://www.isdbweb.org.
Belgisch Centrum voor Farmacotherapeutische Informatie. Folia Farmacotherapeutica.
http://www.bcfi.be.
La Revue Prescrire.http://www.prescrire.org.
Geneesmiddelenbulletin. http://gebu.artsennet.nl/.
Drug & Therapeutics Bulletin. http://dtb.bmj.com.
Australian Prescriber. http://www.australianprescriber.com.
Der Arzneimittelbrief. http://www.der-arzneimittelbrief.de.

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
Arznei-Telegramm. http://www.arznei-telegramm.de.
Therapeutics Initiative.http://www.ti.ubc.ca.
Belgisch Centrum voor Farmacotherapeutische Informatie. Gecommentarieerd
Geneesmiddelenrepertorium 2011. http://www.bcfi.be.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen.
Farmacotherapeutisch Kompas 2011. http://www.fk.cvz.nl.
British National Formulary 2011.http://bnf.org.
Martindale. The Complete Drug Reference, 37th Edition, April 2011. Edited by
Sweetman SC.
Meyler's Side Effects of Drugs. The International Encyclopedia of Adverse Drug
Reactions and Interactions, 2006. Edited by Aronson JK.
Higbee MD, Beizer JL, Semla TP. Geriatric Dosage Handbook. 13th Edition. Lexi-Comp
Inc, 2007.
Hansten PD, Horn JR. Managing Clinically Important Drug Interactions. UA Scott Health
Sci Library, 2005.
AHFS Drug Information. http://www.ahfsdruginformation.com.
Rijksinstituut voor Ziekte en Invaliditeitsverzekering. Consensusvergaderingen - Jury
rapporten. http://www.riziv.fgov.be.
Therapeutisch Magistraal Formularium. Uitgave 2011. http://www.fagg-afmps.be/nl/
binaries/TMF_Artsen_2de_Uitg_tcm290-159055.pdf.
Medisch Farmaceutische Kwaliteitszorg. http://www.mfk.be
Vlaamse Vereniging van Ziekehuisapothekers. Databank pletmedicatie. http://www.plet
medicatie.be
Documentatie apotheker Jan Mannaerts, ZiekenhuisNetwerk Antwerpen.
Documentatie Werkgroep VZA (Vereniging Ziekenhuisapothekers). Werkgroep
pletmedicatie. www.pletmedicatie.be
Notes de galénique (Prof Delattre, ULG) et Informations du Service de Galénique et
de Biopharmacie de l’ULB (Prof Amighi).
Belgisch Centrum voor Farmacotherapeutische Informatie. Geneesmiddelenvormen
die niet mogen geplet of gekauwd worden. Folia Pharmacotherapeutica 1998;25:86.
Marriott JL, Nation RL. Splitting tablets. Aust Presc 2002;25:133-5.
Peek BT, Al-Achi A, Coombs SJ. Accuracy of tablet splitting by elderly patients. JAMA
2002;288:451-2.
Rijksinstituut voor Ziekte en Invaliditeitsverzekering. Voorschrift op stofnaam. http://ri
ziv.fgov.be/drug/nl/drugs/general-information/prescription/index.htm.

Cardiovasculair stelsel
1
2
3
4
5
6
7
8
9
10
11
12
13
14
McKelvie R. Heart failure. BMJ Clinical Evidence 2011;08:204. Search Date August
2010. http://clinicalevidence.bmj.com.
O’Connor CM, Whellan DJ, Lee KL et al. Efficacy and safety of exercise training in
patients with chronic heart failure. JAMA 2009;301:1439-50.
Medical Advisory Secretariat, Ministry of Health and Long-Term Care Ontario.
Community-based care for the specialized management of heart failure: an
evidence-based analysis. Ontario Health Technology Assessment Series 2009;9:1-42.
Davies EJ, Moxham T, Rees K et al. Exercise based rehabilitation for heart failure.
Cochrane Database of Systematic Reviews 2010, Issue 4. Art No.: CD003331. DOI:
10.1002/14651858.CD003331.pub3.
National Institute for Health and Clinical Excellence. Management of chronic heart
failure in adults in primary and secondary care. NICE Clinical Guideline 108, August
2010.http://guidance.nice.org.uk/CG108.
Scottish Intercollegiate Guidelines Network. Management of chronic heart failure.
SIGN Publication 95, February 2007. http://www.sign.ac.uk/pdf/sign95.pdf.
PRODIGY. Heart failure - chronic. PRODIGY 2010. http://prodigy.clarity.co.uk/heart_fai
lure_chronic.
Hunt SA, Abraham WT, Chin MH et al. 2009 Focused update incorporated into the
ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults.
A report of the American College of Cardiology Foundation/American Heart Association
Task Force on Practice Guidelines Developed in Collaboration With the International
Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90.
Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of
European Society of Cardiology et al. ESC Guidelines for the diagnosis and treatment
of acute and chronic heart failure 2008. Developed in collaboration with the Heart
Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive
Care Medicine (ESICM). Eur Heart J 2008;29:2388-442.
Hoes AW, Voors AA, Rutten FH et al. NHG-Standaard Hartfalen. Tweede herziening
Huisarts Wet 2010; 53: 368-89. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/
k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M51_svk.htm.
Rédaction Prescrire. Insuffisance cardiaque chronique: en bref; traitement initial et
traitement des états stables ; traitement des formes évolutives. Idées-forces tirées de
la revue Prescrire jusqu’au n° 308 (juin 2009). http://www.prescrire.org.
Goldberg LR. In the Clinic. Heart Failure. Ann Intern Med 2010;152:ITC6-1-ITC6-16.
Tu K, Mamdani M, Kopp A, Lee D. Comparison of angiotensin-converting enzyme
inhibitors in the treatment of heart failure. Am J Cardiol 2005;95:283-6.
Scherpbier ND, de Grauw WJC, Wetzels JFM, Vervoort GMM. Acute nierinsufficiëntie
bij combinatie RAAS-remmer en dehydratie. Ned Tijdschr Geneeskd 2010;154:1324-8.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
Shibata MC, Tsuyuki RT, Wiebe N. The effects of angiotensin-receptor blockers on
mortality and morbidity in heart failure: a systematic review. Int J Clin Pract
2008;62:1397-402.
Rédaction Prescrire. Sartans et insuffisance cardiaque. Les inhibiteurs de l’enzyme de
conversion de l’angiotensine (IEC) restent la référence. Rev Prescrire 2005;25:367-74.
Philips CO, Kashani A, Ko DK et al. Adverse effects of combination angiotensin II
receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular
dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern
Med 2007;167:1930-6.
Bijl D. Bijwerkingen van combinaties van anhiotensine II-antagonisten en ACE-remmers
bij hartfalen. Gebu 2008;42:25-6.http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Bij
werkingen-van-combinaties-van-angiotensine-IIantagonisten-en-ACEremmers-bijhartfalen.htm.
Lee VC, Rhew DC, Dylan M et al. Meta-analysis: angiotensin-receptor blockers in
chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med
2004;141:693-704.
Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of
nebivolol on mortalitiy and cardiovascular hospital admission in elderly patients with
heart failure (SENIORS). Eur Heart J 2005;26:215-25.
Go AS, Yang J, Gurwitz JH et al. Comparative effectiveness of different beta-adrenergic
antagonists on mortality among adults with heart failure in clinical practice. Arch Intern
Med 2008;168:2415-21.
Kramer JM, Curtis LH, Dupree CS et al. Comparative effectiveness of beta-blockers in
elderly patients with heart failure. Arch Intern Med 2008;168:2422-8.
Dulin BR, Haas SJ, Abraham WT, Krum H. Do elderly systolic heart failure patients
benefit from beta blockers to the same extent as the non-elderly Meta-analysis of >
12,000 patients in large scale trials. Am J Cardiol 2005;95:896-8.
Salpeter SR, Orniston TM, Salpeter EE et al. Cardioselective beta-blockers for chronic
obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005, Issue
4. Art. No.: CD003566. DOI: 10.1002/14651858.CD003566.pub2.
Anonymous. Can beta-blockers be used for people with COPD Drugs Ther Bull
2011;49:2-5.
Hawkins NM, Petrie MC, MacDonald MR et al. Heart failure and chronic obstructive
pulmonary disease. The quandary of beta-blockers and beta-agonists. J Am Coll Cardiol
2011;57:2127-2138.
Belgisch Centrum voor Farmacotherapeutische Informatie. Behandeling van chronisch
hartfalen. Folia Pharmacotherapeutica 2004;31:46-51. http://www.bcfi.be/PDF/Folia/
2004/P31N06B.pdf.
Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a
systematic review of randomized clinical trials. Eur Heart J 2009;30:469-77.
Zannad F, McMurray JJV, Krum H et al. Eplerenone in patients with systolic heart failure
and mild symptoms. N Engl J Med 2011;364:11-21.

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
Kerst AJFA. Eplerenon bij patiënten met systolisch hartaflen en lichte symptomen.
GeBu 2011;45:45-6. Bespreking van: Zannad F, McMurray JJV, Krum H et al. Eplerenone
in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
Kerst AJ. Behandeling van hartfalen met spironolacton: voetangels bij het voorschrijven
buiten onderzoeksverband. Gebu 2004;38:92-3. http://gebu.artsennet.nl/Archief/Tijd
schriftartikel/Behandeling-van-hartfalen-met-spironolacton-voetangels-bij-voorschrijvenbuiten-onderzoeksverband.htm.
Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart
failure. N Engl J Med 2007;357:2248-61.
GISSI-HF Investigators, Tavazzi L, Maggioni AP et al. Effect of rosuvastatin in patients
with chronic heart failure (the GISSI-HF trial): a randomised, double-blind,
placebo-controlled trial. Lancet 2008;372:1231-9.
Cheng JWM, Nayar M. A review of heart failure management in the elderly population.
Am J Ger Pharmacother 2009;7:233-49.
Oghlakian GO, Sipahi I, Fang JC. Treatment of heart failure with preserved ejection
fraction: have we been pursuing the wrong paradigm Mayo Clin Proc 2011;86:531-9.
Jong P, McKelvie R, Yusuf S. Should treatment for heart failure with preserved ejection
fraction differ from that for heart failure with reduced ejection fraction BMJ
2010;341:c4202.
Tzanetos K, Leong D, Wu RC. Office management of patients with diastolic heart
failure. CMAJ 2009;180:520-7.
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van stabiele angor.
Transparantiefiche juni 2008. http://www.bcfi.be/pdf/tft/TN_ANGR.pdf.
Gullikson M, Burell G, Vessby B et al. Randomized controlled trial of cognitive behavioral
therapy vs standard treatment to prevent recurrent cardiovascular events in patients
with coronary heart disease. Arch Intern Med 2011;171:134-140.
Thase ME. Cognitive behavioral therapy reduced risk for recurrence in patients recently
hospitalized with cardiovascular disease events. ACP Journal Club 2011;154;JC5-4.
Bespreking van: Gullikson M, Burell G, Vessby B et al. Randomized controlled trial of
cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular
events in patients with coronary heart disease. Arch Intern Med 2011;171:134-140.
Rutten FH, Bohnen AM, Schreuder BP et al. NHG-Standaard: Stabiele angor pectoris.
Huisarts Wet 2004;47:83-95. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nh
gstandaarden/Samenvattingskaartje-NHGStandaard/M43_svk.htm.
O’Toole L. Angina (chronic stable). BMJ Clinical Evidence 2008;10:213. Search Date
June 2007. http://clinicalevidence.bmj.com.
Gibbons RJ, Abrams J, Chatterjee K et al. ACC/AHA 2002 guideline update for the
management of patients with chronic stable angina – summary article: a report of the
American College of Cardiology/American Heart Association Task Force on practice
guidelines (Committee on the Management of Patients With Chronic Stable Angina).
J Am Coll Cardiol 2003;41:159-68. www.acc.org.
PRODIGY. Angina - stable. PRODIGY 2009. http://prodigy.clarity.co.uk/angina.

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Fox K, Garcia MA, Ardissino D et al. Guidelines on the management of stable angina
pectoris: executive summary: The Task Force on the management of stable angina
pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-81.
Al-Mallah M, Tleyjeh I, Abdel-Latif A et al. Angiotensin-converting enzyme inhibitors
in coronary artery disease and preserved left ventricular systolic function. J Am Coll
Cardiol 2006;47:1576-83.
Danchin N, Cucherat M, Thuillez M et al. Angiotensin-converting enzyme inhibitors
in patients with coronary artery disease and absence of heart failure or left ventricular
systolic dysfunction. Arch Intern Med 2006;166:787-96.
De Cort P, Van Mechelen W. ACE-inibitoren bij patiënten met coronair lijden zonder
hartfalen. Minerva 2007;6:138-9. http://www.minerva-ebm.be/nl/article.aspid=1361.
Baker WL, Coleman CI, Kluger J et al. Systematic review: comparative effectiveness
of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for
ischemic heart disease. Ann Int Med 2009;151:861-71.
Anonymous. Ivabradine for stable angina Drug Ther Bull 2008;46:84-8.
Fox K, Ford I, Steg PS et al. Ivabradine for patients with stable coronary artery disease
and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind,
placebo-controlled trial. Lancet 2008;372:807-16.
Tardif JC, Ponikowski P, Kahan T at al. Efficacy of the I(f) current inhibitor ivabradine
in patients with chronic stable angina receiving beta-blocker therapy: a 4-month,
randomized, placebo-controlled trial. Eur Heart J 2009;30:540-8.
Rédaction Prescrire. Angor stable: pas plus de place pour l’ivrabradine en 2010 qu’en
2006. Rev Prescr 2010;30:555-6.
Scottish Intercollegiate Guidelines Network. Management of stable angina. SIGN
Publication 96, 2007. http://www.sign.ac.uk/pdf/sign96.pdf.
Berger J, Brown D, Becker R. Low-dose aspirin in patients with stable cardiovascular
disease: a meta-analysis. Am J Med 2008;121:43-9.
Snow V, Barry P, Fihn S et al. Primary care management of chronic stable angina and
asymptomatic suspected or known coronary artery disease: a clinical practice guideline
from the American College of Physicians. Ann Intern Med 2004;141:562-7.
De Cort P, Christiaens T, Philips H et al. Aanbeveling voor goede medische
praktijkvoering: Hypertensie. Huisarts Nu 2009;38:340-61. http://www.domusmedi
ca.be/images/stories/aanbevelingen/i5_hnu_b_abv_hyper_09_lr.pdf.
Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of
arterial hypertension: The Task Force for the Management of Arterial Hypertension of
the European Society of Hypertension (ESH) and the European Society of Cardiology
(ESC). Eur Heart J 2007;28:1462-536.
Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:
the JNC 7 report. JAMA 2003;289:2560-71.
National Insititute for Health and Clinical Excellence. Hypertension: The clinical
management of primary hypertension in adults. NICE Clinical Guideline 127, August
2011. http://guidance.nice.org.uk/CG127.

61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
Scottish Intercollegiate Guidelines Network. Hypertension in older people. SIGN
Publication 49, January 2001. http://www.sign.ac.uk/guidelines/fulltext/49/index.html.
Nederlands Huisartsen Genootschap. NHG-Standaard cardiovasculair risicomanagement.
NHG-standaard M84, november 2006. http://nhg.artsennet.nl/kenniscentrum/k_richt
lijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M84_svk.htm.
Cheriyan J, O’Shaugnessy KM, Brown MJ. Primary prevention of CVD: treating
hypertension. BMJ Clinical Evidence 2010;02:14. Search Date December 2007.
http://clinicalevidence.bmj.com.
He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure.
Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD004937. DOI:
10.1002/14651858.CD004937.
Blumenthal JA, Babyak MA, Hinderliter A et al. Effects of the DASH diet alone and in
combination with exercise and weight loss on blood pressure and cardiovascular
biomarkers in men and women with high blood pressure. The ENCORE study. Arch
Intern Med 2010;170:126-35.
Wexler R, Aukerman G. Nonpharmacologic strategies for managing hypertension. Am
Fam Physician 2006;73:1953-6.
Belgisch Centrum voor Farmacotherapeutische Informatie. De startbehandeling van
hypertensie: stand van zaken. Folia Pharmacotherapeutica 2004;31:28-32. http://
www.bcfi.be/PDF/Folia/2004/P31N04B.pdf.
The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes
mellitus. N Engl J Med 2010;362:1575-85.
Bangalore S, Kumar S, Lobach I, Messerli F. Blood pressure targets in subjects with
type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and
Bayesian random-effects meta-analysis of randomized trials. Circulation
2011;123:2799-810.
Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target
in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med
2011;154:541-8.
Weiss JW, Johnson ES, Petrik A et al. Systolic blood pressure and mortality among
older community-dwelling adults with CKD. Am J Kidney Dis 2010;56:1062-71.
Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in
the elderly. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.:
CD000028. DOI: 10.1002/14651858.CD000028.pub2.
Oates DJ, Berlowitz DR, Glickman ME et al. Blood pressure and survival in the oldest
old. J Am Geriatr Soc 2007;55:383-8.
Molander L, Lövheim H, Norman T et al. Lower systolic blood pressure is associated
with greater mortality in people aged 85 and older. J Am Geriatr Soc 2008;56:1853-9.
Aronow WS, Fleg JL, Pepine CJ et al. ACCF/AHA 2011 expert consensus document
on hypertension in the elderly: a report of the Ammerican College of Cardiology
Foundation Task Force on clinical expert consensus documents. Circulation
2011;123;2434-506.

76
77
78
79
80
81
82
83
84
85
86
87
88
89
Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens
to lower blood pressure on major cardiovascular events in older and younger adults:
meta-analysis of randomised trials. BMJ 2008;336:1121-3.
Psaty BM, Lumley T, Furberg CD et al. Health outcomes associated with various
antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA
2003;289:2534-44.
ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major
outcomes in high-risk hypertensive patients randomized to angiotensin-converting
enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and
lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA
2002;288:2998-3007.
Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database of
Systematic Reviews 2009, Issue 3. Art. No.: CD001841. DOI: 10.1002/
14651858.CD001841.pub2.
Moser M, Feig PU. Fifty years of thiazide diuretic therapy for hypertension. Arch Intern
Med 2009;169:1851-6.
Ernst MA, Moser M. Use of diuretics in patients with hypertension. N Engl J Med
2009;361:2153-64.
Tran K, Ho C, Noorani HZ et al. Thiazide diuretics as first-line treatment for
hypertension: meta-analysis and economic evaluation. Canadian Agency for Drugs
and Technologies in Health; Technology report number 95, December 2007. http://
www.cadth.ca/media/pdf/343_Thiazide-Diuretics-Hypertension_tr_e.pdf.
Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years
of age or older. N Engl J Med 2008;358:1887-98.
Rédaction Prescrire. Traiter l’hypertension artérielle après 80 ans. Rev Prescrire
2008;28:851.
Sciaretta S, Palano F, Tocci G et al. Antihypertensive treatment and development of
heart failure in hypertension: a Bayesian network meta-analysis of studies in patients
with hypertension and high cardiovascular risk. Arch Intern Med 2011;171:384-94.
Barzilay JI, Davis BR, Cutler JA et al. Fasting glucose levels and incident diabetes mellitus
in older nondiabetic adults randomized to receive 3 different classes of antihypertensive
treatment; a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT) Arch Intern Med 2006;166:2191-201.
Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens
on major cardiovascular events in individuals with and without diabetes mellitus: results
of prospectively designed overviews of randomized trials. Arch Intern Med
2005;165:1410-9.
Wright JT, Probstfield JL, Cushman WC et al. ALLHAT Findings Revisited in the context
of subsequent analyses, other trials and meta-analyses. Arch Intern Med
2009;169:832-42.
Vijan S. Diabetes: treating hypertension. BMJ Clinical Evidence 2009;11:608. Search
Date February 2009. http://clinicalevidence.bmj.com.

90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
Kostis JB, Wilson AC, Freudenberger RS et al. Long-term effect of diuretic-based
therapy on fatal outcomes in subjects with isolated systolic hypertension with and
without diabetes. Am J Cardiol 2005;95:29-35.
Rédaction Prescrire. HTA: Diurétique en première ligne, même chez les diabétiques.
Rev Prescrire 2005;25:615.
Messerli FH, Makani H, Benjo A et al. Antihypertensive efficacy of hydrochlorothiazide
as evaluated by ambulatory blood pressure moniotoring. J Am Coll Cardiol
2011;57:590-600.
Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJG, Phillips BB et al. Comparative
antihypertensive effects of hydrochlorothiazide and chlorthalidon on ambulatory and
office blood pressure. Hypertension 2006;47:352-8.
Kooter AJ, Smulders YM. Bij hypertensie liever chloortalidon dan hydrochloorthiazide.
Ned Tijdsdchr Geneeskd 2010;154:580-1.
Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in
the treatment of primary hypertension A meta-analysis. Lancet 2005;366:1545-53.
Wiysonge CS, Bradley HA, Mayosi BM, Maroney RT, Mbewu A, Opie LH, Volmink J.
Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2007, Issue
1. Art. No.: CD002003. DOI: 10.1002/14651858.CD002003.pub2.
Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice
Lancet 2004;364:1684-9.
Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in
the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a
randomised trial against atenolol. Lancet 2002;359:995-1003.
Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG et al. Prevention of cardiovascular
events with an antihypertensive regimen of amlodipine adding perindopril as required
versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian
Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre
randomized controlled trial. Lancet 2005;366:895-906.
Cruickshank JK. Review: atenolol may be ineffective for reducing cardiovascular
morbidity or all cause mortality in hypertension. ACP J Club 2005;142:59.
Belgisch Centrum voor Farmacotherapeutische Informatie. Beta-blokkers bij hypertensie.
Folia Pharmacotherapeutica 2007;34:64-67. http://www.bcfi.be/PDF/Folia/2007/
P34N08B.pdf.
Van Bortel L. Is er nog plaats voor beta-blokkers Tijdschr voor Geneesk 2007;63:342-6.
Anonymous. Blood pressure guidelines – where are we now Drug Ther Bull
2008;46:65-9.
Rosendorff C, Black HR, Cannon CP et al. Treatment of hypertension in the prevention
and management of ischemic heart disease: a scientific statement from the American
Heart Association Council for High Blood Pressure Research and the Councils on Clinical
Cardiology and Epidemiology and Prevention. Circulation 2007;115:2761-88.
Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens
on major cardiovascular events: results of prospectively designed overviews of
randomized trials. Lancet 2003;362:1527-35.

106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
Verdecchia P, Angeli F, Cavallini C et al. Blood pressure reduction and
rennin-angiotensin system inhibition for prevention of congestive heart failure: a
meta-analysis. Eur Heart J 2009;30:679-88.
PROGRESS Collaborative Group: Randomised trial of a perindopril-based
blood-pressure-lowering regimen among 6105 individuals with previous stroke or
transient ischemic attack. Lancet 2001;358:1033-41.
Wennberg R, Zimmerman C. The PROGRESS trial three years later: time for a balanced
report of effectiveness. BMJ 2004;329:968-70.
Angeli F, Verdecchia P, Reboldi GP et al. Meta-analysis of effectiveness or lack thereof
of angiotensin-converting enzyme inhibitors for prevention of heart failure in patients
with systemic hypertension. Am J Cardiol 2004;93:240-3.
Wright JT Jr, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack
patients treated with chlortalidone, amlodipine and lisinopril. JAMA
2005;293:1595-608.
PRODIGY. Diabetes Type 2. PRODIGY 2008. http://prodigy.clarity.co.uk/diabetes_type_2.
Heran BS, Wong MMY, Heran IK, Wright JM. Blood pressure lowering efficacy of
angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane
Database of Systematic Reviews 2008, Issue 4. Art No.: CD003823. DOI: 10.1002/
CD003823.pub2.
Messerli FH, Bangalore S, Ruschitzka F. Angiotensin receptor blockers: baseline therapy
in hypertension Eur Heart J 2009:30:2427-30.
Yusuf S, Diener HC, Sacco RL et al. Telmisartan to prevent recurrent stroke and
cardiovascular events. N Engl J Med 2008;359:1225-37.
TRANSCEND investigators, Yusuf S, Teo K et al. Effects of the angiotensin-receptor
blocker telmisartan in cardiovascular events in high-risk patients intolerant to
angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet
2008;372:1174-83.
ONTARGET investigators, Yusuf S, Teo K et al. Telmisartan, ramipril, or both in patients
at high risk for vascular events. N Engl J Med 2008;358:1547-59.
Matchar DB, McCrory DC Orladeo LA et al. Comparative effectiveness of
angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists
(ARBs) for treating essential hypertension. Agency for healthcare research and
quality,publication No. 08-EHC003-EF, November 2007. www.effectivehealthcare.ah
rq.gov/reports/final.cfm. Ook gepubliceerd in: Ann Intern Med 2008;148:16-29.
Meerum Terwogt J, Koopmans R, Roos Y, van Montfrans GA. Angiotensine
II-receptorantagonisten vergeleken met andere antihypertensiva: nog onvoldoende
bewijs voor een lager risico op herseninfarcten. Ned Tijdschr Geneesk 2008;152:71-5.
Anonymous. Aliskiren for hypertension in adults. Drug Ther Bull 2008;46:73-6.
Bijl D. Nieuwe geneesmiddelen: Aliskiren. GeBu 2008;42:83-4. http://gebu.artsennet.nl
/Archief/Tijdschriftartikel/Aliskiren-Rasilez-behandeling-essentiele-hypertensie.htm.
Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin
inhibitors for primary hypertension. Cochrane Database of Systematic Reviews 2008,
Issue 4. Art. No.: CD007066. DOI: 10.1002/14651858.CD007066.pub2.

122
123
124
125
126
127
128
129
130
131
132
133
134
135
Mah GT, Tejani Am, Musini VM. Methyldopa for primary hypertension. Cochrane
Database of Systematic Reviews 2009; Issue 4. Art. No.: CD003893. DOI: 10.1002/
14651858.CD003893.pub3.
Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for
primary hypertension. Cochrane Database of Systematic Reviews 2009, Issue 4. Art.
No.: CD004643. DOI: 10.1002/14651858.CD004643.pub2.
Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention
of cardiovascular disease: meta-analysis of 147 randomised trials in the context of
expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
Anonymous. ACCOMPLISH-Studie: Erste Endpunktstudie zur Hochdrucktherapie mit
initialen Wirkstoffkombinationen. Arznei-telegramm 2009;40:13-5.
Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose
combinations of antihypertensive agents: a meta-analysis. Hypertension
2010;55:399-407.
van Loenen A, Bijl D. Combinatiepreparaten in de dagelijkse praktijk. GeBu
2007;41:125-31. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Combinatieprepa
raten-in-de-dagelijkse-praktijk.htm.
Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B et al. Benazepril plus amlodipine
or hydrochlorothiazide for hyprtension in high risk patients. N Engl J Med
2008;359:2417-28.
De Cort P. ACE_inhibitoren combineren met calciumantagonisten in plaats van met
thiaziden voor de behandeling van hypertensie Minerva 2010;9:88-9. Bespreking
van: Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B et al. Benazepril plus amlodipine
or hydrochlorothiazide for hyprtension in high risk patients. N Engl J Med
2008;359:2417-2428.
Farkouh ME, Bansilal S. Telmisartan and ramipril were equivalent, but their combination
increased adverse events in vascular disease or diabetes. Evid Based Med 2008;13:147.
Messerli FH. The sudden demise of dual renin-angiotensin system blockade or the soft
science of the surrogate end point. J Am Coll Cardiol 2009;53:468-70.
Lip GY, Felmeden DC. Antiplatelet agents and anticoagulants for hypertension.
Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD003186. DOI:
10.1002/14651858.CD003186.pub2.
Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with
non-valvular atrial fibrillation and no previous history of stroke or transient ischemic
attacks. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD001927.
DOI: 10.1002/14651858.CD001927.pub2.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: anti-thrombotic therapy to prevent
stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med
2007;146:857-67.
Camm AJ, Kirchhof P, Lip GYH et al. Guidelines for the management of atrial fibrillation:
the task force for the management of atrial fibrillation of the European Society of
Cardiology (ESC). Eur Heart J 2010;31:2369-2429.

136
137
138
139
140
141
142
143
144
145
146
147
148
149
National Insititute for Health and Clinical Excellence. Atrial fibrillation. National clinical
guideline for management in primary and secondary care. NICE Clinical Guideline 36,
June 2006. http://guidance.nice.org.uk/CG36/Guidance/pdf/English.
Boode BSP, Heeringa J, Konings KTS et al. NHG-Standaard Atriumfibrilleren. Huisarts
Wet 2009:52:646-63. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstan
daarden/Samenvattingskaartje-NHGStandaard/M79_svk.htm.
Keeling D, Baglin T, Campbell T et al. Guidelines on oral anticoagulation with warfarin
– fourth edition. Br J Haematol 2011;154:311-24.
Lip GY, Kalra L. Stroke: secondary prevention. BMJ Clinical Evidence 2010;03:207.
Search Date February 2009. http://www.clinicalevidence.bmj.com.
Aguilar MI, Hart R. Antiplatelet therapy for preventing stroke in patients with
non-valvular atrial fibrillation and no previous history of stroke or transient ischemic
attacks. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD001952.
DOI: 10.1002/14651858.CD001925.pub2.
Serebruany VL, Steinhubl SR, Berger PB et al. Analysis of risk of bleeding complications
after different doses of aspirin in 192036 patients enrolled in 31 randomized controlled
trials. Am J Cardiol 2005;95:1218-22.
Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for
preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke
or transient ischemic attacks. Cochrane Database of Systematic Reviews 2007, Issue
3. Art. No.: CD006186. DOI: 10.1002/14651858.CD006186.pub2.
Saxena R, Koudstaal PJ. Anticoagulants versus antiplatelet therapy for preventing
stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient
ischemic attack. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.:
CD 000187. DOI: 10.1002/14651858.CD000187.pub2.
van Walraven C, Hart RG, Singer DE, Laupacis A, Conolly S et al. Oral anticoagulants
vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA
2002;288:2441-8.
Mant J, Hobbs FD, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an
elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation
Treatment of the Aged study: BAFTA): a randomized controlled trial. Lancet
2007;370:493-503.
Lip GYH, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting
stroke and thromboembolism in atrial fibrillation using a novel risk factor-based
approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137:263-272.
Olesen JB, Lip GYH, Hansen ML et al. Validation of risk stratification schemes for
predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide
cohort study. BMJ 2011;342:d124.
Johnson CE, Lim WK, Workman BS. People aged over 75 in atrial fibrillation on warfarin:
the rate of major hemorrhage and stroke in more than 500 patient-years of follow
up. J Am Geriatr Soc 2005;53:655-9.
Singer DE, Chang Y, Fang MC et al. The net clinical benefit of warfarin anticoagulation
in atrial fibrillation. Ann Intern Med 2009;151:297-305.

150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
Dunn A. Oral anticoagulant therapy safely prevented stroke in older patients with
atrial fibrilllation. Evid Based Med 2009;14:140. Bespreking van: van Walraven C, Hart
RG, Conolly S et al. Effect of age on stroke prevention therapy in patients with atrial
fibrillation: the Atrial Fibrillation Investigators. Stroke 2009;40:1410-6.
Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with
atrial fibrillation. N Engl J Med 2009;361:1139-51.
Chevalier P. Dabigatran of warfarine bij voorkamerfibrillatie Minerva 2010;9:58-59.
http://www.minerva-ebm.be/nl/article.aspid=1903.
van Deventer KR. Dabigatran versus warfarine bij patiënten met atriumfibrilleren. GeBu
2009;43:116-117. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Dabigatran-versuswarfarine-bij-patienten-met-atriumfibrilleren.htm.
Anonymous. Dabigatran – eine Alternatieve zu Vitamin-K-Antagonisten bei
Vorhofflimmern. Arzneimittelbrief 2010;44:6-7.
Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral
anticoagulants. Int J Clin Pract 2010;64:956-67.
Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial
fibrillation. N Engl J Med 2011;365:883-91.
Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients
with atrial fibrillation. N Engl J Med 2011; published early online August 28, 2011.
Lip GY. Don’t add aspirin for associated stable vascular disease in a patient with atrial
fibrillation receiving anticoagulation. BMJ 2008;336:614-5.
ACTIVE-investigators, Connolly S, Pogue J et al. Clopidogrel plus aspirin versus oral
anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with
Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial.
Lancet 2006;367:1903-12.
ACTIVE-investigators, Connolly S, Pogue J et al. Effect of clopidogrel added to aspirin
in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78.
Anonymous. Clopidogrel plus ASS bei Vorhoflimmern. Arznei-telegramm 2009;40:45-6.
Go AS. The ACTIVE pursuit of stroke prevention in patients with atrial fibrillation. N
Engl J Med 2009;360:2127-9.
Belgisch Centrum voor Farmacotherapeutische Informatie. Wanneer een
medicamenteuze behandeling stoppen voor een heelkundige ingreep Folia
Pharmacotherapeutica 2011;38:46-50. http://www.bcfi.be/PDF/Folia/2011/
P38N06B.pdf.
Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging
anticoagulation during interruption of warfarin: assessment of a standardized
peripocedural anticoagulation regimen. Arch Intern Med 2004;164:1319-26.
Garcia DA, Regan S, Henault LE et al. Risk of thromboembolism with short term
interruption of warfarin therapy. Arch Intern Med 2008;168:63-9.
Zimetbaum P. In the clinic. Atrial fibrillation. Ann Intern Med 2010;153:ITC6-1-ITC6-16.
Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control
in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.

168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm
control in patients with recurrent persistent atrial fibrillation. N Engl J Med
2002;347:1834-40.
de Denus S, Sanoski CA, Carlsson J et al. Rate vs rhythm control in patients with atrial
fibrillation: a meta-analysis. Arch Intern Med 2005;165:258-62.
Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation
and heart failure. N Engl J Med 2008;358:2667-77.
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van
voorkamerfibrillatie. Transparantiefiche juni 2008. http://www.bcfi.be/pdf/tft/
TN_VKF.pdf.
Rédaction Prescrire. Fibrillation auriculaire. traitement à visée cardiaque. Idées-Forces
tirées de la revue Prescrire jusqu’au n° 308 (juin 2009). http://www.prescrire.org.
Van Gelder IC, Groenveld HF, Crijns HJGM et al. Lenient versus strict rate control in
patients with atrial fibrillation. N Engl J Med 2010;362:1363-73.
Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment
considerations for a dual epidemic. Circulation 2009;119:2516-25.
Lip GYH, Apostolakis S. Atrial fibrillation (acute onset). BMJ Clinical Evidence
2011;02:210. Search Date April 2010. http://clinicalevidence.bmj.com.
Gjesdal K, Feyzi J, Olsson SB. Digitalis: a dangerous drug in atrial fibrillation An analysis
of the SPORTIF III and V data. Heart 2008;94:191-6.
Lane DA, Apostolakis S, Boos CJ, Lip GYH. Atrial fibrillation (chronic). BMJ Clinical
Evidence 2011;12:217. Search Date June 2011. http://clinicalevidence.bmj.com.
Dierickx C, Tavernier R, Duytschaever M. Richtlijnen in de behandeling van atriale
fibrillatie. Tijdschr voor Geneeskd 2008;64:954-62.
Nault I, Miyazaki S, Forclaz A et al. Drugs vs. ablation for the treatment of atrial
fibrillation: the evidence supporting catheter ablation. Eur Heart J 2010;31:1046-54.
GISSI-AF Investigators, Disertori M, Latini R et al. Valsartan for prevention of recurrent
atrial fibrillation. N Engl J Med 2009;360;1606-17.
Almroth H, Höglund N, Boman K et al. Atorvastatin and persistent atrial fibrillation
following cardioversion: a randomized placebo-controlled multicentre study. Eur Heart
J 2009;30:827-33.
Yusuf S, Healey JS, Pogue J et al. Irbesartan in patients with atrial fibrillation. N Engl
J Med 2011;364:928-38.
Rahimi K, Martin J Sr, Emberson J et al. Effect of statins on atrial fibrillation:
collaborative meta-analysis of published and unpublished evidence from randomized
controlled trials. BMJ 2011;342:d1250.
PRODIGY. Stroke and TIA. PRODIGY 2009. http://prodigy.clarity.co.uk/stroke_and_tia.
Rédaction Prescrire. Prévention cardiovasculaire après un accident vasculaire cérébral
ischémique. Idées-Forces tirées de la revue Prescrire jusqu’au n°298 (août 2008).
http://www.prescrire.org.
Furie KL, Kasner SE, Adams RJ et al. Guidelines for prevention of stroke in patients
with ischemic stroke or transient ischemic attack: a guideline for healthcare
professionals from the American Heart Association/American Stroke Association. Stroke
2011;42:227-76.

187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
Van Binsbergen JJ, Verhoeven S, Van Bentum ST et al. NHG-Standaard TIA (eerste
herziening). Huisarts Wet 2004;47:458-67. http://nhg.artsennet.nl/kenniscentrum/
k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M45_svk.htm.
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized
trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke
in high risk patients. BMJ 2002;324:71-86.
Campbell CL, Smyth S, Montalescot G et al. Aspirin dose for the prevention of
cardiovascular disease: a systematic review. JAMA 2007;297:2018-24.
Belgisch Centrum voor Farmacotherapeutische Informatie. Anti-aggregantia in de
secundaire preventive van cardiovasculaire accidenten. Folia Pharmacotherapeutica
2008;35:4. http://www.bcfi.be/PDF/Folia/2008/P35N01D.pdf.
De Schryver E, Algra A, van Gijn J. Dipyridamole for preventing stroke and other
vascular events in patients with vascular disease. Cochrane Database of Systematic
Reviews 2007, Issue 3. Art. No.: CD 001820. DOI: 10.1002/14651858.CD001820.pub3.
Scottish Intercollegiate Guidelines Network. Management of patients with stroke or
TIA: assessment, investigation, immediate management and secondary prevention. A
national clinical guideline. SIGN Publication 108, December 2008. http://www.sign.ac.uk
/pdf/sign108.pdf.
The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral
ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet
2006;367:1665-73.
Halkes PH, Gray LJ, Bath PM et al. Dipyridamole plus aspirin versus aspirin alone in
secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg
Psychiatry 2008;79:1218-23.
Anonymous. Azetylsalizylsäure plus Dipyridamol – kein Mittel der ersten Wahl.
Arzneimittelbrief 2008;42:93-4.
Chevalier P. Dipyridamol toevoegen aan aspirine na ischemisch CVA Minerva
2006;5:104-6. http://www.minerva-ebm.be/nl/article.aspid=1144.
Uchiyama S, Ikeda Y, Urano Y et al. The Japanese Aggrenox (extended-release
dipyridamole plus aspirin) Stroke Prevention versus Aspirin Programme (JASAP) study:
a randomized, double-blind, controlled trial. Cerebrovasc Dis 2011;31:601-13.
National Institute for Health and Clinical Excellence. Clopidogrel ans modified-release
dipyridamole in the prevention of occlusive vascular events. NICE Technology Appraisal
90, reviewed April 2008. http://guidance.nice.org.uk/TA90.
PRODIGY. Antiplatelet treatment. PRODIGY 2009. http://prodigy.clarity.co.uk/antipla
telet_treatment.
Adams RJ, Albers G, Alberts MJ al. Update to the AHA/ASA recommendations for the
prevention of stroke in patients with stroke and transient ischemic attack. Stroke
2008;39:1647-52.
Wiersma T. Addendum bij de NHG-standaard TIA: voortaan ook dipyridamol. Huisarts
Wet 2006;49:671.
Rédaction Prescrire. Les antiagrégants chez les patients à risqué cardiovasculaire très
élevé. Rev Prescrire 2009;29:278-83.

203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to
prevent recurrent ulcer bleeding. N Engl J Med 2005;352:238-44.
Rédaction Préscrire. IPP après hémorragie ulcéreuse sous aspirine en prévention
cardiovasculaire. Rev Prescrire 2005;25:848-9.
Sacco RL, Diener HC, Yusuf S et al. Aspirin and extended-release dipyridamole versus
clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-51.
Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with
clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk
patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet
2004;364:331-7.
Bogaert M. Aspirine toevoegen aan clopidogrel in secundaire preventie Minerva
2005;4:73-75. http://www.minerva-ebm.be/nl/article.aspid=984.
Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the
prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
Chevalier P. Clopidogrel plus aspirine versus aspirine alleen in cardiovasculaire preventie.
Minerva 2006;5:76-79. http://www.minerva-ebm.be/nl/article.aspid=1126.
Eshaghian S, Kaul S, Amin S et al. Role of clopidogrel in managing atherothrombotic
cardiovascular disease. Ann Intern Med 2007;146:434-1.
ESPRIT Study Group, Halkes PH, van Gijn J et al. Medium intensity oral anticoagulants
versus aspirin after cerebral ischemia of arterial origin (ESPRIT): a randomized controlled
trial. Lancet Neurol 2007;6:115-24.
Sandercock PAG, Gibson LM, Liu M. Anticoagulants for preventing recurrence following
presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. Cochrane
Database of Systematic Reviews 2009, Issue 2. Art. No.: CD000248. DOI: 10.1002/
14651858.CD000248.pub2.
Belgisch Centrum voor Farmacotherapeutische Informatie. Antithrombotische
behandeling: enkele recente publicaties. Folia Pharmacotherapeutica 2009;36:10-14.
http://www.bcfi.be/PDF/Folia/2009/P36N02B.pdf.
Sloan MA. Aspirin plus extended release dipyridamole and clopidogrel were similarly
effective for preventing recurrent stroke. Evid Based Med 2009;14:46-7.
Westover MB, Bianchi MT; Eckman MH, Greenberg SM. Statin use following
intracerebral hemorrhage. A decision analysis. Arch Neurol 2011;68:573-9.
Sachdeva A, Dalton M, Amaragiri SV, Lees T. Elastic compression stockings for
prevention of deep vein thrombosis. Cochrane Database of Systematic Reviews 2010
Issue 7. Art. No.: CD001484. DOI: 10.1002/14651858.CD001484.pub2.
National Institute for Health and Clinical Excellence. Venous thromboembolism:
reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary
embolism) in patients admitted to hospital. NICE Clinical Guideline 92, January 2010.
http://guidance.nice.org.uk/CG92/Guidance/pdf/English.
Rédaction Prescrire. Prévention primaire des embolies pulmonaires. Première et
deuxième partie. Rev Prescrire 2002;22:440-9.
Goodacre S. In the clinic: Deep venous thrombosis. Ann Intern Med 2008;149:
ITC3-1-ITC3-16.

220
221
222
223
224
225
226
227
228
229
230
231
232
233
Scottish Intercollegiate Guidelines Network. Prevention and management of venous
thromboembolism. SIGN Publication 122. December 2010. http://www.sign.ac.uk/pdf
/sign122.pdf.
Vicaretti M. Compression therapy for venous disease. Aust Prescr 2010;33:186-90.
Rédaction Prescrire. Prévention primaire des embolies pulmonaires. Troisième partie.
Rev Prescrire 2002;22:516-29.
Belgisch Centrum voor Farmacotherapeutische informatie. Behandeling en preventie
van diepe veneuze trombose. Folia Pharmacotherapeutica 2008;35:1-2. http://www.bc
fi.be/PDF/Folia/2008/P35N01B.pdf.
National Health Service. Should prophylactic doses of low molecular weight heparins
be used in patients with renal impairment NeLM Medicines Q&A 257.1, February 19,
2009. http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Q--A/Shouldprophylactic-doses-of-low-molecular-weight-heparins-be-used-in-patients-with-renalimpairment.
Testroote M, Stigler WAH, de Visser DC, Janzing HMJ. Low molecular weight heparin
prevention of venous thromboembolism in patients with lower-leg immobilization.
Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD006681. DOI:
10.1002/14651858.CD006881.pub2.
Ramos J, Perrotta A, Badariotti G, Berenstein G. Interventions for preventing venous
thromboembolism in adults undergoing knee arthroscopy. Cochrane Database of
Systematic Reviews 2008, Issue 4. Art. No.: CD005259. DOI: 10.1002/
14651858.CD005259.pub3.
Dentali F, Douketis JD, Gianni M et al. Meta-analysis: anticoagulant prophylaxis to
prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann
Intern Med 2007;146:278-88.
Wein L, Wein S, Haas SJ et al. Pharmacological venous thromboembolism prophylaxis
in hospitalized medical patients. A meta-analysis of randomized controlled trials. Arch
Intern Med 2007;167:1476-86.
Alikhan R, Cohen AT. Heparin for the prevention of venous thromboembolism in
general medical patients (excluding stroke and myocardial infarction). Cochrane
Database of Systematic Reviews 2009, Issue 3. Art. No. CD003747. DOI: 10.1002/
14651858.CD003747.pub2.
Anonymous. Fraktionierte Heparine zur Akut-therapie venöser Thromboembolien.
Arznei-telegramm 2009;40:1-4.
Turpie AG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for the
thromboprophylaxis after Total knee arthroplasty (RECORD4): a randomized trial.
Lancet 2009;373:1673-80.
Belgisch Centrum voor Farmacotherapeutische Informatie. Nieuwe anticoagulantia
voor oraal gebruik in de preventie van veneuze trombo-embolie bij otrhopedische
chirurgie. Folia Pharmacotherapeutica 2010;37:19-22. http://www.bcfi.be/PDF/Folia/
2010/P37N03B.pdf.
Anonymous. Anticoagulation with dabigatran or rivaroxaban. Drugs Ther Bull
2009;47:116-20.

234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
Lassen MR, Raskob GE, Gallus A et al. Apixaban versus enoxaparin for the
thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind
trial. Lancet 2010;375:807-815.
Lassen MR, Gallus A, Raskob GE et al. Apixaban versus enoxaparin for
thromboprophylaxis after hip replacement. N Engl J Med 2010;363:2487-98.
Eikelboom JW, Weitz JI. New oral anticoagulants for thromboprophylaxis in patients
having hip or knee arthroplasty. BMJ 2011;342:c7270.
Rédaction Prescrire. Dabigatran (Pradaxa): en rester à une héparine, mieux connue.
Rev Prescrire 2008;28:806-10.
Rédaction Prescrire. Rivaroxiban (Xarelto): après prothèse de hanche ou du genou:
une HBPM semble plus sure. Rev Prescrire 2009;29:326-9.
Kearon C, Ginsberg JS, Kovacs MJ et al. Comparison of low-intensity warfarin therapy
with conventional-intensity warfarin therapy for long-term prevention of recurrent
venous thromboembolism. N Engl J Med 2003;349:631-9.
McManus RJ, Fitzmaurice DA, Murray E, Taylor C et al. Thromboembolism. BMJ Clinical
Evidence 2011;03:208. Search Date June 2010. http://clinicalevidence.bmj.com.
PRODIGY. Deep vein thrombosis. PRODIGY 2009. http://prodigy.clarity.co.uk/
deep_vein_thrombosis.
Kolbach DN, Sandbrink MW, Hamulyak K et al. Non-pharmaceutical measures for
prevention of post-thrombotic syndrome. Cochrane Database of Systematic Reviews
2003, Issue 3. Art. No.: CD004174. DOI: 10.1002/14651858.CD004174.pub2.
Musani MH, Matta F, Yaekoub AY et al. Venous compression for prevention of
postthrombotic syndrome: a meta-analysis. Am J Med 2010;123:735-40.
Erkens P, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus
adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database
of Systematic Reviews 2010, Issue 9. Art. No.: CD001100. DOI: 10.1002/
14651858.CD001100.pub3.
Belgisch Centrum voor Farmacotherapeutische Informatie. Gecommentarieerd
geneesmiddelenrepertorium, editie 2011. www.bcfi.be.
National Health Service. Are low molecular weight heparins preferred to unfractionated
heparin in people with renal impairment being treated for venous thromboembolism
and myocardial infarction NeLM Medicines Q&A 238.1, February 12, 2009. http://
www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Q--A/Are-low-molecular-weightheparins-preferred-to-unfractionated-heparin-in-people-with-renal-impairment-beingtreated-for-venous-thromboembolism-and-myocardial-infarction.
Oudega R, Van Weert H, Stoffers H et al. NHG-Standaard: Diepe veneuze trombose.
Huisarts Wet 2008;51:24-37. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nh
gstandaarden/Samenvattingskaartje-NHGStandaard/M86_svk.htm.
Boutitie F, Pinede L, Schulman S et al. Influence of preceding length of anticoagulant
treatment and initial presentation of venous thromboembolism on risk of recurrence
after stopping treatment: analysis of individual participant’s data from seven trials.
BMJ 2011;342:d3036.

249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
Campbell IA, Bentley DP, Prescott RJ et al. Anticoagulation for three versus six months
in patients with deep vein thrombosis or pulmonary embolism, or both; randomized
trial. BMJ 2007;334:674-80.
PRODIGY. Anticoagulation - oral. PRODIGY 2009. http://prodigy.clarity.co.uk/anticoa
gulation_oral.
Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic
venous thromboembolism. Cochrane Database of Systematic Reviews 2006, Issue 1.
Art. No.: CD001367. DOI: 10.1002/14651858.CD001367.pub2.
Anonymous. Preventing recurrent venous thromboembolism. Drug Ther Bull
2009;47:38-40.
Rédaction Prescrire. Prévention des récidives thromboemboliques: 3 mois d’antivitamine
K. Rev Prescrire 2009;29:132.
Prandoni P, Prins MH, Lensing AWA et al. Residual thrombosis on ultrasonography to
guide the duration of anticoagulation in patients with deep venous thrombosis: a
randomized trial. Ann Intern Med 2009:150:577-85.
Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment
of acute venous thromboembolism. N Engl J Med 2009;361:2342-2352.
Gandara E. Dabigatran was noninferior to warfarin for preventing recurrent venous
thromboembolism. ACP Journal Club 2010;152:JC4-7.
The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism.
N Engl J Med 2010;363:2499-510.
Thijs A. Dabigatran lijkt gelijk aan warfarine bij patiënten met veneuze trombo-embolie.
Ned Tijdschr Geneeskd 2010;154:1170.
Chevalier P. Rivaroxaban voor diepe veneuze trombo-embolie Minerva 2011;10:36-7.
http://www.minerva-ebm.be/nl/article.aspid=2024. Bespreking van: The EINSTEIN
Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J
Med 2010;363:2499-510.
van der Heijden JF, Hutten BA, Büller HR, Prins HM. Vitamin K antagonists or
low-molecular-weight heparin for the long term treatment of symptomatic venous
thromboembolism. Cochrane Database of Systematic Reviews 2001, Issue 3. Art. No.:
CD002001. DOI: 10.1002/14651858.CD002001.
Akl EA, Labedi N, Barba M et al. Anticoagulation for the long-term treatment of venous
thromboembolism in patients with cancer. Cochrane Database of Systematic Reviews
2011, Issue 6. Art. No.: CD006650. DOI: 10.1002/14651858CD006650.pub3.
DeZee KJ, Shimeall WT, Douglas KM et al. Treatment of excessive anticoagulation with
phytomenadione (vitamin K). Arch Intern Med 2006;166:391-7.
Crowther MA, Ageno W, Garcia D et al. Oral vitamin K versus placebo to correct
excessive anticoagulation in patients receiving warfarin. A randomized trial. Ann Intern
Med 2009;150:293-300.
Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K
antagonists. Chest 2008;133:160S-198S.
Boland B, Christiaens T, Goderis G et al. Globaal cardiovasculair risicobeheer. Huisarts
Nu 2007;36:339-69. http://www.domusmedica.be/images/stories/aanbevelingen/
h36_7_ab_cardio.pdf.

266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
National Institute for Health and Clinical Excellence. Lipid modification. NICE Clinical
Guideline 67, May 2008. http://guidance.nice.org.uk/CG67/Guidance/pdf/English.
Krumholz H, Hayward R. Shifting views on lipid lowering therapy. BMJ 2010;341:332-3.
Anonymous. Statintherapie: LDL-Zielwert oder fixe Dosis Arznei-telegramm
2011;42,28-9.
Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of
cardiovascular disease. SIGN publication 97, February 2007. http://www.sign.ac.uk/
pdf/sign97.pdf.
PRODIGY. Lipid modification - CVD prevention. PRODIGY 2008. http://prodigy.clari
ty.co.uk/lipid_modification_cvd_prevention.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of
cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized
placebo-controlled trial. Lancet 2002;360:7-22.
Collins R, Armitage J, Parish S et al. Effects of cholesterol-lowering with simvastatin
on stroke and other major vascular events in 20536 people with cerebrovascular
disease or other high-risk conditions. Lancet 2004;363:757-67.
Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of
vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-30.
Afilalo J, Duque G, Steele R et al. Statins for secondary prevention in elderly patients.
A Hierarchical Bayesian meta-analysis. J Am Coll Cardiol 2008;51:37-45.
Ray KK, Seshasai SRK, Erqou S et al. Statins and all-cause mortality in high-risk primary
prevention. Arch Intern Med 2010;170:1024-31.
Maron DJ. Review: statins do not reduce mortality in patients with no history of
cardiovascular disease. ACP J Club 2010;153:JC3-4. Bespreking van: Ray KK, Seshasai
SRK, Erqou S et al. Statins and all-cause mortality in high-risk primary prevention. Arch
Intern Med 2010;170:1024-1031.
Kaess BM, Vasan RS. Statins are not associated with a decrease in all cause mortality
in a high-risk primary prevention setting. Evid Based Med 2011;16:8-9. Bespreking
van: Ray KK, Seshasai SRK, Erqou S et al. Statins and all-cause mortality in high-risk
primary prevention. Arch Intern Med 2010;170:1024-1031.
Taylor F, Ward K, Moore THM et al. Statins for the primary prevention of cardiovascular
disease. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No: CD004816.
DOI: 10.1002/14651858.CD004816.pub4.
Belgisch Centrum voor Farmacotherapeutische Informatie. Statines in primaire preventie:
een Cochrane-review. Folia Pharmacotherapeutica 2011;38:22. http://www.bcfi.be/
PDF/Folia/2011/P38N03D.pdf . Bespreking van: Taylor F, Ward K, Moore THM et al.
Statins for the primary prevention of cardiovascular disease. Cochrane Database of
Systematic Reviews 2011, Issue 1. Art. No: CD004816. DOI: 10.1002/
14651858.CD004816.pub4.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized
to pravastatin vs usual care: the Antihypertensive and Kipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.

281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G et al. Prevention of coronary and
stroke events with atorvastatin in hypertensive patients who have average or
lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac
Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled
trial. Lancet 2003;361:1149-58.
Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to prevent vascular events in
men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
Belgisch Centrum voor Farmacotherapeutische Informatie. De JUPITER-studie over het
gebruik van rosuvastaine in primaire preventie van cardiovasculaire incidenten. Folia
Pharmacotherapeutica 2009;36:5-7. http://www.bcfi.be/PDF/Folia/2009/P36N01E.pdf.
de Lorgeril M, Salen P, Abramson J et al. Cholesterol lowering, cardiovascular diseases
and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med
2010;170:1032-6.
Glynn RJ, Koenig W, Nordestgaard BG et al. Rosuvastatin for primary prevention in
older persons with elevated C-reactive protein and low-density lipoprotein cholesterol
levels: exploratory analysis of a randomized trial. Ann Intern Med 2010;152:488-96.
Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative
meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
Anonymous. Bei älteren Patienten ist unter Therapie mit Statinen das Risiko für Diabetes
mellitus Typ 2 leicht erhöht. Arzneimittelbrief 2010;44:31-2.
Kerst AJFA. Statinen en het risico op diabetes mellitus: een meta-analyse. GeBu
2010;44:68-9. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Statinen-en-het-risicoop-diabetes-mellitus-een-metaanalyse.htm.
Bhatia L, Byrne CD. There is a slight increase in incident diabetes risk with the use of
statins, but benefits likely outweigh any adverse effects in those with moderate-to-high
cardiovascular risk. Evid Based Med 2010;15:84-5.
Belgisch Centrum voor Farmacotherapeutische Informatie. Recente gegevens in verband
met statines. Folia Pharmacotherapeutica 2010;37:60. http://www.bcfi.be/PDF/Folia/
2010/P37N07D.pdf.
Brouns K, Muls E. Lipiden op leeftijd: wat met de 70-plussers Tijdschr voor Geneeskd
2008;64:861-71.
Belgisch Centrum voor Farmacotherapeutische Informatie. Hoge doses van een statine:
wat is de evidentie Folia Pharmacotherapeutica 2009;36:73-6. http://www.bcfi.be/
PDF/Folia/2009/P36N09B.pdf.
Zhou Z, Rahme E, Pilote L. Are statins created equal Evidence from randomized trials
of pravastatin, simvastatin and atorvastatin for cardiovasculas disease prevention. Am
Heart J 2006;151:273-81.
Canadian Agency for Drugs and Technologies in Health. Comparative effectiveness
of rosuvastatin versus other statins: a review of clinical effectiveness. CADTH Rapid
Response Report, 15 February 2011. http://www.cadth.ca/media/pdf/htis/feb-2011/
L0247-Rosuvastatin_final.pdf
Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive
lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26
randomised trials. Lancet 2010;376:1670-81.

296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
Mills EJ, O'Regan C, Eyawo O et al. Intensive statin therapy compared with moderate
dosing for prevention of cardiovascular events: a meta-analysis of >40000 patients.
Eur Heart J 2011;32:1409-15.
Preiss D, Seshasai SRK, Welsh P et al. Risk of incident diabetes with intensive-dose
compared with moderate-dose statin therapy: a meta-analysis. JAMA
2011;305:2556-64.
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
Collaborative Group. Intensive lowering of LDL cholesteriol with 80 mg versus 20 mg
simvastatin daily in 12064 survivors of myocardial infarction: a double blind randomized
trial. Lancet 2010;376:1658-69.
Tikkanen MJ, Holme I, Cater NB et al. Comparison of efficacy and safety of atorvastatin
(80 mg) to simvastatin (20 to 40 mg) in patients aged < 65 versus ≥ 65 years with
coronary heart disease (from the Incremental Decrease through Aggressive Lipid
Lowering [IDEAL] Study). Am J Cardiol 2009;103:577-82.
Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end A review
of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age
Ageing 2010;39:674-80.
Mangin D, Sweeney K, Heath I. Preventive health care in elderly people needs
rethinking. BMJ 2007;335:285-7.
Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes: a systematic
review and meta-analysis. Lancet 2010;375:1875-84.
Sharma M, Ansari MT, Abou-Setta AM et al. Systematic review: comparative
effectiveness and harms of combination therapy and monotherapy for dyslipidemia.
Ann Intern Med 2009;151:622-30.
ACCORD Study Group, Ginsberg HN, Elam MB et al. Effects of combination lipid
therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
Anonymous. Ezetemibe: a new cholesterol-lowering drug. Drug Ther Bull 2004;42:65-7.
Ara R, Tumur I, Pandor A et al. Ezetimibe for the treatment of hypercholesterolaemia:
a systematic review and economic evaluation. Health Technol Assess 2008;12:1-212.
Al Badarin FJ, Kullo IJ, Kopecky SL et al. Impact of ezetimibe on atherosclerosis: is the
jury still out Mayo Clin Proc 2009;84:353-61.
Anonymous. Nicht verordnen: Ezetemib (Ezetrol ua) nach wie vor ohne Nutzenbelege.
Arznei-telegramm 2008;39:19-21.
Anonymous. Ezetimib plus Simvastatin (Inegy) - erhöhtes Krebsrisiko Arznei-telegramm
2008;39:87.
Anonymous. Ezetimib, Cholesterinspiegel und Malignomrisiko. Arzneimittelbrief
2009;43:11-2.
Belgisch Centrum voor Farmacotherapeutische Informatie. Recente informatie:
nicotinezuur + laropiprant. Folia Pharmacotherapeutica 2010;37:51. http://www.bc
fi.be/PDF/Folia/2010/P37N06C.pdf.
Rédaction Prescrire. Acide nicotinique + laropiprant: le laropiprant ajoute des effets
indésirables. Rev Prescr 2009;29:726-9.
Anonymous. Lipidsenker Tredaptive: Nikotinsaüre ohne Flush Arzneitelegramm
2009;40:104-5.

314
315
316
317
318
319
320
321
322
323
324
325
326
327
Anonymous. Tredaptive – neue UAW beim Verquch die bekannten UAW von
Nikotinsaüre zu verringern. Arzneimittelbrief 2010;44:29-30.
Cassar K. Peripheral arterial disease. BMJ Clincal Evidence 2011;01:211. Search Date
May 2010. http://clinicalevidence.bmj.com.
Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Guidelines for the management
of patients with peripheral arterial disease (lower extremity, renal, mesenteric and
abdominal aortic): Executive summary. J Am Coll Cardiol 2006;47:1239-312.
Scottish Intercollegiate Guidelines Network. Diagnosis and management of peripheral
arterial disease. SIGN Publication 89, October 2006. http://www.sign.ac.uk/pdf/
sign89.pdf.
Bartelink ML, Stoffers HE, Boutens EJ et al. NHG-Standaard perifeer arterieel vaatlijden.
Huisarts Wet 2003;46:848-58. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/
k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M13_svk.htm.
Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. Cochrane Database
of Systematic Reviews 2008, Issue 4. Art. No.: CD000990. DOI:10.1002/
14651858.CD000990.pub2.
Nicolaï SPA, Prins MH, Teijink JAW. Gesuperviseerde looptherapie effectiever dan
loopadvies bij patiënten met claudicatio intermittens; gerandomiseerde multicentrische
studie. Ned Tijdschr Geneeskd 2011;155:55-62.
Brett AS. Exercise vs. revascularization for intermittent claudication. JWatch Gen Med
February 19, 2009 [online], www.general-medicine.jwatch.org. Bespreking van: Spronk
S, Bosch JL, den Hoed PT, Veen F, Pattynama PM, Hunink MG. Intermittent claudication:
clinical effectiveness of endovascular revascularization versus supervised hospital-based
exercise traning – randomized controlled trial. Radiology 2009;250:586-95.
Crismer A. Claudicatio intermittens: endovasculaire revascularisatie of looptraining
onder supervisie in het ziekenhuis. Minerva 2009;8:142-43. http://www.minervaebm.be/nl/article.aspid=1800.
Bespreking van Spronk S, Bosch JL, den Hoed PT, Veen
F, Pattynama PM, Hunink MG. Intermittent claudication: clinical effectiveness of
endovascular revascularization versus supervised hospital-based exercise traning –
randomized controlled trial. Radiology 2009;250:586-95.
Wilson JF. In the clinic: peripheral arterial disease. Ann Intern Med
2007;146:ITC3-1-ITC3-16.
Belch J, MacCuish A, Campbell I et al. The prevention of progression of arterial disease
and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin
and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.
BMJ 2008;337:a1840.
Fowkes FG, Price JF, Stewart MCW et al. Aspirin for prevention of cardiovascular events
in a general population screened for a low ankle brachial index: a randomized controlled
trial. JAMA 2010;303:841-8.
Berger JS, Kranz MJ, Kittelson JM et al. Aspirin for the prevention of cardiovascular
events in patients with peripheral artery disease. A meta-analysis of randomized trials.
JAMA 2009;301:1909-19.
Chevalier P. Aspirine voor alle patiënten met diabetes Minerva 2009;8:8-9. http://
www.minerva-ebm.be/nl/article.aspid=1608.

328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
Anonymous. Mehr Schaden als Nutzen durch ASS bei niedrigem Knöchel-Arm-Index.
Arzneitelegramm 2010;41:31.
Chevalier P. Lage enkelarmindex: aspirine toedienen als preventie Minerva Online
2010-05-27. http://www.minerva-ebm.be/nl/review.aspid=20. Bespreking van: Fowkes
FG, Price JF, Stewart MCW et al. Aspirin for prevention of cardiovascular events in a
general population screened for a low ankle brachial index: a randomized controlled
trial. JAMA 2010;303:841-848.
Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial
disease in the CHARISMA trial. Eur Heart J 2009;30:192-201.
Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S et al.
Oral anticoagulant and antiplatelet tjerapy and peripheral arterial disease. N Engl J
Med 2007;357:217-27.
De Backer T, Vander Stichele R, Lehert P et al. Naftidrofuryl for intermittent claudication:
meta-analysis based on individual patient data. BMJ 2009:338:b603.
National Institute for Health and Clinical Excellence. Cilostazol, naftidrofuryl oxalate,
pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in
people with peripheral arterial disease. NICE technology appraisal guidance 223. May
2011. http://guidance.nice.org.uk/TA223/Guidance/pdf/English.
Bijl D. Fatale cardiale en neurologische bijwerkingen van buflomedil. GeBu
2011;45:67-8. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Fatale-cardiale-enneurologische-bijwerkingen-van-buflomedil.htm.
Nicolaï SPA, Kruidenier LM, Bendermacher BLW et al. Ginkgo biloba for intermittent
claudication. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.:
CD006888. DOI: 10.1002/14651858.CD006888.pub2.
Martinez-Zapata, Bonfill Cosp X, Moreno RM. Phlebotonics for venous insufficiency.
Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD 003229. DOI:
10.1002/14651858.CD003229.pub2.
Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency.
Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD003230. DOI:
10.1002/14651858.CD003230.pub3.
Schweitzer BP, Doorenbosch J, Glotzbach R et al. NHG-Standaard ulcus cruris venosum.
Huisarts Wet 2000;43:128-33. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/
k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M16_svk.htm.
Nelson EA. Venous leg ulcers. BMJ Clinical Evidence 2011;12:1902. Search Date June
2011. http://clinicalevidence.bmj.com.
Anonymous. Risk of harm from compression stockings. Drug Ther Bull 2011;49:40.
PRODIGY. Thrombophlebitis - superficial. PRODIGY 2009. http://prodigy.clarity.co.uk
/thrombophlebitis_superficial.
Di Nisio M, Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitis of
the leg. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD 004982.
DOI: 10.1002/14651858.CD004982.pub3.
van Weert H, Dolan G, Wichers I et al. Oppervlakkinge tromboflebitis verhoogt het
risico op een diepe veneuze trombose. Huisarts Wet 2006;49:414-7.

344
345
346
347
348
Binder B, Lackner HK, Salmhofer W et al. Association between superficial vein
thrombosis and deep vein thrombosis of the lower extremities. Arch Dermatol
2009:145:753-7.
Decousus H, Quéré I, Presles E et al. Superficial venous thrombosis and venous
thromboembolism: a large prospective epidemiologic study. Ann Intern Med
2010;152:218-24.
Timmermans SH, Wlazlo N, Mom EMA, Stoffers HEJH. Tromboflebitis van het been.
Diagnostiek en behandeling door de huisarts. Ned Tijdschr Geneeskd 2010;154:A1098.
Decousus H, Prandoni P, Mismetti P et al. Fondaparinux for thetreatment of superficial
vein thrombosis in the legs. N Engl J Med 2010;363:1222-32.
Goldman L, Ginsberg J. Superficial phlebitis and phase 3.5 trials. N Engl J Med
2010;1278-80. Editoriaal bij: Decousus H, Prandoni P, Mismetti P et al. Fondaparinux
for thetreatment of superficial vein thrombosis in the legs. N Engl J Med
2010;363:1222-32.

Gastro-intestinaal stelsel
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
National Institute for Health and Clinical Excellence. Dyspespia: managing dyspepsia
in adults in primary care. NICE Clinical Guideline CG17, August 2004. http://guidan
ce.nice.org.uk/CG17/Guidance/pdf/English.
Kwaliteitsinstituut voor de Gezondheidszorg CBO, Nederlands Huisartsen Genootschap
(NHG). Multidisciplinaire Richtlijn Maagklachten 2004. http://www.diliguide.nl/docu
ment/2165/maagklachten.html.
Vakil N, Moayyedi P, Fennerty MB et al. Limited value of alarm features in the diagnosis
of upper gastrointestinal malignancy: systematic review and meta-analysis.
Gastroenterology 2006;131:390-401.
Loyd RA, McClellan DA. Update on the evaluation and management of functional
dyspepsia. Am Fam Physician 2011;83:547-52.
Veldhuyzen van Zanten S. Dyspespia and reflux in primary care: rough DIAMOND of
a trial. Lancet 2009;373:187-8.
Talley NJ, Vakil NH, Moayyedi P. American Gastroenterological Association technical
review on the evaluation of dyspepsia. Gastroenterology 2005;129:1756-80.
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van functionele
dyspepsie. Folia Pharmacotherapeutica 2007;34:13-4. http://www.bcfi.be/PDF/Folia/
2007/P34N02D.pdf.
Soo S, Forman D, Delaney BC et al. A systematic review of psychological therapies for
nonulcer dyspepsia. Am J Gastroenterol 2004;99:1817-22.
Anonymous. Therapie der Dyspepsie. Arznei-Telegramm 2008;39:95-7.
Duggan AE, Elliott CA, Miller P et al. Clinical trial: a randomized trial of early endoscopy,
H. pylori testing and empirical therapy for the management of dyspepsia in primary
care. Aliment Pharamcol Ther 2009;29:55-68.
Numans ME, de Wit NJ, Dirven JAM et al. NHG Standaard Maagklachten, tweede
herziening. Huisarts Wet 2003;690-700. http://nhg.artsennet.nl/kenniscentrum/k_richt
lijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M36_svk.htm.
van Marrewijk C, Mujakovic S, Fransen G et al. Effect and cost-effectiveness of step-up
versus step-down treatment with antacids, H2-receptor antagonists, and proton pump
inhibitors in patients with new onset dyspepsia (DIAMOND study): primary-care-based
randomised controlled trial. Lancet 2009;373:215-25.
PRODIGY. Dyspepsia: Proven non-ulcer. PRODIGY 2008. http://prodigy.clarity.co.uk/
dyspepsia_proven_non_ulcer.
Moayyedi P, Soo S, Deeks J et al. Pharmacological interventions for non-ulcer dyspepsia.
Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD001960. DOI:
10.1002/14651858.CD001960.pub3.
Abraham N, Moayyedi P, Daniels B et al. Systematic review: the methodological quality
of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia.
Aliment Pharmacol Ther 2004;19:631-41.

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
Veldhuyzen van Zanten S, Chiba N, Armstrong D et al. A randomized trial comparing
omeprazole, ranitidine, cisapride or placebo in Helcobacter pylori negative primary
care patients with dyspepsia: the CADET-HN study. Am J Gastroenterol
2005;100:1477-88.
Kleibeuker JH, Thijs JC. Functional dyspepsia. Curr Opin Gastroenterol 2004;20;546-50.
Delaney B, Qume M, Moayyedi P et al. Helicobacter pylori test and treat versus proton
pump inhibitor in initial management of dyspepsia in primary care: multicentre
randomised controlled trial (MRC-CUBE trial). BMJ 2008;336:651-4.
Lassen AT, Hallas J, Schaffalitzky de Muckadell OB. Helicobacter pylori test and eradicate
versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow up
of a randomised trial. Gut 2004;53:1758-63.
Duggan A, Elliott C, Miller P et al. Clinical trial: a randomized trial of early endoscopy,
Helicobacter pylori testing and empirical therapy for the management of dyspepsia in
primary care. Aliment Pharmacol Ther 2009;29:55-68.
Wildner-Christensen M, Møller Hansen J, Schaffalitzky De Muckadell OB. Rates of
dyspepsia one year after Helicobacter pylori screening and eradication in a Danish
population. Gastroenterology 2003;125:372-9.
Jarbol D, Kragstrup J, Stovring H et al. Proton pump inhibitor or testing for Helicobacter
pylori as the first step for patients presenting with dyspepsia A cluster-randomized
trial. Am J Gastroenterol 2006;101:1200-8.
de Wit NJ, van Barneveld TA, Festen HP et al. Richtlijn ‘Maagklachten’ Ned Tijdschr
Geneeskd 2005;149:1386-92.
Jackson JL, O’Malley PG, Tomkins G et al. Treatment of functional gastrointestinal
disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72.
Dickerson L, King D. Evaluation and management of nonulcer dyspepsia. Am Fam
Physician 2004;70:107-14.
Dent J, El-Serag H, Wallander M et al. Epidemiology of gastro-oesophageal reflux
disease: a systematic review. Gut 2005;54:710-7.
Pilotto A, Franceschi M, Paris F. Recent advances in the treatment of Gerd in the elderly:
focus on proton pump inhibitors. Int J Clin Pract 2005;59:1204-9.
Thomson AB. Gastro-oesophageal reflux in the elderly: role of drug therapy in
management. Drugs Aging 2001;18:409-14.
Lee J, Anggiansah A, Anggiansah R et al. Effects of age on the gastroesophageal
junction, oesophageal motility, and reflux disease. Clin Gastroenterol Hepatol
2007;5:1392-8.
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van maagklachten.
Transparantiefiche Juni 2010. http://www.bcfi.be/pdf/tft/TN_Maag_Lng.pdf.
Galmiche JP, Letessier E, Scarpignato C. Treatment of gastro-oesophageal reflux disease
in adults. BMJ 1998;316:1720-3.
Dent J, Jones R, Kahrilas P et al. Management of gastro-oesophageal reflux disease in
general practice. BMJ 2001;332:344-7.
Fass R, Ofman J. Gastroesophagal reflux disease – should we adopt a new conceptual
framework Am J Gastroenterol 2002;97:1901-9.

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Moayyedi P, Delaney B, Forman D. GORD in adults. BMJ Clinical Evidence 2008;06:403.
Search Date July 2007. http://clinicalevidence.bmj.com.
Kaltenbach T, Crockett S, Gerson L. Are lifestyle measures effective in patients with
gastroesophagal reflux disease Arch Intern Med 2006;166:965-71.
Rijksinstituut voor Ziekte- en Invaliditeitsverzekering. Doelmatig gebruik van
zuurremmers bij gastro-oesofagale reflux en dyspepsie. Juryrapport
Consensusvergadering RIZIV, 15 mei 2003. http://www.riziv.fgov.be/drug/nl/statisticsscientific-information/consensus/2003-05-15/pdf/lv.pdf.
Rédaction Prescrire. Les inhibiteurs de la pompe à protons chez l’adulte. Rev Prescrire
2001;21:687-92.
van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump
inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux
disease-like symptoms and endoscopy negative reflux disease. Cochrane Database of
Systematic Reviews 2006, Issue 1. Art. No.: CD002095. DOI: 10.1002/
14651858.CD002095.pub3.
van der Linden MW. Behandeling van gastro-oesofageale reflux en dyspepsie met
H2-receptorblokkerende geneesmiddelen en protonpompremmers. Gebu
2009;43:37-43. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Behandeling-vangastrooesofageale-reflux-en-dyspepsie-met-H2receptorblokkerende-geneesmiddelenen-protonpompremmers.htm.
Anonymous. Protonenpumpenhemmer: zu häufige Verordnung und Risiken bei
Dauertherapie. Arzneimittelbrief 2008;42:49-52.
Targownik L, Lix L, Metge C et al. Use of proton pump inhibitors and risk of
osteoporosis-related fractures. CMAJ 2008;179:319-26.
Targownik L, Lix L, Leung S et al. Proton pump inhibitor use is not associated with
osteoporosis or accelerated bone minral density loss. Gastroenterology
2009;136:A170-1.
Rédaction Prescrire. Inhibiteurs de la pompe à protons et fractures Rev Prescrire
2009;29:265.
Rédaction Prescrire. Inhibiteurs de la pompe à protons et fractures (suite) Rev Prescrire
2011;31:49.
Aseeri M, Schroeder T, Kramer J et al. Gastric acid suppression by proton pump
inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized
patients. Am J Gastroenterol 2008;103:2308-13.
Linsky A, Gupta K, Lawler E et al. Proton pump inhibitors and risk for recurrent
Clostridium difficile infection. Arch Intern Med 2010;170:772-8.
Belgisch Centrum voor Farmacotherapeutische Informatie. Mogelijke interactie tussen
de protonpompinhibitoren en clopidogrel: stand van zaken. Folia Pharmacotherapeutica
2010;37:1-2. http://www.bcfi.be/PDF/Folia/2010/P37N01B.pdf.
Ray W, Murray K, Griffin M et al. Outcomes with concurrent use of clopidogrel and
proton-pump inhibitors. Ann Intern Med 2010;52:337-45.
Belgisch Centrum voor Farmacotherapeutische Informatie. Protonpompinhibitoren en
clopidogrel: geen evidentie van klinisch significante interactie. Folia
Pharmacotherapeutica 2011;38:6-7. http://www.bcfi.be/PDF/Folia/2011/P38N01D.pdf.

50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
Eurich D, Sadowski C, Simpson S et al. Recurrent community-acquired pneumonia in
patients starting acid-suppressing drugs. Am J Med 2010;123:47-53.
Eom C-S, Jeon CY, Lim J-W et al. Use of acid-suppressive drugs and risk of pneumonia:
systematic review and meta-analysis. CMAJ 2011;183:310-9.
Meijvis SSA, Cornips MC, Voorn GP et al. Microbial evaluation of proton pump
inhibitors and the risk of pneumonia. Eur Resp J 2011;38:1165–72.
Rédaction Prescrire. Oméprazole: hypomagnésémies symptomatiques. Rev Prescrire
2010:30:672.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Tractus
digestivus / Protonpompremmers. Farmacotherapeutisch Kompas. 2011.http://
www.fk.cvz.nl.
Numans M et al. Proefbehandeling met protonpompremmers ongeschikt als test voor
gastro-oesofageale refluxziekte: een meta-analyse van de
diagnostische-testeigenschappen. Ned Tijdschr Geneeskd 2004;148:1924-8.
Rédaction Prescrire. Esoméprazole, un isomère de l’oméprazole, sans progrès
thérapeutique. Rev Prescrire 2002;22:248-50.
Spriet I. Overzicht van de beschikbare zuurremmers: door het bos de bomen zien.
Tijdschr voor Geneeskunde 2007;63:1125-30.
Moayyedi P, Santana J, Khan M, et al. Medical treatments in the short term
management of reflux oesophagitis. Cochrane Database of Systematic Reviews 2007,
Issue 2. Art. No.: CD003244. DOI: 10.1002/14651858.CD003244.pub2.
de Wit NJ, de Boer W, Geldhof H et al. Treatment of gastro-oesophagal reflux disease
with rabeprazole in primary and secondary care does Helicobacter pylori infection
affect proton pump inhibitor effectiveness Aliment Pharmacol Ther 2004;20:451-8.
Conio M. et al. Long-term endoscopic surveillance of patients with Barrett’s esophagus.
Incidence of dysplasia and adenocarcinoma: a prospective study. AJG 2003;98:1931-7.
Rédaction Prescrire. Inhibiteurs de la pompe à protons: quelle spécialité choisir Rev
Prescrire 2010;30:795.
Leontiadis G, Ford A, Moayyedi P. Helicobacter pylori infection. BMJ Clinical Evidence
2009;10:406. Search Date September 2007. http://clinicalevidence.bmj.com.
Dent J, Brun J, Fendrick AM, Fennerty AM, Janssens J, Kahrilas PJ, Lauritsen K, Reynolds
JC, Shaw M, Talley NJ. An evidence-based appraisal of reflux diseases management
– the Genval Workshop Report. Gut 1999;44(suppl 2):S1-S16.
PRODIGY. Dyspepsia: Proven peptic ulcer. PRODIGY 2008. http://prodigy.clarity.co.uk
/dyspepsia_proven_peptic_ulcer.
Ford AC, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease
in Helicobacter pylori positive patients. Cochrane Database of Systematic Reviews
2006, Issue 2. Art. No.: CD003840. DOI: 10.1002/14651858.CD003840.pub4.
Database of Abstracts of Reviews of Effect. Single vs. double dose of a proton pomp
inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Database
of Abstracts of Reviews of Effect 2010, Issue 4, CRD: DARE-12002001373.
Fuccio L, Minardi M, Zagari R e al. Meta-analysis: duration of first-line proton-pump
inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Intern Med
2007;147:553-62.

68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
Rédaction Prescrire. Hélicobacter pylori: peu de bénéfices à traiter plus de 7 jours. Rev
Prescrire 2008;28:927-8.
Jafri N, Hornung C, Howden C. Meta-analysis: sequential therapy appears superior to
standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann
Intern med 2008;148:923-31.
Rokkas T, Sechopoulos P, Robotis I et al. Cumulative H. pylori eradicaton rates in clinical
practice by adopting first and second-line regimens proposed by the Maastricht III
Consensus and a third-line empirical regimen. Am J Gastroenterol 2009;104:21-5.
Chey W, Wong B, Practice Parameters Committee of the American College of
Gastroenterology. American College of Gastroenterology guideline on the management
of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25.
Goldstein J, Johansen C, Hawkeye C et al. Healing of NSAID-associated gastric ulcers
in patients continuing NSAID therapy- a randomized study comparing ranitidine with
esomeprazole. Aliment Pharmacol Ther 2007;26:1101-11.
Troost SJ, Maring JG. Anti-emetica. Welk middel voor welke toepassing Pharma
Selecta 1997;13:82-6.
American Gastroenterological Association. American Gastroenterological Association
medical position statement: nausea and vomiting. Gastroenterology 2001;120:261-2.
Belgisch Centrum voor Farmacotherapeutische Informatie. Gecommentarieerd
Geneesmiddelenrepertorium 2011.http://www.bcfi.be
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Tractus
digestivus / Middelen bij misselijkheid en braken. Farmacotherapeutisch Kompas 2011.
http://www.fk.cvz.nl.
Belgisch Centrum voor Farmacotherapeutische Informatie. Behandeling van het
prikkelbare-darmsyndroom. Folia Pharmacotherapeutica 2009;36:98-9. http://www.bc
fi.be/PDF/Folia/2009/P36N11E.pdf
Rédaction Prescrire. Troubles fonctionnels intestinaux récurrents. Une évolution bénigne,
des traitements symptomatiques. Rev Prescrire 2008;28:359-64.
American College of Gastroenterology. An evidence-based systematic review on the
management of irritable bowel syndrome. Am J Gastroenterol 2009;104;S1-S35.
National Institute for Health and Clinical Excellence. Irritable bowel syndrome in adults.
Diagnosis and management of irritable bowel syndrome in primary care. NICE Clinical
Guideline CG61, February 2008. http://guidance.nice.org.uk/CG61/Guidance/pdf/En
glish
Bijkerk R, Muris J, Knottnerus A et al. Vezels zijn maar weinig effectief bij het
prikkelbaardarmsyndroom: een systematische review. Huisarts Wet 2005;48:158-64.
Ford A, Talley N, Veldhuyzen van Zanten S et al. Will the history and physical
examination help establish that irritable bowel syndrome is causing this patient’s lower
gastrointestinal tract symptoms JAMA 2008;300:1793-805.
Spiller R, Aziz Q, Creed F et al. Guidelines for the management of irritable bowel
syndrome: mechanisms and practical management. Gut 2007;56:1770-98.
Jellema P, van der Windt D, Schellevis F et al. Systematic review accuracy of
symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. Alim
Pharm Ther 2009;30:695-706.

85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
van der Horst HE. Het prikkelbaredarmsyndroom: is er een plaats voor medicamenteuze
therapie GeBu 2002;36:15-21. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Hetprikkelbaredarmsyndroom-is-er-een-plaats-voor-medicamenteuze-therapie.htm.
Mertz H. Irritable bowel syndrome. N Engl J Med 2003;349;2136-46.
Quartero AO, Meiniche-Schmidt V, Muris J et al. Bulking agents, antispasmodic and
antidepressant medication for the treatment of irritable bowel syndrome. Cochrane
Database of Systematic Reviews 2005, Issue 2. Art. No.: CD003460. DOI: 10.1002/
14651858.CD003460.pub2.
Ford AC, Talley NJ, Spiegel BM et al. Effect of fibre, antispasmodics, and peppermint
oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.
BMJ 2008;337:a2313.
Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal
disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72.
Anonymous. Probiotics for gastrointestinal disorders. Drug Ther Bull 2005;42:85-8.
Moayyedi P, Ford AC, Talley NJ et al. The efficacy of probiotics in the treatment of
irritable bowel syndrome: a systematic review. Gut 2010;59:325-32.
Bles H, Knuistingh Neven A. Probiotica bij irritable bowel syndrome. Huisarts Wet
2011;54:346.
Rédaction Prescrire. Des plantes pour soulager les troubles fonctionnels digestifs. La
menthe poivrée semble efficace. Rev Prescrire 2007;27:578-80.
Belgisch Centrum voor Farmacotherapeutische Informatie. Pepermuntolie magistraal
bij prikkelbare-darmsyndroom. Folia Pharmacotherapeutica 2010;37:78. http://www.bc
fi.be/PDF/Folia/2010/P37N09H.pdf.
Shen Y, Nahas R. Complementary and alternative medicine for treatment of irritable
bowel syndrome. Can Fam Physician 2009;55:143-8.
Ford A, Vandvik P. Irritable bowel syndrome. BMJ Clinical Evidence 2010;01:410.
Search Date July 2009. http://clinicalevidence.bmj.com.
Ford A, Talley N, Schoenfeld P et al. Efficacy of antidepressants and psychological
therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut
2009;58:367-78.
Cash B. Review: antidepressants and psychological therapies improve symptoms of
irritable bowel syndrome. Evid Based Med 2009;14:119.
Lesbros-Pantoflickova D, Michetti P, Fried M et al. Meta-analysis: the treatment of
irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:1253-69.
Camilleri M, Kim DY. What is the relevance of a systematic review of pharmacological
management in irritable bowel syndrome to older people J Am Geriatr Soc
2001;49:1252-2.
Kaptchuk TJ, Friedalnder E, Kelley JM et al. Placebos without deception: a randomized
controlled trial in irritable bowel syndrome. PLoS ONE 2010;5:e15591.
Stollman N, Raskin JP. Diverticular disease of the colon. Lancet 2004;363:631-9.
Jung H, Choung R, Locke G et al. Diarrhea-predominant irritable bowel syndrome is
associated with diverticular disease: a population-based study. Am J Gastroenterol
2010;105:652-61.

104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
PRODIGY. Diverticular disease. PRODIGY 2008. http://prodigy.clarity.co.uk/diverticu
lar_disease.
Draaisma W, van de Wall B, Vermeulen J et al. Geen goed onderzochte behandelingen
voor diverticulitis. Ned Tijdschr Geneeskd 2009;153:1919-23.
Aldoori W, Ryan-Harshman M. Preventing diverticular disease. Review of recent
evidence on high-fibre diets. Can Fam Physician 2002;48:1632-7.
Humes D, Smith J, Spiller R. Colonic diverticular disease. BMJ Clinical Evidence
2011;03:405. Search Date May 2010. http://clinicalevidence.bmj.com.
Kang JY, Melville D, Maxwell JD. Epidemiology and management of diverticular disease
of the colon. Drugs Aging 2004;21:211-28.
Smith J, Humes DJ, Spiller RC. Should we treat uncomplicated symptomatic diverticular
disease with fibre BMJ 2011;342:1306-7.
Declercq T. Obstipatie bij ouderen: hoe te behandelen Huisarts Nu (Minerva)
2001;30:429-30.
Anonymous. Managing constipation in the elderly. A CME-Accredited activity. Geriatrics
August 2007.
McCallum I, Ong S, Mercer-Jones M. Chronic constipation in adults. BMJ
2009;338:763-6.
Registered Nurses’ Association of Ontario. Prevention of Constipation in the Older
Adult Population. (Revised). RNAO Nursing Best Practice Guideline, Revised March
2005. http://www.rnao.org/Storage/11/610_BPG_Prevent_Constipation_rev05.pdf.
Diemel JM, Van den Hurk AP, Muris JW et al. NHG-Standaard Obstipatie. Huisarts Wet
2010;53:484-98. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaar
den/Samenvattingskaartje-NHGStandaard/M94_svk.htm.
American College of Gastroenterology Chronic Constipation Task Force. An
evidence-based approach to the management of chronic constipation in North America.
Am J Gastroenterol 2005;100(suppl 1):S1-S4.
Brandt L, Prather C, Quigley E et al. Systematic review on the management of chronic
constipation in North America. Am J Gastroenterol 2005;100(suppl 1):S5-S22.
Muller-Lisner S, Wald A. Constipation in adults. BMJ Clinical Evidence 2010;07:413.
Search Date October 2009. http://clinicalevidence.bmj.com.
Rédaction Prescrire. Constipation chez les adultes: traitement. Rev Prescrire
2010;30:373.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Tractus
digestivus / Obstipatie. Farmacotherapeutisch Kompas. 2011. http://www.fk.cvz.nl.
Attar A, Lémann M, Ferguson A et al. Comparison of a low dose polyethylene glycol
electrolyte solution with lactulose for treatment of chronic constipation. Gut
1999;44:226-30.
Ramkumar D, Rao S. Efficacy and safety of traditional medical therapies for chronic
constipation: a systematic review. Am J Gastroenterol 2005;10:936-71.
Rédaction Prescrire. Macrogol 3350, un laxatif osmotique de plus. Rev Prescrire
1998;181:94-5.
Lederle F, Busch D, Mattox K et al. Cost-effective treatment in the elderly. A randomized
double-blind comparison of sorbitol and lactulose. Am J Med 1990;89:597-601.

124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
Bosshard W, Dreher R, Schnegg J-F. et al. The treatment of chronic constipation in
elderly people. An update. Drugs Aging 2004;21:911-30.
Lederle FA. Epidemiology of constipation in elderly patients. Drug utilization and
cost-containment strategies. Drugs Aging 1995;6:465-9.
National Prescribing Centre. The management of constipation. MeReC Bulletin
2004;14:21-4. http://www.npc.nhs.uk/merec/other_non_clinical/resources/merec_bul
letin_vol14_no6.pdf.
Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol
for chronic constipation. Cochrane Database of Systematic Reviews 2010, Issue 7. Art.
No.: CD007570. DOI: 10.1002/14651858.CD007570.pub2.
Bijl D. Lactulose versus macrogol voor obstipatie: meta-analyse. GeBu 2011:45:69-70.
http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Lactulose-versus-macrogol-voor-ob
stipatie-metaanalyse.htm.
Chevalier P. De Cort R. Picosulfaat voor chronische obstipatie Minerva 2011;10:17-8.
http://www.minerva-ebm.be/nl/article.aspid=2007.
Katan M. De probiotische yoghurt Activia: versnelde darmpassage wel aangetoond,
maar bevordering van de stoelgang niet. Ned Tijdschr Geneeskd 2008;152:727-9.
PRODIGY. Gastroenteritis. PRODIGY 2007. http://prodigy.clarity.co.uk/gastroenteritis.
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van acute diarree.
Folia Pharmacotherapeutica 2005;32:64-8. http://www.bcfi.be/PDF/Folia/2005/
P32N08B.pdf.
Hiele M. Acute diarree bij volwassenen: oorzaken en behandeling. Tijdschr voor
Geneeskunde. 2008;64:1166-9.
Gottlieb T, Heather CS. Diarrhoea in adults (acute). BMJ Clinical Evidence 2011;02:901.
Search Date January 2010. http://clinicalevidence.bmj.com.
Hickson M, D’Souza A, Muthu N. et al. Use of probiotic Lactobacillus preparation to
prevent diarrhoea associated with antibiotics: randomised double blind placebo
controlled trial. BMJ 2007;335:80-3.
Anonymous. Probiotika zur Prophylaxe und Therapie van Durchfällen
Arznei-Telegramm 2007;38:89-91.
Rédaction Prescrire. Nifuroxazide dans la diarrhée aiguë. Rev Prescrire 1999;197:489-91.
Brühl Ph, Lammers H, Van Dongen A et al. NHG Standaard Acute diarree. Huisarts
Wet 2007;50:103-13. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstan
daarden/Samenvattingskaartje-NHGStandaard/M34_svk.htm.
World Health Organisation. Department of child and adolescent health and
development. Reduced osmolarity oral rehydration salts (ORS) formulation. Report
from a meeting of experts jointly organized by Unicef and WHO. Unicef House, New
York, USA, 18th July 2001.
Duggen C, Fontaine O, Pierce N et al. Scientific rationale for a change in the
composition of oral rehydration solution. JAMA 2004;291:2628-31.
Nalin D, Hirschhorn N, Greenough W et al. Clinical concerns about reduced-osmolarity
oral rehydration solution. JAMA 2004;291:2632-5.
World Health Organisation. Division of Diarrhoeal and Acute Respiratory Disease
Control. Rice-based oral rehydration salts. Update n° 7, August 1990.

143
144
145
146
147
148
149
150
151
152
153
154
National Health Service. Can potassium be given by subcutaneous infusion NeLM
Medicines Q&A 45.5, June 30, 2009. http://www.nelm.nhs.uk/en/NeLM-Area/Eviden
ce/Medicines-Q--A/Can-potassium-be-given-by-subcutaneous-infusion.
Rédaction Prescrire. La perfusion sous-cutanée. Efficace pour réhydrater des patients
âgés modérément déshydratés. Rev Prescrire 2004;250:372-6.
PRODIGY. Roundworm. PRODIGY 2007. http://prodigy.clarity.co.uk/roundworm.
Keiser J, Utzinger J Efficacy of current drugs against soil-transmittefd helminth
infections: systematic review and meta-analysis. JAMA 2008;299:1937-48.
PRODIGY. Threadworm. PRODIGY 2007. http://prodigy.clarity.co.uk/threadworm.
Nelson R. Anal fissure (Chronic). BMJ Clinical Evidence 2010;03:407. Search Date
August 2009. http://clinicalevidence.bmj.com.
Orsay C, Rakinic J, Perry W et al. Practice parameters for the management of anal
fissures(revised). Dis Colon Rectum 2004;47:2003-7.
Rédaction Prescrire. Fissures anales chroniques des adultes. Des moyens simples d’abord.
Rev Prescrire 2007;27:920-2.
Jensen SL. Treatment of first episodes of acute anal fissure: prospective randomised
study of lignocaine ointment versus hydrocortisone ointment or warm sitz baths plus
bran. BMJ 1986;292:1167-9.
Witte M, Klaase J. Gunstige resultaten van lokale injectie met botuline A toxine bij
patiënten met chronische anale fissuren die niet reageren op behandeling met
isosorbidedinitraatzalf. Ned Tijdschr Geneeskd 2006;150:1513-7.
Nelson R. Non surgical therapy for anal fissure. Cochrane Database of Systematic
Reviews 2006, Issue 3. Art. No.: CD003431. DOI: 10.1002/14651858.CD003431.pub2.
Nelson RL. Operative procedures for fissure in ano. Cochrane Database of Systematic
Reviews 2008, Issue 3. Art. No.: CD002199. DOI: 10.1002/14651858.CD002199.pub2.

Ademhalingsstelsel
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Irwin R, Baumann M, Bolser D et al. Diagnosis and management of cough executive
summary: ACCP evidence-based clinical practical guidelines. Chest
2006;129(suppl):1S-23S.
Morice A, McGarvey L, Pavord I and on behalf of the British Thoracic Society Cough
Guideline Group. Recommendations for the management of cough in adults. Thorax
2006;61:1-24.
Chung KF, Pavord I. Prevalence pathogenesis, and causes of chronic cough. Lancet
2008;371:1364-74.
Pavord I, Chung KF. Management of chronic cough. Lancet 2008;371:1375-84.
Verheij TJM, Hopstaken RM, Prins JM et al. NHG-Standaard acuut hoesten. Huisarts
Wet 2011;54:68–92 http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstan
daarden/Samenvattingskaartje-NHGStandaard/M78_svk.htm..
Smyrnios NA, Irwin RS, Curley FJ, French CL. From a prospective study of chronic
cough: diagnostic and therapeutic aspects in older adults. Arch Intern Med
1998;158:1222-8.
Widdicombe J, Kamath S. Acute cough in the elderly: aetiology, diagnosis and therapy.
Drugs Aging 2004;21:243-58.
Vertigan A, Theodoros D, Gibson P, Winkworht AL. Efficacy of speech pathology
management for chronic cough: a randomised placebo controlled trial of treatment
efficacy. Thorax 2006;61:1065-9.
Coenen S, Van Royen P, Van Poeck K et al. Aanbeveling voor goede medische
praktijkvoering: Acute hoest. Huisarts Nu 2002;31:391-411. http://www.domusmedi
ca.be/images/stories/aanbevelingen/hoest_ab.pdf.
Smith SM, Schroeder K, Fahey T. Over-the-counter medications for acute cough in
children and adults in ambulatory settings. Cochrane Database of Systematic Reviews
2008, Issue 1. Art. No.: CD001831. DOI: 10.1002/14651858.CD001831.pub3.
Lee PCL, Jawad MS, Eccles R. Antitussive efficacy of dextromethorphan in cough with
acute respiratory tract infection. J Pharm Pharmacol 2000;52:1137-42.
van Beek Z, Eekhof J, Knuistingh Neven A. Symptomatische behandeling van
niet-specifieke hoest. Huisarts Wet 2005;48:139-41.
Chang CC, Cheng AC, Chang AB. Over-the-counter (OTC) medications to reduce
cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane
Database of Systematic Reviews 2007, Issue 4. Art. No.: CD006088. DOI: 10.1002/
14651858.CD006088.pub2.
Anonymous. Neuropsychiatrische verschijnselen bij gebruik van dextromethorfaan.
GeBu 1998;32:11.
Anonymous. Potentieel misbruik van dextromethorfan bevattende hoestmiddelen.
GeBu 2005;39:142-3. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Potentieelmisbruik-van-dextromethorfan-bevattende-hoestmiddelen.htm..

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
Bijl D. Dextrometorfan. GeBu 2008;42:106. http://gebu.artsennet.nl/Archief/Tijdschrift
artikel/Dextromethorfan.htm.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Hoest.
Farmacotherapeutisch Kompas 2011.http://www.fk.cvz.nl.
Eccles R. Mechanisms of the placebo effect of sweet cough syrups. Respir Physiol
Neurobiol 2006;152:340-8.
Ponsioen B, Hop W, Vermue N et al. De werkzaamheid van fluticason bij hoesten: een
gerandomiseerde dubbelblinde placebo-gecontroleerde trial. Huisarts Wet
2006;49:62-67.
Chang AB, Lasserson TJ, Gaffney J et al. Gastro-oesophageal reflux treatment for
prolonged non-specific cough in children and adults. Cochrane Database of Systematic
Reviews 2011, Issue 1. Art. No.: CD004823. DOI: 10.1002/14651858.CD004823.pub4.
Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet 2010;376:803-13.
Bellia V, Battaglia S, Catalano F et al. Aging and disability affect misdiagnosis of COPD
in elderly astmatics. The SARA study. Chest 2003;123:1066-72.
Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma
(GINA). 2010 http://www.ginasthma.org.
Scottish Intercollegiate Guidelines Network. British Guideline on the management of
asthma. SIGN Clinical Guideline No. 101. May 2008, revised May 2011. http://
www.sign.ac.uk/pdf/sign101.pdf.
Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of
pressurised metered dose inhalers versus other hand held inhaler devices for delivering
corticosteroids in asthma. BMJ 2001;323:896-900.
Ram F, Wright J, Brocklebank D et al. Systematic review of clinical effectiveness of
pressurised metered dose inhalers versus other hand held inhaler devices for delivering
beta2 agonist bronchodilators in asthma. BMJ 2001;323:901-7.
Cates C, Crilly J, Rowe B. Holding chambers (spacers) versus nebulisers for beta-agonist
treatment of acute asthma. Cochrane Database of Systematic Reviews 2008, Issue 3.
Art. No.: CD000052. DOI: 10.1002/14651858.CD000052.pub2
PRODIGY. Asthma. PRODIGY 2008. http://prodigy.clarity.co.uk/asthma..
Dolovich M, Ahrens R, Hess D et al. Device selection and outcomes of aerosol therapy:
evidence-based guidelines: American College of Chest Physicians/American College
of Asthma, Allergy and Immunology. Chest 2005;127:335-71.
SIT Stad Gent. DVD: Correct gebruik van inhalatiemedicatie bij astma of COPD. 2004.
http://www.farmaka.be/home.phpusub=42&nav=4&lang=be_NL.
Mehuys E. Het belang van de inhalatietechniek bij de behandeling van astma. Tijdschr
voor Geneeskd 2008;64:299-303.
Gajadin S, van den Blink B. Inhalatiemedicatie: niet alleen voorschrijven, ook voordoen.
Ned Tijdschr Geneeskd 2011;155:86).
Dolovich MB, Dhand R. Aerosol drug delivery: development in device design and clinical
use. Lancet 2011;377:1032-45.
Dekhuijzen P, van Schayck C, Wesseling G et al. Behandeling van astma: aanwijzingen
voor een verandering van aanpak. Ned Tijdschr Geneeskd 2006;150:237-41.

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
Thomas S, Bueving HJ. De standaard ‘Astma bij volwassenen’ (tweede herziening’)
van het Nederlands Huisartsen Genootschap; reactie vanuit de huisartsgeneeskunde.
Ned Tijdschr Geneeskd 2008;152:1136-7.
Belgisch Centrum voor Farmacotherapeutische Informatie. Farmacotherapie bij
chronisch astma. Folia Pharmacotherapeutica 2005;32:91-9. http://www.bcfi.be/PDF
/Folia/2005/P32N11B.pdf.
Dennis R, Solarte I. Asthma in adults (chronic). BMJ Clinical Evidence 2011;07:1512;
Search Date April 2010.http://clinicalevidence.bmj.com.
Salpeter S. Cardiovascular safety of β2-adrenoceptor agonist use in patients with
obstructive airway disease. Drugs Aging 2004;21:405-14.
Lipworth BJ. Treatment of acute asthma. Lancet 1997; 350 (suppl II):18-23.
Westby MJ, Benson MK, Gibson PG. Anticholinergic agents for chronic asthma in
adults. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD003269.
DOI: 10.1002/14651858.CD003269.pub2.
Bateman E, Boushey H, Bousquet J et al. Can guideline-defined asthma control be
achieved The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med
2004;170:836-44.
O’Byrne P, Bisgaard H, Godard P et al. Budesonide/formoterol combination therapy
as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med
2005;171:129-36.
Rabe K, Atienza T, Magyar P et al. Effect of budesonide in combination with formoterol
for reliever therapy in asthma exacerbations: a randomised controlled, double-blind
study. Lancet 2006;368:744-53.
Rabe K, Pizzichini E, Ställberg B et al. Budesonide/fomoterol in a single inhaler for
maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial.
Chest 2006;129:246-56.
National Prescribing Service. Budesonide with eformoterol dry powder inhaler
(Symbicort) maintenance and reliever regimen for asthma. NPS RADAR, 1 August
2007. http://www.nps.org.au/health_professionals/publications/nps_radar/issues/cur
rent/august_2007/budesonide_with_eformoterol.
Rédaction Prescrire. Budésonide + formotérol et crise d’asthme: une régression. Rev
Prescrire 2007;27:901-2.
Cates CJ, Lasserson TJ. Combination formoterol and budesonide as maintenance and
reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and
children. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD007313.
DOI: 10.1002/14651858.CD007313.pub2
Powell H, Gibson P. Initial starting dose of inhaled corticosteroids in adults with asthma:
a systematic review. Thorax 2004;59:1041-5.
Leone F, Fish J, Szefler S et al. Systemic review of the evidence regarding potential
complications of inhaled corticosteroid use in asthma. Chest 2003;124:2329-40.
Adams NP, Lasserson TJ, Cates CJ, Jones P. Fluticasone versus beclomethasone or
budesonide for chronic asthma in adults and children. Cochrane Database of Systematic
Reviews 2007, Issue 3. Art. No.: CD002310. DOI: 10.1002/14651858.CD002310.pub4

51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Adams N, Bestall J, Malouf R et al. Inhaled beclometasone versus placebo for chronic
asthma. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD002738.
DOI: 10.1002/14651858.CD002738.pub2.
Shepherd J, Rogers G, Anderson R et al. Systematic review and economic analysis of
the comparative effectiveness of different inhaled corticosteroids and their usage with
long-acting beta2-agonists for the treatment of chronic asthma in adults and children
aged 12 years and over. Health Technol Assess 2008;12(20):1-174. http://
www.hta.ac.uk/execsumm/summ1220.htm.
National Heart, Lung and Blood Institute. National Asthma Education and Prevention
Program. Expert panel report. Guidelines for the diagnosis and management of asthma.
2007.http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.
Adams NP, Bestall JC, Jones P. Beclomethasone at different doses for chronic asthma.
Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No.: CD002879. DOI:
10.1002/14651858.CD002879.
Adams NP, Bestall JC, Jones P, et al. Fluticasone at different doses for chronic asthma
in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 3. Art.
No.: CD003534. DOI: 10.1002/14651858.CD003534.pub3.
Chevalier P. Inhalatiecorticosteroïden bij astma: dosis Minerva 2009;8:55. http://
www.minerva-ebm.be/nl/article.aspid=1679.
National Institute for Health and Clinical Excellence. Asthma (in adults) - corticosteroids.
NICE Technology appraisal guidance 138. March 2008. http://www.nice.org.uk/nice
media/live/11945/40099/40099.pdf.
Ni Chroinin M, Greenstone IIG, Ducharme F, Masse V, Danish A. Long-acting
beta2-agonists versus placebo in addition to inhaled corticosteroids in children and
adults with chronic asthma. Cochrane Database of Systematic Reviews 2005, Issue 4.
Art. No.: CD005535. DOI: 10.1002/14651858.CD005535.
Dekhuijzen P. Voorzichtigheid geboden bij het voorschrijven van lang werkende
β2-adrenerge agonisten aan patiënten met astma. Ned Tijdschr Geneeskd
2006;150:889-91.
Walters EH, Gibson PG, Lasserson TJ, Walters JAE. Long-acting beta2-agonists for
chronic asthma in adults and children where background therapy contains varied or
no inhaled corticosteroid. Cochrane Database of Systematic Reviews 2007, Issue 1.
Art. No.: CD001385. DOI: 10.1002/14651858.CD001385.pub2.
Beasley R, Perrin K, Weatherall M. Call for withdrawal of LABA single-therapy inhaler
in asthma. Lancet 2010;376:750-1.
Rédaction Prescrire. Traitement de l’asthme au long cours. Adapter la corticothérapie
à la sévérité. Rev Prescrire 2007;27:522-6.
Salpeter S, Buckley N, Ormiston T. et al. Meta-analysis: effect of long-acting β2-agonists
on severe asthma exacerbations and asthma-related deaths. Ann Intern Med
2006;114:904-12.
Nelson H, Weiss S, Bleecker E et al. The salmeterol multicenter asthma research trial.
A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus
salmeterol. Chest 2006;129:15-26.
O’Byrne P, Ädelroth E. β2 Déjà vu. Chest 2006;129:3-5.

66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
Glassroth J. The role of long-acting β2-agonists in the management of asthma: analysis,
meta-analysis, and more analysis. Ann Intern Med 2006;144:936-7.
Belgisch Centrum voor Farmacotherapeutische Informatie.. In verband met de
langwerkende β2-mimetica. Folia Pharmacotherapeutica 2006;33:52–53. http://www.bc
fi.be/PDF/Folia/2006/P33N06E.pdf.
Ernst P, McIvor A, Ducharme F et al. Safety and effectiveness of long-acting inhaled
β-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med
2006;145:692-4.
Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic
asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue
4. Art. No.: CD006923. DOI: 10.1002/14651858.CD006923.pub2.
Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with formoterol and inhaled
steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic
Reviews 2009, Issue 2. Art. No.: CD006924. DOI: 10.1002/14651858.CD006924.pub2
Kips JC, Pauwels RA. Long-acting inhaled beta2-agonist therapy in asthma. Am J Respir
Crit Care Med 2001;164:923-32.
Rédaction Prescrire. Compléments de gamme. Fluticasone + salmétérol. Rev Prescrire
2001;21:664-5.
Regional Drug and Therapeutics Centre. Steroid/long-acting beta2 agonist combination
inhalers in asthma and COPD. Drug Update N° 39. March 2005. http://
www.nyrdtc.nhs.uk/docs/dud/DU_39_Steroid_Long_Acting_Beta2_a.pdf
Rédaction Prescrire. Asthme: en rester à deux spécialités séparées. Rev Prescrire
2008;28:328.
Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of inhaled
long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma
in steroid-naive adults and children. Cochrane Database of Systematic Reviews 2009,
Issue 4. Art. No.: CD005307. DOI: 10.1002/14651858.CD005307.pub2.
Anonymous. Seretide® and Symbicort® in asthma management. Drug Ther Bull
2002;40:62-4.
Peters SP, Kunselman SJ, Icitovic N et al. Tiotropium bromide step-up therapy for adults
with uncontrolled asthma (TALC-study). N Eng J Med 2010; 363:1715-26.
Chevalier P. Tiotropium ook geschikt voor astma Minerva 2010;9:110-1. http://
www.minerva-ebm.be/nl/article.aspid=1978.
The American Lung Association Asthma Clinical Research Centers. Clinical trial of
low-dose theophylline and montelukast in patients with poorly controlled asthma. Am
J Respir Crit Care Med 2007;175:223-34.
Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single
agent asthma treatment: systematic review of current evidence. BMJ 2003;621-5.
Price D, Musgrave SD, Shepstone L et al. Leukotriene antagonists as First-line or add-on
asthma-controller therapy. N Engl J Med 2011;364:1695-1707.
Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in
patients with astma:systematic review of current evidence. BMJ 2002;324:1545-8.
Diamant Z, Dekhuyzen PN. Behandeling van matig, persisterend astma:
inhalatiecorticosteroïden combineren met langwerkende 2-adrenerge agonisten

84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
(luchtverwijders) dan wel met leukotrieenreceptorantagonisten (ontstekingsremmers);
het ‘stap-3-dilemma’. Ned Tijdschr Geneeskd 2003;147:1681-5.
Vaquerizo MJ, Casan P, Castillo J et al. CASIOPEA (Capacidad de Singulair Oral en la
Prevencion de Exacerbaciones Asmaticas) Study Group. Effect of montelukast added
to inhaled budesonide on control of mild to moderate asthma. Thorax 2003;58:204-10.
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van een acute
astma-aanval in de eerste lijn. Folia Pharmacotherapuetica 2008;35:19-22. http://
www.bcfi.be/PDF/Folia/2008/P35N03B.pdf.
Rodrigo G, Castro-Rodriguez J. Anticholinergics in the treatment of children and adults
with acute asthma: a systematic review with meta-analysis. Thorax 2005;60:740-6.
Rowe BH, Spooner C, Ducharme F, Bretzlaff J , Bota G. Corticosteroids for preventing
relapse following acute exacerbations of asthma. Cochrane Database of Systematic
Reviews 2007, Issue 3. Art. No.: CD000195. DOI: 10.1002/14651858.CD000195.pub2.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Astma.
Farmacotherapeutisch Kompas 2011. http://www.fk.cvz.nl.
Parameswaran K, Belda J, Rowe BH. Addition of intravenous aminophylline to
beta2-agonists in adults with acute asthma. Cochrane Database of Systematic Reviews
2000, Issue 4. Art. No.: CD002742. DOI: 10.1002/14651858.CD002742.
Sheikh A, Alves B, Dhami S. Pneumococcal vaccine for asthma. Cochrane Database
of Systematic Reviews 2008, Issue 3. Art. No.: CD002165. DOI: 10.1002/
14651858.CD002165.
Global Strategy for the Diagnosis, Management and Prevention of COPD. Global
Initiative for Chronic Obstructive Lung Disease (GOLD). 2010. http://www.goldcopd.org.
Vaz Fragoso CA. Defining chronic obstructive pulmonary disease in an aging population.
JAGS 2010;58:2224-6.
McIvor RA, Tunks M, Todd DC. COPD BMJ Clinical Evidence 2011;06:1502. Search
Date April 2010. http://clinicalevidence.bmj.com.
Anonymous. Preventing exacerbations in chronic obstructive pulmonary disease. DTB
2010;48:74-7.
Casaburi R, ZuWllack R. Pulmonary rehabilitation for management of chronic obstructive
pulmonary disease. N Engl J Med 2009;360:1329-35.
Maltais F, Bourbeau J, Shapiro S et al. Effects of home-based pulmonary rehabilitation
in patients with chronic obstructive pulmonary disease. Ann Intern Med
2008;149:869-78.
Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic
obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue
2. Art. No.: CD003793. DOI: 10.1002/14651858.CD003793.pub2.
Kwaliteitsinstituut voor de Gezondheidszorg CBO. Conceptrichtlijn Ketenzorg COPD.
Actualisatie maart 2010.http://www.diliguide.nl/document/2487/copd-diagnostieken-behandeling-van.html.
Beauchamp MK, Nonoyama M, Goldstein RS et al. Interval versus continuous training
in individuals with chronic obstructive pulmonary disease: a systematic review. Thorax
2010;65:157-64.

100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
Appleton S, Jones T, Poole P, Pilotto L, Adams R, Lasserson TJ, Smith B, Muhammed
J. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive
pulmonary disease. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.:
CD001387. DOI: 10.1002/14651858.CD001387.pub2.
Salpeter S, Buckley N, Salpeter E. Meta-analysis: anticholinergica, but not β2-agonists,
reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med
2006;21:1011-9.
National Institute of Health and Clinical Excellence. Chronic obstructive pulmonary
disease: Management of chronic obstructive pulmonary disease in adults in primary
and secondary care. NICE Clinical Guideline N° 101, June 2010. http://guidance.ni
ce.org.uk/CG101/Guidance/pdf/English.
Barr RG, Bourbeau J, Camargo CA, Ram FSF. Tiotropium for stable chronic obstructive
pulmonary disease. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.:
CD002876. DOI: 10.1002/14651858.CD002876.pub2.
Vincken W. Improved health outcomes in patients with COPD during one year’s
treatment with tiotropium. Eur Respir J 2002;19:209-16.
Neyt M, Van den Bruel A, Gailly J et al. Tiotropium in de behandeling van Chronisch
Obstructief Longlijden (COPD): Health Technology Assessment (HTA). Brussel: Federaal
Kenniscentrum voor de Gezondheidszorg (KCE). 2009. KCE reports 108A. http://
www.kce.fgov.be/sites/default/files/page_documents/d20091027318.pdf.
Singh S, Loke Y, Furberg C et al. Inhaled anticholinergics and risk of major adverse
cardiovascular events in patients with chronic obstructive pulmonary disease: a systemic
review and meta-analysis. JAMA 2008;300:1439-50
Tashkin D, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive
pulmonary disease. N Engl J Med 2008;359:1543-54.
Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium. The FDA conclusions. N Engl
J Med 2010;363:1097-9.
Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MM, Cates CJ. Long-acting
beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane
Database of Systematic Reviews 2006, Issue 3. Art. No.: CD001104. DOI: 10.1002/
14651858.CD001104.pub2.
Dahl R., Fan Chung K, Buhl R et al. Efficacity of a new once-daily long-acting inhaled
beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax
2010;65:473-9.
Donohue JF, Fogarty C, Lötvall J et al. INHANCE Study Investigators. Once-daily
bronchodilatators for chronic obstructive pulmonary disease: indacaterol versus
tiotropium. Am J Respir Crit Care Med 2010;18:155-62.
Kornmann O, Dahl R, Centanni S et al. Once-daily indacaterol versus twice-daily
salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37:273-9.
Belgisch Centrum voor Farmacotherapeutische Informatie.. Recente informatie april
2011:. Indacaterol (Onbrez Breezhaler®). Folia Pharmacotherapeutica 2011;38:44.
http://www.bcfi.be/PDF/Folia/2011/P38N05D.pdf.
Chevalier P. Indacaterol, een nieuw bèta-2-mimeticum voor de behandeling van COPD
Minerva 2011;10:10-1. http://www.minerva-ebm.be/nl/article.aspid=1996.

115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
Rédaction Prescrire. Indacatérol. Un bêta-2 stimulant de longue durée d’action, sans
plus dans la BPCO. Rev Prescrire 2011;31:328-32.
Finnish Medical Society Duodecim. COPD in: EBM Guidelines. Duodecim Medical
Publications Ltd; 2005.
Kerstjens HA, Postma DS. Medicamenteuze onderhoudsbehandeling bij chronisch
obstructief longlijden (COPD). Ned Tijdschr Geneeskd 2002;146:1631-5.
Yang IA, Fong KM, Sim EHA, Black PN, Lasserson TJ. Inhaled corticosteroids for stable
chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews
2007, Issue 2. Art. No.: CD002991. DOI: 10.1002/14651858.CD002991.pub2.
Drummond MB, Dasenbrook EC, Pitz MW et al. Inhaled corticosteroids in patients
with stable chronic obstructive pulmomary disease: a systematic review and
meta-analysis. JAMA 2008;300:2407-16.
Singh S, Amin A, Loke Y. Long-term use of inhaled corticosteroids and the risk of
pneumonia in chronic obstructive pulmonary disease. A meta-analysis. Arch Intern
Med 2009;169:219-29.
Hubbard R. et al. Inhaled corticosteroids and hip fracture: a population-based case
control study. Am J Respir Crit Care Med 2002;166:1563-6.
Kanda N. et al. Prevalence of esophageal candidiasis among patients treated with
inhaled fluticasone propionate. AJG 2003;98:2146-8.
Marcovitch H. High dose inhaled steroids pose cataract risk. BMJ 2003;327:833
Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol
in the management of chronic obstructive pulmonary disease. Eur Respir J
2003;21:74-81.
Calverley P. et al. Maintenance therapy with budesonide and formoterol in chronic
obstructive pulmonary disease. Eur Resp J 2003;32:912-9.
Calverley P, Pauwels R, Vestbo J et al. Combined salmeterol and fluticasone in the
treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Lancet 2003;361:449-56.
Hanania N, Darken P, Horstmann D et al. The efficacy and safety of fluticasone
propionate (250µg)/salmeterol(50µg) combined in the diskus inhaler for the treatment
of COPD. Chest 2003;124:834-43.
Jadwiga A, Calverley P, Seemungal T et al. The prevention of chronic obstructive
pulmonary disease exacerbation by salmeterol/fluticasone propionate or tiotropium
bromide. Am J Respir Crit Care Med 2008;177:19-26
Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and
survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting
beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary
disease. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD006826.
DOI: 10.1002/14651858.CD006826.
Rédaction Prescrire. BPCO: pas de fluticasone + salmétérol. Rev Prescrire 2007;27:692
Anonymous. Are Seretide and Symbicort useful in COPD DTB 2004;42:18-21.

133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
Aaron S, Vandemheen K, Fergusson D et al. Tiotropium in combination with placebo,
salmeterol or fluticasone-salmeterol for treatment of chronic obstructive pulmonary
disease. A randomised trial. Ann Intern Med 2007;146:545-5.
Karner C, Cates CJ. Combination inhaled steroid and long-acting beta2-agonist in
addition to tiotropium versus tiotropium or combination alone for chronic obstructive
pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No.:
CD008532. DOI: 10.1002/14651858.CD008532.pub2
Walters JAE, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic
obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005, Issue
3. Art. No.: CD005374. DOI: 10.1002/14651858.CD005374.
Ram F, Jardin J, Atallah A et al. Efficacy of theophylline in people with stable chronic
obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med
2005;99:135-44.
Currie G, Lee D, Lipworth B. ABC of chronic obstructive pulmonary disease.
Pharmacological management –oral treatment. BMJ 2006;332:1497-9.
Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive
pulmonary disease. Cochrane Database of Systematic Reviews 2010, Issue 2. Art. No.:
CD001287. DOI: 10.1002/14651858.CD001287.pub3.
Gerrits C, Herings R, Leufkens H et al. N-acetylscysteine reduces the risk of
re-hospitailisation among patients with chronic obstructive pulmonary disease. Eur
Respir J 2003;21:795-8.
Decramer M, Rutten-van Mölken M, Dekhuijzen P et al. Effects of N-acetylcysteine on
outcomes in chronic obstructive pulmonary disease (Bronchitis randomized on NAC
cost-utility, BRONCUS) a randomised placebo-controlled trial. Lancet 2005;365:1552-60.
Zheng J, Kang J, Huang S et al. Effect of carbocisteine on acute exacerbation of chronic
obstructive pulmonary disease (PEACE-study): a randomised placebo-controlled study.
Lancet 2008;371:2013-8.
Albert P, Calverley P. A PEACE-ful solution to COPD exacerbations Lancet
2008:371:1975-6.
Cranston JM, Crockett A, Moss J, Alpers JH. Domiciliary oxygen for chronic obstructive
pulmonary disease. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.:
CD001744. DOI: 10.1002/14651858.CD001744.pub2.
Van Meerhaeghe A, Annemans L, Haentjens P et al. Zuurstoftherapie thuis. Federaal
Kenniscentrum voor de Gezondheidszorg, KCE Reports Vol. 156A, Juni 2011. http://
www.kce.fgov.be/sites/default/files/page_documents/kce_156a_zuurstoftherapie.pdf.
PRODIGY. Chronic obstructive pulmonary disease. PRODIGY 2010. http://prodigy.cla
rity.co.uk/chronic_obstructive_pulmonary_disease.
Walters JAE, Gibson PG, Wood-Baker R, Hannay M, Walters EH. Systemic corticosteroids
for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database
of Systematic Reviews 2008, Issue 4. Art. No.: CD001288. DOI: 10.1002/
14651858.CD001288.pub3.
Quon B, Qi Gan W, Sin D. Contemporary management of acute exacerbations of
COPD: a systematic review and meta-analysis. Chest 2008;13:756-66.

148
149
150
151
152
153
Aaron S. et al. Outpatient oral prednisolone after emergency treatment of chronic
obstructive pulmonary disease. N Engl J Med 2003;348:2618-24.
Niewoehner D, Erbland M, Deupree R et al. Effect of systemic glucocorticoids on
exacerbations of chronic obstructive pulmonary disease. N Engl J Med
1999;340:1941-53.
Barr G. et al. Methylxanthines for exacerbations of chronic obstructive pulmonary
disease: meta-analysis of randomised trials. BMJ 2003;327:643-6.
Ram F, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC.
Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane
Database of Systematic Reviews 2006, Issue 2. Art. No.: CD004403. DOI: 10.1002/
14651858.CD004403.pub2.
Puhan M, Vollenweider D, Steurer J et al. Where is the supporting evidence for treating
mild to moderate chronic obstructive pulmonary disease exacerbations with antbiotics
A systematic review. BMC Med 2008;6:28.
Puhan M, Scharplatz M, Troosters T et al. Pulmonary rehabilitation following
exacerbations of chronic obstructive pulmonary disease. Cochrane Database of
Systematic Reviews 2009, Issue 1. Art. No.: CD005305. DOI: 10.1002/
14651858.CD005305.pub2.

Hormonaal stelsel
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Belgisch Centrum voor Farmacotherapeutische Informatie. Type 2-diabetes en orale
antidiabetica. Folia Pharmacotherapeutica 2003;30:28-32. http://www.bcfi.be/PDF/Fo
lia/2003/P30N04B.pdf.
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van diabetes type
2. Transparantiefiche Januari 2008. http://www.bcfi.be/pdf/tft/TN_DIAB.pdf .
Belgisch Centrum voor Farmacotherapeutische Informatie. Geglycosyleerd hemoglobine
(HbA1c) sinds 1 juni 2011 uitgedrukt in mmol/mol. Folia Pharmacotherapeutica
2011;38:62. http://www.bcfi.be/PDF/Folia/2011/P38N07E.pdf.
Belgisch Centrum voor Farmacotherapeutische Informatie. Intensieve behandeling van
type 2-diabetes. Folia Pharmacotherapeutica 2010;37:96. http://www.bcfi.be/PDF/Fo
lia/2010/P37N11C.pdf.
Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type
2 diabetes. N Engl J Med 2008;358:2545-59.
Patel A, MacMahon S, Chalmers J et al. Effects of intensive blood glucose control on
vascular outcomes in patients with type 2 diabetes mellitus: results of the ADVANCE
trial. N Engl J Med 2008;358:2560-2572.
Duckworth W, Abraira C, Moritz T et al. Glucose Control and Vascular Complications
in Veterans with Type 2 Diabetes. N Engl J Med 2009;360:129-39.
Hemmingsen B, Lund SS, Gluud C et al. Targeting intensive glycaemic control versus
targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane
Database of Systematic Reviews 2011, Issue 6. Art. N°. :CD008143. DOI : 10.1002/
14651858.CD008143.pub2.
Wens J, Sunaert P, Nobels F et al. Aanbeveling voor goede medische praktijkvoering:
Diabetes mellitus type 2. Wetenschappelijke Vereniging Vlaamse Huisartsen, Vlaamse
Diabetesvereniging, 2005. http://www.zorgtraject.be/NL/Bibliotheek/pdf/N_RBP_Dia
betes2_NL.pdf.
Redactie WZC-Formularium. Type 2-diabetes bij ouderen: specifieke aandachtspunten
en praktische aanbevelingen. Geneesmiddelenbrief 2009;16:17-28. http://www.far
maka.be/nl/geneesmiddelenbrief/2009_06_geneesmiddelenbrief.pdf .
Lee SJ, Eng C. Goals of glycemic control in frail older patients with diabetes. JAMA
2011;305;1350-51.
Roussel R, Travert F, Pasquet B et al. Metformin use and mortality among patients
with diabetes and atherothrombosis. Arch Intern Med 2010 ;170:1892-1899.
Evans JMM, Doney ASF, Alzadjali MA et al. Effect of metformin on mortality in patients
with heart failure and type 2 diabetes mellitus. Am J Cardiol 2010;106:1006-10.
Bennett W, Maruthur NM, Singh S et al. Comparative effectiveness and safety of
medications for type 2 diabetes : an update including new drugs and 2-drug
combinations. Ann Intern Med 2011;155:67-68.
Kooy A, de Jager J, Lehert P et al. Meerwaarde van toevoeging metformine aan
insulinetherapie bij type 2-diabetes. Ned Tijdschr Geneeskunde 2009;153:1005-13.

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Kooy A, de Jager J, Lehert P et al. Long-term effects of metformin on metabolism and
microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
Arch Intern Med 2009;169:616-25.
Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic
acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of
Systematic Reviews 2010, Issue 4. Art. No.: CD002967. DOI: 10.1002/
14651858.CD002967.pub4.
Rutten GEHM, De Grauw WJC, Nijpels G et al. NHG-standaard diabetes mellitus type
2. Huisarts Wet 2006;49:137-152.http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen
/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M01_svk.htm.
National Institute for Health and Clinical Excellence. Type 2 diabetes: the management
of type 2 diabetes. NICE Clinical Guideline 87, May 2009. http://guidance.nice.org.uk
/CG87/Guidance/pdf/English.
Smits P. Orale bloedglucoseverlagende geneesmiddelen. GeBu 2000;34:103-10.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control
with metformin on complications in overweight patients with type 2 diabetes (UKPDS
34). Lancet 1998;352:854-5.
Davis TM, Colagiuri S. The continuing legacy of the United Kingdom prospective
diabetes study. Med J Aust 2004;180:104-5.
Sillars B, Davis WA, Hirsch IB et al. Sulphonylurea-metformin combination therapy,
cardiovascular disease and all-cause mortality : the Fremantle Diabetes Study. Diabetes
Obes Metab 2010;12:757-65.
Waugh N, Cummins E, Royle P et al. Newer agents for blood glucose control in type
2 diabetes : systematic review and economic evaluation. Health Technol Assess
2010;14:1-248.
Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular
events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone
Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet
2005;366:1279-89.
van Driel M, Christiaens T. Pioglitazon bij diabetes: ongefundeerd optimisme. Minerva
2006;5:74-76.http://www.minerva-ebm.be/nl/article.aspid=1125.
Belgisch Centrum voor Farmacotherapeutische Informatie. Verhoogd risico van fracturen
door glitazonen. Folia farmacotherapeutica 2008;35:59. http://www.bcfi.be/PDF/Folia
/2008/P35N07D.pdf.
Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in
type 2 diabetes: a meta-analysis CMAJ 2009;180:32-9.
Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten. Rosiglitazone:
aanbeveling van EMA tot schorsing van de vergunning voor het in de handel brengen
(VHB) van Avandia, Avandamet en Avaglim. AFMPS News, 23 september 2010.
http://www.fagg-afmps.be/nl/news/news_rosiglitazone_2010_09_23.jsp.
Rédaction Prescrire. Répaglinide : un hypoglycémiant oral sans intérêt clinique. Rev
Prescrire 2010;30:820-21.

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
Belgisch Centrum voor Farmacotherapeutische Informatie. Ongewenste effecten van
drie nieuwe antidiabetica: exenatide, sitagliptine en vildagliptine. Folia
Pharmacotherapeutica 2009;36:54. http://www.bcfi.be/PDF/Folia/2009/P36N06I.pdf.
Rédaction Prescrire. Exénatide: pertes de poids excessives. Rev Prescrire
2010;30(321):509.
Elashoff M, Matveyenko AV, Gier B et al. Increased incidence of pancreatitis and cancer
among patients given glucagon like peptide-1 based therapy. Gastroenterology
2011;141:150-6.
Strippoli GFM, Craig ME, Craig JC et al. Antihypertensive agents for preventing diabetic
kidney disease. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.:
CD004136. DOI: 10.1002/14651858.CD004136.pub2.
Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes.
N Engl J Med 2004 ;351 :1941-51.
Bilous R, Chaturvedi N, Sjolie AK et al. Effect of candesartan on microalbuminuria and
albumin excretion rate in diabetes: Three Randomized Trials. Ann Intern Med
2009;151:11-20.
Haller H, Ito S, Izzo JL et al. Olmesartan for the delay of prevention of microalbuminuria
in type 2 diabetes. N Engl J Med 2011;364:907-17.
Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and
combination therapy with inhibitors of the renin angiotensin system on proteinuria in
renal disease. Ann Intern Med 2008;148:30-48.
Cushman WC, Evans GW, Byington RP et al. Effects of intensive blood-pressure control
in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85.
Rédaction Prescrire. Diabète de type 2 : viser moins de 140/80 mmHg. Rev Prescrire
2010;30:924.
Anderson RJ, Bahn GD, Moritz TE et al. Blood pressure and cardiovascular disease risk
in the veterans affairs diabetes trial (VADT). Diabetes Care 2011;34:34-8.
Bangalore S, Kumar S, Lobach I et al. Blood Pressure Targets in Subjects With Type 2
Diabetes Mellitus/Impaired Fasting Glucose observations from traditional and bayesian
random effects meta analysis of randomized trials. Circulation 2011;123:2799-810.
Boland B, Christiaens T, Goderis G, et al. Globaal cardiovasculair risicobeheer.
Aanbeveling voor goede medische praktijkvoering. Huisarts Nu 2007;36:339-69.
http://www.domusmedica.be/images/stories/aanbevelingen/h36_7_ab_cardio.pdf.
Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in type
2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
De Berardis G, Sacco M, Strippoli GFM et al. Aspirin for primary prevention of
cardiovascular events in people with diabetes: meta-analysis of randomised controlled
trials. BMJ 2009;339:b4531.
Belgisch Centrum voor Farmacotherapeutische Informatie. Flash: acetylsalicylzuur in
de primaire preventie van cardiovasculaire events bij diabetespatiënten. Folia
Pharmacotherapeutica 2010;37:76. http://www.bcfi.be/PDF/Folia/2010/P37N09E.pdf.
Chew EY, Ambrosius WT, Davis MD et al. Effects of medical therapies on retinopathy
progression in type 2 diabetes. N Engl J Med 2010;363:233-44.

48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Brett AS. ACCORD : microvascular outcomes. JWatch General Medicine december
30, 2010. http://general-medicine.jwatch.org.
Nygaard B. Primary hypothyroidism. BMJ Clinical Evidence 2010;01:605. Search Date
September 2009. http://clinicalevidence.bmj.com.
Turner MR, Camacho X, Fischer HD et al. Levothyroxine dose and risk of fractures in
older adults : nested case-control study. BMJ 2011;342:d2238.
Mueller PS. Levothyroxine and fracture risk in elders. JWatch General Medicine May
17, 2011. http://general-medicine.jwatch.org.
PRODIGY. Hypothyroidism. PRODIGY, 2011. http://prodigy.clarity.co.uk/hypothyroidism.
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van hypothyreoïdie
bij volwassenen. Folia Pharmacotherapeutica 2010;37:25-7. http://www.bcfi.be/PDF/
Folia/2010/P37N03E.pdf.
Rodondi N, den Elsen WPJ, Bauer DC et al. Subclinical hypothyroïdism and the risk of
coronary heart disease and mortality. JAMA 2010;304:1365-74.
Villar HCCE, Saconato H, Valente O, Atallah AN. Thyroid hormone replacement for
subclinical hypothyroidism. Cochrane Database of Systematic Reviews 2007, Issue 3.
Art. No.: CD003419. DOI: 10.1002/14651858.CD003419.pub2.
Ochs N, Auer R, bauer D. Meta-analysis: subclinical thyroid dysfunction and the risk
for coronary heart disease and mortality. Ann Intern Med 2008;148:832-45.
Nygaard B. Hyperthyroidism. BMJ Clinical Evidence 2010;07:611. Search Date February
2010. http://.clinicalevidence.bmj.com.
Belgisch Centrum voor Farmacotherapeutische Informatie. Gecommentarieerd
geneesmiddelenrepertorium 2011. http://www.bcfi.be.
Rossouw JE, Anderson GL, Prentice RL et al; Writing Group for the Women's Health
Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy
postmenopausal women: principal results from the Women's Health Initiative
randomized controlled trial. JAMA 2002;288:321-33.
Grady D, Herrington D, Bittner V et al; HERS Research Group. Cardiovascular disease
outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin
Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement
therapy in the million Women Study. Lancet 2003;362:419-27.
Chlebowski RT, Hendrix SL, Langer RD et al for the Women’s Health Initiative
Investigators. Influence of estrogen plus progestin on breast cancer and mammography
in healthy postmenopausal women. JAMA 2003;289:3243-53.
Hulley S, Furberg C, Barrett-Connor E; HERS Research Group. Noncardiovascular disease
outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin
Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
Beral V, Reeves G, Bull D et al. Breast cancer risk in relation to the interval between
menopause and starting hormone therapy. J Natl Cancer Inst 2011;103:296-305.
Belgisch Centrum voor Farmacotherapeutische Informatie. Goed om weten: hormonale
substitutie en risico van invasieve borstkanker. Folia Pharmacotherapeutica
2011;38:4-5.http://www.bcfi.be/PDF/Folia/2011/P38N01C.pdf.

66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in
postmenopausal women with hysterectomy: the Women's Health Initiative randomized
controlled trial. JAMA 2004;291:1701-12.
Stefanick M, anderson G, Margolis K et al. Effects of conjugated equine estrogens on
breast cancer and mammography screening in postmenopausal women with
hysterectomy. JAMA 2006;295:1647-57.
Saxena T, Lee E, Henderson KD et al. Menopausal hormone therapy and subsequent
risk of specific invasive breast cancer subtypes in the california teachers study. Cancer
Epidemiol Biomarkers Prev 2010;19:2366-78.
Rédaction Prescrire. Tibolone et cancer du sein. Rev Prescrire 2010;30:432.
Burbis N, Morris EP. Menopausal symptoms. BMJ Clinical Evidence 2011;06:804. Search
Date June 2010. http://clinicalevidence.bmj.com.
Salpeter SR, Cheng J, Thabane L et al. Bayesian meta-analysis of hormone therapy
and mortality in younger postmenopausal women. Am J Med. 2009;122:1016-22.
Rédaction Prescrire. Tibolone et cancer du sein. Rev Prescrire 2010;320:432.
Lethaby A, Suckling J, Barlow D et al. Hormone replacement therapy in postmenopausal
women: endometrial hyperplasia and irregular bleeding. Cochrane Database of
Systematic Reviews 2004, Issue 3. Art. No.: CD000402.pub2. DOI: 10.1002/
14651858.CD000402.pub2.
Beral V, Bull D, Reeves G; Million Women Study Collaborators. Endometrial cancer
and hormone-replacement therapy in the Million Women Study. Lancet
2005;365:1543-51.
Weiderpass E, Baron JA, Adami HO et al. Low-potency oestrogen and risk of
endometrial cancer: a case-control study. Lancet 1999;353:1824-8.
Vooijs GP, Geurts TB. Review of the endometrial safety during intravaginal treatment
with estriol. Eur J Obstet Gynecol Reprod Biol 1995;62:101-6.
Beral B, Bull D, Green J et al. Ovarian cancer and hormone replacement therapy in the
Million Women Study. Lancet 2007;369:1703-10.
Morch LS, Lokkegaard E, Andreasen AH et al. Hormone therapy and ovarian cancer.
JAMA 2009;302:298-305.
Pearce CL, Chung K, Pike MC et al. Increased ovarian cancer risk associated with
menopausal estrogen therapy is reduced by adding progestin. Cancer
2009;115:531-539.
Heiss G, Wallace R, Anderson GL et al. Health risks and benefits 3 years after stopping
randomized treatment with estrogen and progestin. JAMA 2008;299:1036-45.
Chlebowski RT, Schwartz AG, Wakelee H et al. estrogen plus progestin and lung cancer
in postmenopausal women (Women’s Health Initiative Trial): a post-hoc analysis of a
randomised controlled trial. Lancet 2009;374:1243-51.
Hsia J, Langer R, Manson JE et al. Conjugated equine estrogens and coronary heart
disease. Arch Intern Med 2006;166:357-65.
Cherry N, Gilmour K, Hannaford P; ESPRIT team. Oestrogen therapy for prevention of
reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet
2002;360:2001-8.

84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
Vickers MR, MacLennan AH, Lawton B et al. Main morbidities recorded in the women’s
international study of long duration oestrogen after menopause (WISDOM): a
randomised controlled trial of hormone replacement therapy in postmenopausal
women. BMJ 2007;335:239.
Rossouw J, Prentice R, Manson J et al. Postmenopausal hormone therapy and risk of
cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77.
Wassertheil-Smoller S, Hendrix SL, Limacher M et al; WHI Investigators. Effect of
estrogen plus progestin on stroke in postmenopausal women. The Women’s Health
Initiative: a randomized trial. JAMA 2003;289:2673-84.
Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent
stroke: a meta-analysis. BMJ 2005;330:342-5.
Grodstein F, Manson JE, Stampfer MJ et al. Postmenopausal hormone therapy and
stroke. Arch Intern Med 2008;168:861-6.
Michiels B. Tibolon voor oudere menopauzale vrouwen Minerva 2008;7:146-47.
http://www.minerva-ebm.be/nl/article.aspid=1577. Bespreking van: Cummings SR,
Ettinger B, Delmas PD et al. The effects of tibolone in older postmenopausal women.
N Engl J Med 2008;359:697-708.
Renoux C, Dell’Aniello S, Garbe E et al. Transdermal and oral hormone replacement
therapy and the risk of stroke : a nested case-control study. BMJ 2010;340:c2519.
Canonico M, Plu-Bureau G, Lowe GDO, Scarabin P. Hormone replacement therapy
and risk of venous thromboembolism in postmenopausal women: systematic review
and meta-analysis. BMJ 2008;336:1227-31.
Canonico M et al. Postmenopausal hormone therapy and risk of idiopathic venous
thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol
2010;30:340.
Cauley JA, Robbins J, Chen Z et al; Women's Health Initiative Investigators. Effects of
estrogen plus progestin on risk of fracture and bone mineral density. The Women’s
Health Initiative Randomized trial. JAMA 2003;290:1729-38.
Cirillo DJ, Wallace RB, Rodabough RJ et al. Effect of estrogen therapy on gallbladder
disease. JAMA 2005;293:330-9
Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy
for cognitive function in postmenopausal women. Cochrane Database of Systematic
Reviews 2008, Issue 1. Art. No.: CD003122. DOI: 10.1002/14651858.CD003122.pub2.
Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in
postmenopausal women. Cochrane Database of Systematic Reviews 2003, Issue 4.
Art. No.: CD001500. DOI: 10.1002/14651858.CD001500.pub2.
Helmerhorst F, Bijl D. Behandeling van overgangsklachten. GeBu 2002;36:109-15.
http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Behandeling-van-overgangsklach
ten.htm.
Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CMA. Oestrogen therapy for
urinary incontinence in post-menopausal women. Cochrane Database of Systematic
Reviews 2009, Issue 4. Art. No.: CD001405. DOI: 10.1002/14651858.CD001405.pub2.
Teunissen D. Oestrogenen voor preventie van recidiverende urineweginfecties bij
postmenopauzale vrouwen. Huisarts Wet 2008;51:513-14.

100
101
102
103
104
105
106
Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent
urinary tract infection in postmenopausal women. Cochrane Database of Systematic
Reviews 2008, Issue 2. Art. No.: CD005131. DOI:10.1002/14651858.CD005131.pub2.
Van Haaren K, Visser H, Van Vliet S et al. NHG Standaard Urineweginfecties Huisarts
Wet 2005:341-52. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaar
den/Samenvattingskaartje-NHGStandaard/M05_svk.htm..
Brunner R, Gass M, Aragaki A et al. Effects of conjugated equine estrogen on
health-related quality of life in postmenopausal women with hysterectomy. Arch Intern
Med 2005;165:1976-86.
Burbis N, Morris EP. Menopausal symptoms. BMJ Clinical Evidence 2011;06:804. Search
Date June 2010. http://clinicalevidence.bmj.com.
Nelson HD, Kimberly KV Naney E et al. Nonhormonal therapies for menopausal hot
flashes systematic review and meta-analysis. JAMA 2006;295:2057-71.
Rada G, Capurro D, Pantoja T et al. Non-hormonal interventions for hot flushes in
women with a history of breast cancer. Cochrane Database of Systematic Reviews
2010, Issue 9. Art. No.: CD004923.DOI:10.1002/14651858.CD004923.pub2.
Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens
for vasomotor menopausal symptoms. Cochrane Database of Systematic Reviews
2007, Issue 4. Art. No.: CD001395. DOI: 10.1002/14651858.CD001395.pub3.

Urogenitaal stelsel
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van
urine-incontinentie in de eerste lijn. Folia Pharmacotherapeutica 2008;35:28-30.
http://www.bcfi.be/PDF/Folia/2008/P35N04B.pdf.
Lagro-Janssen ALM, Breedveldt Boer HP, Van Dongen JJAM et al. NHG-Standaard
Incontinentie voor urine (eerste herziening). Huisarts Wet 2006:49(10):501-10. http:
//nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-
NHGStandaard/M46_svk.htm.
Collerton J, Davies K, Jagger C. Health and disease in 85 year olds : baseline findings
from the newcastle 85+ cohort study. BMJ 2009;339:b4904.
Thirugnanasothy S. Managing urinary incontinence in older people. BMJ
2010;341:c3835.
Landelijk Expertisecentrum Verpleging en Verzorging, Beroepsvereniging van
zorgprofessionals. Richtlijn urine-incontinentie bij kwetsbare ouderen.LEVV. September
2010.http://www.venvn.nl/LinkClick.aspxfileticket=Yxcf468Hnrc%3d&tabid=1454.
Nygaard I. Idiopathic urgency urinary incontinence. N Engl J Med 2010;363:1156-62.
Wing RR et al. Improving urinary incontinence in overweight and obese women through
modest weight loss. Obstet Gynecol 2010;116:284-92.
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van
urine-incontinentie. Transparantiefiche Augustus 2011.http://www.bcfi.be/pdf/tft/
TN_URINCNT_Lng.pdf .
Burgio KL, Kraus SR, Menefee S et al. Urinary Incontinence Treatment Network.
Behavioral therapy to enable women with urge incontinence to discontinue drug
treatment. Ann Intern Med 2008;149:161-9.
Roxburgh C, Cook J, Dublin N. Anticholinergic drugs versus other medications for
overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews
2007, Issue 4. Art. No.: CD003190. DOI: 10.1002/14651858.CD003190.pub4.
Nabi G, Cody JD, Ellis G et al. Anticholinergic drugs versus placebo for overactive
bladder syndrome in adults. Cochrane Database of Systematic Reviews 2006, Issue 4:
Art. No.: CD003781. DOI: 10.1002/1465185.CD003781.pub2.
Ancelin ML, Artero S, Portet F et al. Non-degenerative mild cognitive impairment in
elderly people and use of anticholinergic drugs: Longitudinal cohort study. BMJ
2006;332:455-9.
Rehman H, Bezerra CCB, Bruschini H et al. Traditional suburethral sling operations for
urinary incontinence in women (review). Cochrane Database of Systematic Reviews
2011, Issue 1. Art. No.: CD001754. DOI : 10.1002/14651858.CD001754.pub3.
Mariappan P, Alhasso AA, Grant A, N’Dow JMO. Serotonin and noradrenaline reuptake
inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Database of
Systematic Reviews 2005, Issue 3. Art. No.: CD004742. DOI:10.1002/
14651858.CD004742.pub2.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van benigne
prostaathypertrofie. Transparantiefiche Juli 2008http://www.bcfi.be/pdf/tft/TN_BPH.pdf.
National Institute for Health and Clinical Excellence. The management of lower urinary
tract symptoms in men. NICE Clinical Guideline CG 97, May 2010. http://guidance.ni
ce.org.uk/CG97.
PRODIGY. Lower urinary tract symptoms in men, age-related (including symptoms of
benign prostatic hyperplasia/hypertrophy). PRODIGY 2010. http://prodigy.clarity.co.uk
/luts_in_men_age_related_prostatism
Slee P, Bijl D. Tamsulosine en ernstige oogheelkundige bijwerkingen na
cataractchirurgie. GeBu 2009;43:88. http://gebu.artsennet.nl/Archief/Tijdschriftartikel
/Tamsulosine-en-ernstige-oogheelkundige-bijwerkingen-na-cataractchirurgie.htm.
Belgisch Centrum voor Farmacotherapeutische Informatie. Tamsulosine en “Floppy
Iris Syndrome”. Folia Pharmacotherapeutica 2007;34:9. http://www.bcfi.be/PDF/Folia
/2007/P34N01F.pdf.
Belgisch Centrum voor Farmacotherapeutische Informatie. Tamsulosine en
post-operatieve complicaties na cataractchirurgie. Folia Pharmacotherapeutica
2010;37:27. http://www.bcfi.be/PDF/Folia/2010/P37N03F.pdf.
Tacklind J, Fink HA, MacDonald R et al. Finasteride for benign prostatic hyperplasia
Cochrane Database of Systematic Reviews 2010, Issue 10. Art. No. : CD006015. DOI:
10.1002/14651858.CD006015.pub3.
Roehrborn CG, Siami P, Barkin J et al. The effects of dutasteride, tamsulosin and
combination therapy on lower urinary tract symptoms in men with benign prostatic
hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol
2008;179:616-21.
Medecines ans Healthcare products Regulatory Agency. The risk of male breast cancer
with finasteride. MHRA public assessment report. December 2009. http://
www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con065504.pdf.
Belgisch Centrum voor Farmacotherapeutische Informatie. Finasteride : risico van
borstkanker bij mannen Folia Pharmacotherapeutica 2010;37:99.http://www.bcfi.be
/PDF/Folia/2010/P37N11F.pdf.
Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the
development of prostate cancer. N Engl J Med 2003;349:215-24.
Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic
hyperplasia. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.:
CD001423. DOI: 10.1002/14651858.CD001423.pub2.
Obyn C, Mambourg F. Rapid assessment van enkele nieuwe behandelingen voor
prostaatkanker en goedaardige prostaathypertrofie. Federaal Kenniscentrum voor de
Gezondheidszorg (KCE). KCE reports Vol. 89A, Oktober 2008. http://www.kce.fgov.be
/sites/default/files/page_documents/d20081027361.pdf.
Worster A, Richards C. Fluids and diuretics for acute ureteric colic. Cochrane Database
of Systematic Reviews 2005, Issue 3. Art. No.: CD004926. DOI: 10.1002/
14651858.CD004926.pub2
Tseng TY, Preminger GM. Kidney stones. BMJ Clinical Evidence Search date June 2011.
http://clinicalevidence.bmj.com.

30
31
32
Rédaction Prescrire. Coliques néphrétiques chez les adultes. Rev Prescrire
2009;29:355-60.
Arndt UP, Van KoningsBruggen PIW, Salden NMA, et al. NHG-Standaard
Urinesteenlijden, eerste herziening. Huisarts Wet 2007:50(5):215-21. http://nhg.art
sennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHG
Standaard/M63_svk.htm.
Holdgate A, Pollock T. Nonsteroidal anti-inflammatory drugs (NSAIDS) versus opioids
for acute renal colic. Cochrane Database of Systematic Reviews 2004, Issue 1. Art.
No.: CD004137. DOI: 10.1002/14651858.CD004137.pub3.

Pijn en koorts
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Robertson J. Review: no evidence exists that paracetamol and ibuprofen differ for
short term pain relief or safety in children, but ibuprofen more effectively reduces
fever. Evid Based Nurs 2005;8:10.
Hay AD, Redmond NM, Costelloe C et al. Paracetamol and ibuprofen for the treatment
of fever in children: the PITCH randomised controlled trial. Health Technol Assess
2009;13(27):1–163.
Davis MP, Srivastava M. Demographics, assessment and management of pain in the
elderly. Drugs Aging 2003:20:23-57.
Michaelene P. Jansen (edit). Managing Pain in the Older Adult. Publication date 03/
2008. ISBN 978-0-8261-1567-6. p 3-15.
Lövheim H, Sandman P, Kallin K et al. Poor staff awareness of analgesic treatment
jeopardises adequate pain control in the care of older people. Age Aging
2006;35:257-61.
Bertakis K, Azari R, Callahan E. Patient pain in primary care: factors that influence
physician diagnosis. Ann Fam Med 2004;2:224-30.
Herr K, Bjoro K, Decker S. Tools for assessment of pain in nonverbal older adults with
dementia: a state-of-the-science review. J Pain Symptom Manage 2006;31:170-92.
Zwakhalen S, Hamers J, Huijer Abu-Saad H et al. Pain in elderly people with severe
dementia: a systematic review of behavioural pain assessments tools. BMC Geriatr
2006;6:3.
Scott D, Kowalczyk A. Osteoarthritis of the knee. BMJ Clinical Evidence 2007;12:1121.
Search Date October 2006. http://clinicalevidence.bmj.com.
Conaghan P, Dickson I, Grant R. Care and management of osteoarthritis in adults:
summary of NICE guidance. BMJ 2008;336;502-3.
Ottawa Panel evidence-based clinical practice guidelines for therapeutic exercises and
manual therapy in the management of osteoarthritis. Phys Ther 2005;85:907-71.
Bartels EM, Lund H, Hagen KB et al. Aquatic exercise for the treatment of knee and
hip osteoarthritis. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.:
CD005523. DOI: 10.1002/14651858.CD005523.pub2.
Chou R. Low back pain (Chronic). BMJ Clinical Evidence 2010;10:1116. Search Date
April 2009. http;//clinicalevidence.bmj.com.
Frost H, Lamb S, Doll H. et al. Randomised controlled trial of physiotherapy compared
with advice for low back pain. BMJ 2004;329:708-11.
French SD, Cameron M, Walker BF et al. Superficial heat or cold for low back pain.
Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004750. DOI:
10.1002/14651858.CD004750.pub2.
Chou R, Huffman N. Nonpharmacologic therapies for acute and chronic low back
pain: a review of the evidence for an American Pain Society/American College of
Physicians clinical practice guideline. Ann Intern Med 2007;147:492-504.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
van Duijvenbode ICD, Jellema P, van Poppel MNM, van Tulder MW. Lumbar supports
for prevention and treatment of low back pain. Cochrane Database of Systematic
Reviews 2008, Issue 2. Art. No.: CD001823. DOI: 10.1002/14651858.CD001823.pub3.
Rédaction Prescrire. Les traitements des douleurs d’origine arthrosique en bref. Rev
Prescrire 2000;20:486-7.
Eccleston C, Williams ACDC, Morley S. Psychological therapies for the management
of chronic pain (excluding headache) in adults. Cochrane Database of Systematic
Reviews 2009, Issue 2. Art. No.: CD007407. DOI: 10.1002/14651858.CD007407.pub2.
Anonymous. Key principles of the WHO method of cancer pain relief. Cancer Pain
Release 2006;19:1 http://www.whocancerpain.wisc.edu/indexq=node/87.
AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in
older persons. JAGS 2002;50:S205-S224.
National Prescribing Service. Analgesic options for pain relief. NPS News August
2006;47. http://www.nps.org.au/__data/assets/pdf_file/0017/23822/news47_pain_re
lief_0806.pdf.
Barden J, Edwards J, Moore A, McQuay H. Single dose oral paracetamol
(acetaminophen) for postoperative pain. Cochrane Database of Systematic Reviews
2004, Issue 1. Art. No.: CD004602. DOI: 10.1002/14651858.CD004602.
Jalan R, Williams R, Bernuau J. Paracetamol: are therapeutic doses entirely safe Lancet
2006;368:2195-6.
Martindale: The Complete Drug Reference, 35th edition.
National Collaborating Centre for Chronic Conditions. Osteoarthritis: national clinical
guideline for care and management in adults.NICE Clinical Guideline CG 59, February
2008. http://guidance.nice.org.uk/CG59/Guidance/pdf/English.
PRODIGY. Osteoarthritis. PRODIGY 2008. http://prodigy.clarity.co.uk/osteoarthritis.
Gøtzsche P. Non-steroidal anti-inflammatory drugs. BMJ Clinical Evidence
2010;06:1108. Search Date September 2009. http://.clinicalevidence.bmj.com.
Rédaction Prescrire. Effets indésirables digestifs des AINS: au-delà du duodénum aussi.
Rev Prescrire 2005;25:830-4.
Hiele M. Bijwerkingen van niet-steroïdale anti-inflammatoire geneesmiddelen op de
maagdarmtractus. Tijdschr voor Geneeskd 2005;61:581-8.
PRODIGY. Nonsteroidal anti-inflammatory drugs (standard or coxibs) - prescribing
issues. PRODIGY 2008. http://prodigy.clarity.co.uk/nsaids_prescribing_issues.
Kwaliteitsinstituut voor de Gezondheidszorg CBO. NSAID-gebruik en preventie van
maagschade. CBO 2003. http://www.diliguide.nl/document/2188/nsaid-gebruik-enpreventie-van-maagschade.html.
Folmer H, Draijer L, Verduijn M. Farmacotherapeutische richtlijn pijnbestrijding/
analgetica. NHG februari 2005. http://download.nhg.org/FTP_NHG/standaarden/FTR/
Pijnbestrijding_text.html.
Kerst A. Het risico van gastroduodenale bloedingen bij oudere en nieuwere NSAID’s.
GeBu 2005:39:58-9. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Het-risico-vangastroduodenale-bloedingen-bij-oudere-en-nieuwere-NSAIDs.htm.
Rostom A, Dubé C, Jolicoeur E et al. Gastroduodenal ulcers associated with the use
of nonsteroidal anti-inflammatory drugs: a systematic review of preventive

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
pharmacological interventions. Canadian Coordinating Office for Health Technology
Assessment. Technology overview no 12; March 2004. http://www.cadth.ca/media/
pdf/261_gastro_ov_e.pdf.
Jüni P et al. Older people should NOT be prescribed ‘coxibs’ in place of conventional
NSAIDs. Age Ageing 2004;33:100-4.
Topol E, Falk G. A coxib a day won’t keep the doctor away. Lancet 2004;364:639-40.
Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal
anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.
Belgisch Centrum voor Farmacotherapeutische Informatie. Gecommentarieerd
Geneesmiddelenrepertorium 2011. www.bcfi.be.
National Prescribing Centre. Update on the prescribing of NSAIDs. MeRec Monthly
2008 No. 2. http://www.npc.nhs.uk/merec/pain/musculo/resources/merec_month
ly_no02.pdf.
Medicines and Healthcare products Regulatory Agency, Commission on Human
Medicines. Non-steroidal anti-inflammatory drugs: cardiovascular risk. Drug Safety
Update 2009;2:3. http://www.mhra.gov.uk/home/groups/pl-p/documents/publication
/con038626.pdf.
Rostom A, Dube C, Wells GA et al. Prevention of NSAID-induced gastroduodenal
ulcers. Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No.: CD002296.
DOI: 10.1002/14651858.CD002296.
Spiegel B, Farid M, Dulai G et al. Comparing rates of dypepsia with coxibs vs NSAID+PPI:
a meta-analysis. Am J Med 2006;119:448.e27-36.
Anonymous. Reducing NSAID-induced gastrointestinal complications. Drug Ther Bull
2011;18-21.
Chou R, Fanciullo GJ, Fine PG et al. Clinical guidelines for the use of chronic opioid
therapy in chronic noncancer pain. J Pain 2009;10:113-30.
Martell B, O’Connor P, Kerns R et al. Systematic review: opioid treatment for chronic
back pain: prevalence, efficacy, and association with addiction. Ann Intern Med
2007;146:116-27
Deshpande A, Furlan A, Mailis-Gagnon A et al. Opioids for chronic low-back pain.
Cochrane Database of Systematic Review 2007, Issue 3. Art. No.: CD004959. DOI:
10.1002/14651858.CD004959.pub3.
Kalso E. Opioids for persistent non-cancer pain (Editorial). BMJ 2005;330:156-7.
Kalso E, Edwards J, Moore R. et al. Opioids in chronic non-cancer pain: systematic
review of efficacy and safety. Pain 2004;112:372-80.
Moore A, Collins S, Carroll D et al. Paracetamol with and without codeine in acute
pain: a quantitative systematic review. Pain 1997;70:193-201.
Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet
2011;377:2226-35.
Kabel J, Van Puijenbroek E. Bijwerkingen van tramadol: 12 jaar ervaring in Nederland.
Ned Tijdschr Geneeskd 2005;149:754-7.
Rédaction Prescrire. Syndrome de sevrage et dépendance: le tramadol aussi. Rev
Prescrire 2003;23:112-3

54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
Rédaction Prescrire. Syndrome de sevrage et dépendance : le tramadol aussi. Rev
Prescrire 2011;31:23.
Kaye K. Trouble with tramadol (Editorial). Aust Prescr 2004;27:26-7
Ravenscroft PJ. Opioids - clinical applications in palliative care. Austr Prescr
1996;19:66-8.
Wiffen PJ, McQuay HJ. Oral morphine for cancer pain. Cochrane Database of Systematic
Reviews 2007, Issue 4. Art. No.: CD003868. DOI: 10.1002/14651858.CD003868.pub2
Anonymous. Drugs for pain. The Medical Letter 2000;42:73-8.
Gomes T, Mandani MM, Dhalla IA et al. Opioid dose and drug-related mortality in
patients with nonmalignant pain. Arch Intern Med 2011;171:686-691.
Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database of
Systematic Reviews 2002, Issue 1. Art. No.: CD003447. DOI: 10.1002/
14651858.CD003447.
Rédaction Prescrire. Hydromorphone. Pas mieux que la morphine per os. Rev Prescrire
2000;20:327-9.
Rédaction Prescrire. A quoi bon un morphinique de plus Rev Prescrire 2001;21:157.
Rédaction Prescrire. Oxycodone orale et injectable : nouvelle forme orale et nouveaux
dosages, sans plus. Rev Prescrire 2009:29;822
Verduijn MM. Intoxicatie met fentanylpleister door onjuist gebruik. GeBu 2008,42:24-5.
http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Intoxicatie-met-fentanylpleisters-dooronjuist-gebruik.htm.
Belgisch Centrum voor Farmacotherapeutische Informatie. Recente information maart
2011. Folia Pharmacotherapeutica 2011;38:31. http://www.bcfi.be/PDF/Folia/2011/
P38N04D.pdf.
Brouwers JRBJ, Delhaas EM. Medicamenteuze behandeling van chronische pijn bij
volwassenen. GeBu 1998;32:111-8. http://gebu.artsennet.nl/Archief/Tijdschriftartikel
/Medicamenteuze-behandeling-van-chronische-pijn-bij-volwassenen.htm.
Rédaction Prescrire. Hépatite sous buprénorphine. Rev Prescrire 2002;22:30.
National Health Service. Transdermal buprenorphine. Regional Drug and Therapeutics
Centre. Drug Update No. 36, December 2004. http://www.nyrdtc.nhs.uk/docs/dud/
DU_36_Buprenorphine_a.pdf.
National Prescribing Service. Buprenorphine transdermal patches for chronic severe
pain. NPS RADAR Dec 2005. http://www.nps.org.au/__data/assets/pdf_file/0008/14687
/buprenorphine.pdf.
Bijl D. Buprenorfine transdermaal, behandeling ernstige chronische pijn. GeBu
2008;42:18-9. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Buprenorfine-transder
maal-Transtec-behandeling-ernstige-chronische-pijn.htm.
Duehmke RM, Hollingshead J, Cornblath DR. Tramadol for neuropathic pain. Cochrane
Database of Systematic Reviews 2006, Issue 3. Art. No.: CD003726. DOI: 10.1002/
14651858.CD003726.pub3
PRODIGY. Neuropathic pain – drug treatment. PRODIGY 2010. http://prodigy.clari
ty.co.uk/neuropathic_pain_drug_treatment.

73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
Biegstraaten M, van Leersum L, van Schalk N. Medicamenteuze behandeling van
perifere neuropathische pijn. GeBu 2007;41:83-92. http://gebu.artsennet.nl/Archief/
Tijdschriftartikel/Medicamenteuze-behandeling-van-perifere-neuropathische-pijn.htm.
Belgisch Centrum voor Farmacotherapeutische Informatie. Medicamenteuze
behandeling van neuropathische pijn. Folia Pharmacotherapeutica. 2006;33:28-31.
http://www.bcfi.be/PDF/Folia/2006/P33N04B.pdf.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database of
Systematic Reviews 2007, Issue 4. Art. No.: CD005454. DOI: 10.1002/
14651858.CD005454.pub2.
National Institute for Health and Clinical Excellence. Neuropathic pain. The
pharmacological management of neuropahic pain in adults in non-specialist settings.
NICE Clinical Guideline 96 March 2010. http://guidance.nice.org.uk/CG96/Guidance/
pdf/English.
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van neuropathische
pijn. Transparantiefiche juni 2010. http://www.bcfi.be/pdf/tft/TN_Neuralg_Lng.pdf.
Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain
and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 3.
Art No.: CD007938. DOI : 10.1002/14651858.CD007938.pub2.
Semel D, Murphy TK, Zlateva G et al. Evaluation of the safety and efficacy of pregabalin
in older patients with neuropathic pain: results from a pooled analysis of 11 clinical
studies. BMC Family Practice 2010;11:85.
Bril V, England J, Franklin GM et al. Evidence-based guideline: Treatment of painful
diabetic neuropathy. Neurology 2011;76:1758-65
Rédaction Prescrire. Prégabaline : Idées suicidaires. Rev Prescrire 2010;30:824.
Zakrzewska J, Linskey M. Trigeminal neuralgia. BMJ Clinical Evidence 2009;03:1207.
Search Date September 2007. http://clinicalevidence.bmj.com.
van den Muijsenbergh M. Tramadol tegen neuropathische pijn Huisarts Wet
2004;47:537-8.
Devulder J. Oxycodon effectief bij pijn door diabetische neuropathie. Minerva
2004;3:106-8. http://www.minerva-ebm.be/nl/article.aspid=845.
Eisenberg E, McNicol E, Carr D. Efficacy and safety of opioid agonists in the treatment
of neuropathic pain of nonmalignant origin. Systematic review and meta-analysis of
randomized controlled trials. JAMA 2005;293:3043-52.
Devulder J. Neuropathische pijn: harde klinische eindpunten. Tijdschr voor Geneeskd
2007;63:347.
Geerlings SE, Hoepelman IM. Farmacotherapie van herpes zoster en postherpetische
neuralgie. GeBu 1997;31:53-8. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Far
macotherapie-van-herpes-zoster-en-postherpetische-neuralgie.htm.
Nurmikko TJ, Nash TP, Wiles JR. Control of chronic pain. BMJ 1998;317:1438-41
Derry S, Lloyd R, Moore RA, McQuay HJ. Topical capsaicin for chronic neuropathic
pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.:
CD007393. DOI: 10.1002/14651858.CD007393.pub2.
Rédaction Prescrire. Douleurs postzostériennes: traitement symptomatique. Idées-Forces
tirées de la Revue Prescrire jusqu’au n° 318 (avril 2010). http://www.prescrire.org.

Palliatieve zorg
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
Wanrooij BS, de Graeff A, Koopmans RT et al. redactie. Palliatieve zorg in de dagelijkse
praktijk. Bohn Stafleu van Loghum uitgevers. 2010.
Federatie paliatieve zorg Vlaanderen. http://www.palliatief.be.
Smith AK, Stijacic Cenzer I, Knight SJ et al. The epidemiology of pain during the last
2 years of life. Ann Intern Med 2010;153:563-9.
Raphael J, Ahmedzai S, Hester J et al. Cancer pain: part 1: pathophysiology; oncological,
pharmacological, and psychological treatment: a perspective from the British Pain
Society endorsed by the UK Association of palliative medicine and the Royal College
of general practitioners. Pain Medicine 2010;11:742-64.
Van Den Noortgate N. Evaluatie van pijn bij ouderen. In: Morlion B, Lecart MP,
Verschueren H, Vanduynhoven E. Pijn en ouderen een praktische gids. Lannoo Campus,
Leuven, 2010.
Integraal Kankercentrum Nederland. Richtlijnen Palliatieve Zorg. www.pallialine.nl.
Moryl N, Coyle N, Foley K. Managing an acute pain crisis in a patient with advanced
cancer. JAMA 2008;299:1457-67.
Brouwers R, Delhaas E. Medicamenteuze behandeling van chronische pijn bij
volwassenen. GeBu 1998;10:111-8. http://gebu.artsennet.nl/Archief/Tijdschriftartikel
/Medicamenteuze-behandeling-van-chronische-pijn-bij-volwassenen.htm.
Belgisch Centrum voor Farmacotherapeutische Informatie. Levertoxiciteit van
paracetamol aan therapeutische dosis bij risicopatiënten. Folia Pharmacotherapeutica
2011;38:36. http://www.bcfi.be/PDF/Folia/2011/P38N04F.pdf.
PRODIGY. Palliative cancer care – pain. PRODIGY 2009. http://prodigy.clarity.co.uk/
palliative_cancer_care_pain.
MacDonald N, MacLeod S. Has the time come to phase out codeïne CMAJ.
2010;182:1825.
Scottish Intercollegiate Guidelines Network. Control of pain in patients with cancer.
SIGN Publication 106, November 2008. http://www.sign.ac.uk/pdf/SIGN106.pdf.
Rédaction Prescrire. Tramadol. Rev Prescrire 1997;17:639-42.
Kabel JS, van Puijenbroek EP. Bijwerkingen van tramadol: 12 jaar ervaring in Nederland.
Ned Tijdschr Geneeskd 2005;149:754-7.
Quigley C. Opioids in people with cancer-related pain. BMJ Clinical Evidence
2008;07:2408. Search Date July 2007.http://clinicalevidence.bmj.com.
Portenoy R, Hagen N. Breaktrough pain: definition, prevalence and characteristics.
Pain 1990;41:273-81.
Davies A, Dickman A, Reid C et al. Breakthough cancer pain. BMJ 2008;337:a2689.
Mercadante S, Arcuri E. Breakthrough pain in cancer patients. Pain: Clinical Updates
2006;14:1-4. http://www.iasp-pain.org/AM/AMTemplate.cfmSection=Home&TEM
PLATE=/CM/ContentDisplay.cfm&SECTION=Home&CONTENTID=7611
Rédaction Prescrire. Fentanyl comprimés sublinguaux. Rev Prescrire 2009;29:814.

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
Belgisch Centrum voor Farmacotherapeutische Informatie. Recente informatie maart
2011. Folia Pharmacotherapeutica 2011;38:31-2. http://www.bcfi.be/PDF/Folia/2011
/P38N04D.pdf
Rédaction Prescrire. Oxycodone orale et injectable. Rev Prescrire 2009;29:822.
Rédaction Prescrire. Oxycodone. Forme à libération immédiate: pas plus d’utilité
démontrée que pour la forme LP. Rev Prescrire 2005;25:9.
Anonymous. Targinact – opioid pain relief without constipation Drug Ther Bull
2010;48:138-40.
Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database of
Systematic Reviews 2002, Issue 1. Art. No.: CD003447. DOI: 10.1002/
14651858.CD003447.
Anonymous. Hydromorphone. Aust Prescr 2000;23:85.
Anonymous. Opioid analgesics for cancer pain in primary care. Drug Ther Bull
2005;43:9-12.
Rowbotham M, Twilling L, Davies P et al. Oral opioid therapy for chronic peripheral
and central neuropathic pain. N Engl J Med 2003;348:1223-32.
National Health Service. What are the equivalent doses of oral morphine to other oral
opioids when used as analgesics in adult palliative care National Electronic Library of
Medicine. Medicines Q & A 42.5. 11 May 2010. http://www.nelm.nhs.uk/en/NeLM-
Area/Evidence/Medicines-Q--A/What-are-the-equivalent-doses-of-oral-morphine-toother-oral-opioids-when-used-as-analgesics-in-adult-palliative-care.
Vissers KC, Besse K, Hans G et al. Opioid rotation in the management of chronic pain:
where is the evidence Pain Practice 2010;10:85-93.
Rédaction Prescrire. Fentanyl en patchs: pour certaines douleurs. Rev Prescrire
2009;29:104.
Botterman J. Orale of transdermale toediening van sterke opiaten bij pijn van
kankerpatiënten Tijdschr voor Geneeskd 2008;64:734-8.
National Health Service. How should conversion from oral morphine to fentanyl patches
be carried out National Electronic Library of Medicine. Medicines Q & A 302.1. 10
May 2010. http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Q--A/Howshould-conversion-from-oral-morphine-to-fentanyl-patches-be-carried-out.
Regional Drug and Therapeutics Centre. Transdermal buprenorphine. Drug Update
36, December 2004. http://www.nyrdtc.nhs.uk/docs/dud/DU_36_Buprenorphine_a.pdf.
National Prescribing Service. Buprenorphine transdermal patches for chronic severe
pain. NPS RADAR December 2005. http://www.nps.org.au/__data/assets/pdf_file/0008
/14687/buprenorphine.pdf.
Schalkwijk A, Verhagen CA, Engels Y et al. Valkuilen bij de behandeling van
neuropathische pijn bij patiënten met kanker. Ned Tijdschr Geneeskd 2011;155:345-9.
Eisenberg E, McNicol ED, Carr DB. Opioids for neuropathic pain. Cochrane Database
of Systematic Reviews 2006, Issue 3. Art. No.: CD006146. DOI: 10.1002/
14651858.CD006146.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database of
Systematic Reviews 2007, Issue 4. Art. No.: CD005454. DOI: 10.1002/
14651858.CD005454.pub2.

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
Wiffen P, McQuay H, Moore R. Carbamazepine for acute and chronic pain. Cochrane
Database of Systematic Reviews 2005, Issue 3. Art. No.:CD005451.DOI:10.1002/
14651858.CD005451.
Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain
and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 3.
Art. No.: CD007938. DOI: 10.1002/14651858.CD007938.pub2.
Mellegers M, Furlan A, Mailis A. Gabapentin for neuropathic pain: systematic review
of controlled and uncontrolled litterature. Clin J Pain 2001;17:284-95.
Wiffen P, Collins S, McQuay H et al. Anticonvulsant drugs for acute and chronic pain.
Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD001133. DOI:
10.1002/14651858.CD001133.
Biegstraaten M, van Schaik I. Pregabaline bij de behandeling van neuropathische pijn.
Ned Tijdschr Geneeskd 2007;151:1561-5.
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van neuropathische
pijn. Transparantiefiche Juni 2010. http://www.bcfi.be/pdf/tft/TN_Neuralg_Lng.pdf.
Semel D, Murphy TK, Zlateva G et al. Evaluation of the safety and efficacy of pregabalin
in older patients with neuropathic pain: results from a pooled analysis of 11 clinical
studies. BMC Family Practice 2010;11:85.
Plested M, Budhia S, Gabriel Z. Pregabalin, the lidocaine plaster and duloxetine in
patienst with refractory neuopathic pain: a systematic revew. BMC Neurology
2010;10:116.
Derry S, Lloyd R, Moore RA, McQuay HJ. Topical capsaicin for chronic neuropathic
pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.:
CD007393. DOI: 10.1002/14651858.CD007393.pub2.
Anonymous. Koanalgetica bei chronischen Schmerzen. Arzneimittelbrief 2001;35:89-93.
Wong R, Shukla V, Mensinkai S et al. Bisphosphonate agents for the management of
pain secondary to bone metastases: a systematic review of effectiveness and safety.
Canadian Coordination Office for Health Technology Assessment; 2004. Technology
report no 45. http://www.cadth.ca/media/pdf/170_bisphosphonate_tr_e.pdf.
Wong R, Wiffen P. Bisphosphonates for the relief of pain secondary to bone metastases.
Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD002068. DOI:
10.1002/14651858.CD002068.
Vyvey M. Les stéroides comme adjuvants pour soulager la douleur. Can Fam Phys
2010;56:e415-e417.
Jackson KC, Lipman AG. Drug therapy for anxiety in adult palliative care patients.
Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD004596. DOI:
10.1002/14651858.CD004596.
Breithart W, Alici Y. Agitation and delirium at the end of life. JAMA
2008;300:2898-910.
Keeley P. Delirium at the end of life. BMJ Clinical Evidence 2009;07:2405. Search date
February 2009. http://clinicalevidence.bmj.com.
Hirst A, Sloan R. Benzodiazepines and related drugs for insomnia in palliative care.
Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No.: CD003346. DOI:
10.1002/14651858.CD003346.

55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
PRODIGY. Palliative cancer care: dyspnoea. PRODIGY 2007. http://prodigy.clarity.co.uk
/palliative_cancer_care_dyspnoea.
Ben-Aharon I, Gafter-Gvili A, Paul M et al. Interventions for alleviating cancer-related
dyspnea: a systematic review. J Clin Oncol 2008;26:2396-404.
Abernethy AP, McDonald CF, Frith PA et al. Effect of palliative oxygen versus room
air in relief of breathlessness in patients with refractory dyspnoea: a double-blind,
randomised controlled trial. Lancet2010;376:784-93.
Anonymous. Sauerstoff gegen Luftnot bei schweren Erkrankungen Arznei-Telegramm
2010;41:112-3.
Abernethy A, Currow D, Frith P et al. Randomised, double blind, placebo controlled
crossover trial of sustained release morphine for the management of refractory
dyspnoea. BMJ 2003;327:523-8.
Jennings A, Davies A, Higgins J et al. A systematic review of the use of opioids in the
management of dyspnoea. Thorax 2002;57:939-44.
Muers M. Opioids for dyspnoea. Thorax 2002;57:922-3.
Gallagher R. The use of opioids for dyspnea in advanced disease. CMAJ 2011;183:1170.
Jennings AL, Davies AN, Higgins JPT, Anzures-Cabrera J, Broadley KE. Opioids for the
palliation of breathlessness in terminal illness. Cochrane Database of Systematic Reviews
2001, Issue 4. Art. No.: CD002066. DOI: 10.1002/14651858.CD002066.
Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness
in advanced malignant and non-malignant diseases in adults. Cochrane Database of
Systematic Reviews 2010, Issue 1. Art. No.: CD007354. DOI: 10.1002/
14651858.CD007354.pub2.
Navigante A, Cerchietti L, Castro M et al. Midazolam as adjunct therapy to morphine
in the alleviation of severe dyspnea perception in patients with advanced cancer. J
Pain Symptom Manage 2006;31:38-47.
PRODIGY. Palliative cancer care: cough. PRODIGY 2009. http://prodigy.clarity.co.uk/
palliative_cancer_care_cough.
PRODIGY. Palliative cancer care: secretions. PRODIGY 2007. http://prodigy.clarity.co.uk
/palliative_cancer_care_secretions.
Wildiers H, Dhaenekint C, Demeulenaere P et al. Atropine, hyoscine butylbromide, or
scopolamine are equally effective for the treatment of death rattle in terminal care. J
Pain Symptom Manage 2009;38:124-33.
Back I, Jenkins K, Blower A et al. A study comparing hyoscine hydrobromide and
glycopyrrolate in the treatment of death rattle. Palliat Med 2001;15:329-36.
National Health Service. Hypersalivation – can glycopyrronium be used to treat it
NeLM Medicines Q&A 52.4. September 15 2010. http://www.nelm.nhs.uk/en/NeLM-
Area/Evidence/Medicines-Q--A/Hypersalivation---can-glycopyrronium-be-used-to-treatit2.
Keeley P. Nausea and vomiting in people with cancer and other chronic diseases. BMJ
Clinical Evidence 2009;01:2406. Search Date April 2008. http://clinicaleviden
ce.bmj.com.
Koelewijn M, Wanrooij B. De behandeling van misselijkheid en braken in de palliatieve
fase. Huisarts Wet 2005;48:179-85.

73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
Perkins P, Dorman S. Haloperidol for treatment of nausea and vomiting in palliative
care patients. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.:
CD006271. DOI: 10.1002/14651858.CD006271.pub2.
O’Brien C. Nausea and vomiting. Can Fam Phys 2008;54:861-3.
Hesketh P. Chemotherapy-induced nausea.and vomiting. N Engl J Med
2008;358:2482-94.
Belgisch Centrum voor Farmacotherapeutische Informatie. Therapeutisch gebruik van
cannabis. Folia Pharmacotherapeutica 2002;29:14-5. http://www.bcfi.be/PDF/Folia/
2002/P29N02E.pdf
PRODIGY. Hiccups. PRODIGY 2008. http://prodigy.clarity.co.uk/hiccups.
Woelk CJ. Prise en charge du hoquet. Can Fam Phys 2011;57:e198-e201.
Rédaction Prescrire. Méthylnaltrexone. Constipation sous morphinique: guère plus
efficace qu’un placebo. Rev Prescrire 2009;29:172.
Anonymous. Methylnaltrexon (Relistor) bei opioidinduzierter obstipation.
Arznei-Telegramm 2008;39:102-4.
Candy B, Jones L, Goodman ML et al. Laxatives or methylnaltrexone for the
management of constipation in palliative care patients. Cochrane Database of
Systematic Reviews 2011, Issue 1. Art. No.: CD003448. DOI: 10.1002/
14651858.CD003448.pub3.
de Groot JW, Peters FT, Reyners AK. Behandeling van obstipatie in de palliatieve fase.
Ned Tijdschr Geneeskd 2010;154:2277-82.
PRODIGY. Palliative cancer care: constipation. PRODIGY 2008. http://prodigy.clari
ty.co.uk/palliative_cancer_care_constipation.
Baines M. ABC of palliative care. Nausea, vomiting, and intestinal obstruction. BMJ
1997;315:1148-50.
Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ
1997;315:1219-22.
Good P, Cavenagh J, Mather M, Ravenscroft P. Medically assisted nutrition for palliative
care in adult patients. Cochrane Database of Systematic Reviews 2008, Issue 4. Art.
No.: CD006274. DOI: 10.1002/14651858.CD006274.pub2.
Good P, Cavenagh J, Mather M, Ravenscroft P. Medically assisted hydration for adult
palliative care patients. Cochrane Database of Systematic Reviews 2008, Issue 2. Art.
No.: CD006273. DOI: 10.1002/14651858.CD006273.pub2.
Denys K, Dannau B, Van den Noortgate N. Verantwoorde toediening van kunstmatige
voeding en vocht op het einde van het leven. Tijdschr voor Geneeskunde
2010;66:436-40.
Kurien M, McAlindon ME, Westaby D et al. Percutaneous endoscopic gastrostomy
(PEG) feeding. BMJ 2010;340:1074-8.
Sampson EL, Candy B, Jones L. Enteral tube feeding for older people with advanced
dementia. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.:
CD007209. DOI: 10.1002/14651858.CD007209.pub2.
Reddy M. Pressure ulcers BMJ Clinical Evidence 2011;05:1901. Search date June 2010.
http://clinicalevidence.bmj.com.

92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
Wanrooij B, Koelewijn M, de Graeff A. Het gebruik van corticosteroïden in de palliatieve
zorg. Huisarts Wet 2006;49:466-71.
Rédaction Prescrire. Médroxyprogestérone et soins palliatifs. Pas d’impact sur la qualité
de vie. Rev Prescrire 2000; 20:338-9.
Reuben D, Hirsch S, Zhou K et al. The effects of megestrol acetate suspension for
elderly patients with reduced appetite after hospitalization : a phase II randomized
clinical trial. J Am Geriatr Soc 2005;53:970-5.
Berenstein G, Ortiz Z. Megestrol acetate for treatment of anorexia-cachexia syndrome.
Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD004310. DOI:
10.1002/14651858.CD004310.pub2.
Goedendorp MM, Gielissen MFM, Verhagen CAHHVM, Bleijenberg G. Psychosocial
interventions for reducing fatigue during cancer treatment in adults. Cochrane Database
of Systematic Reviews 2009, Issue 1. Art. No.: CD006953. DOI: 10.1002/
14651858.CD006953.pub2.
Minton O, Richardson A, Sharpe M et al. Drug therapy for the management of cancer
related fatigue. Cochrane Database of Systematic Reviews 2010, Issue 7. Art. No.:
CD006704. DOI: 10.1002/14651858.CD006704.pub3.
Peuckmann-Post V, Elsner F, Krumm N, Trottenberg P, Radbruch L. Pharmacological
treatments for fatigue associated with palliative care. Cochrane Database of Systematic
Reviews 2010, Issue 11. Art. No.: CD006788. DOI: 10.1002/
14651858.CD006788.pub2.
Tonelli M, Hemmelgarn B, Reiman T et al. Benefits and harms of
erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ
2009;180:E62–71.
Regnard C, Allport S, Stephenson L. ABC of palliative care. Mouth care, skin care, and
lymphoedema. BMJ 1997;315:1002-5.
PRODIGY. Palliative cancer care: oral. PRODIGY 2009. http://prodigy.clarity.co.uk/pal
liative_cancer_care_oral.
Rédaction Prescrire. Pilocarpine orale. Rev Prescrire 2002;22:167-70.
Taspinar A. Pilocarpine. GeBu 2002;36:10-1. http://gebu.artsennet.nl/Archief/Tijdschrift
artikel/Pilocarpine-Salagen-parasympathicomimeticum.htm.
Fedorowicz Z, Aljufairi H, Nasser M, Outhouse TL, Pedrazzi V. Mouthrinses for the
treatment of halitosis. Cochrane Database of Systematic Reviews 2008, Issue 4. Art.
No.: CD006701. DOI: 10.1002/14651858.CD006701.pub2.
Chevalier P. Antiseptische mondspoelingen voor de behandeling van halitose. Minerva
2009;8:46-7. http://www.minerva-ebm.be/nl/article.aspid=1673.
Scully C, Porter S. Halitosis. BMJ Clinical Evidence 2008;07:1305. Search Date July
2008. http://clinicalevidence.bmj.com.
Clarkson JE, Worthington HV, Eden TOB. Interventions for preventing oral candidiasis
for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews
2007, Issue 1. Art. No.: CD003807. DOI: 10.1002/14651858.CD003807.pub3.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Middelen
bij keel-, neus- en ooraandoeningen. Farmacotherapeutisch Kompas 2006:625-44.
http://www.fk.cvz.nl.

109
110
111
112
113
114
115
116
117
118
119
120
121
122
Pankhurst C. Candidiasis (oropharyngeal). BMJ Clinical Evidence 2009;03:1304. Search
Date September 2008. http://clinicalevidence.bmj.com.
Worthington HV, Clarkson JE, Bryan G et al. Interventions for preventing oral mucositis
for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews
2011, Issue 4. Art. No.: CD000978. DOI: 10.1002/14651858.CD000978.pub5.
Rédaction Prescrire. Aphtose buccale commune. Guérison spo,ntanée en une à deux
semaines, traitements décevants. Rev Prescr 2010;30:365-370.
Redactie WZC-Formularium. Chronische wonden bij ouderen: oorzaken en preventie.
Geneesmiddelenbrief 2007;14:33-42. http://www.farmaka.be/nl/geneesmiddelenbrief
/2007_09_geneesmiddelenbrief.pdf.
Redactie WZC-Formularium.. Behandeling van decubitus. Geneesmiddelenbrief
2008;15:33-44. http://www.farmaka.be/nl/geneesmiddelenbrief/2008_09_geneesmid
delenbrief.pdf.
PRODIGY. Palliative cancer care: malignant ulcer of the skin. PRODIGY 2009. http://
prodigy.clarity.co.uk/palliative_cancer_care_malignant_ulcer.
Redactie WZC-Formularium. Palliatieve zorg deel 3: Keuzes rond het levenseinde in
RVT. Geneesmiddelenbrief 2010;17:1-8. http://www.farmaka.be/nl/geneesmiddelen
brief/2010_02_geneesmiddelenbrief.pdf.
Quill T, Lo B, Brock D et al. Last-resort options for palliative sedation. Ann Intern Med
2009;151:421-4.
Verhagen E, Hesselman G, Besse T et al. Palliatieve sedatie. Ned Tijdschr Geneeskd
2005;149:458-61.
Koninklijke Nederlandsche Maatschappij tot bevordering der Geneeskunst. Palliatieve
sedatie. KNMG-richtlijn 2009. http://knmg.artsennet.nl/Richtlijnen/KNMGpublicatie/
KNMGrichtlijn-palliatieve-sedatie-2009.htm.
Claessens P, Menten J, Schotsmans P et al. Palliative sedation, not slow euthanasia: a
prospective, longitudinal study of sedation in Flemish pallaitive care units. J Pain
Symptom Manage 2011;41:14-24.
Belgische Overheid. Euthanasie: een streng gereglementeerd recht. http://www.belgi
um.be/nl/gezondheid/gezondheidszorg/levenseinde/euthanasie.
Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten.
Onbeschikbaarheid van Pentothal voor injectie: distributie van een gelijkwaardig
geneesmiddelen in België. Bericht FAGG, laatste update 20 september 2011. http://
www.fagg-afmps.be/nl/news/news_pentothal_indisponibilite_13_09_2011.jsp.
De Laat M. Farmaca gebruikt als euthanatica. Tijdschr voor Geneeskd 2008;64:799-802.

Osteo-articulaire aandoeningen
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Conaghan P, Dickson I, Grant R. Care and management of osteoarthritis in adults:
summary of NICE guidance. BMJ 2008;336;502-3.
Mason L. et al. Systematic review of topical capsaicin for the treatment of chronic
pain. BMJ 2004;328:991-4.
Geerlings SE, Hoepelman IM. Farmacotherapie van herpes zoster en postherpetische
neuralgie. GeBu 1997;31:53-8. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Far
macotherapie-van-herpes-zoster-en-postherpetische-neuralgie.htm.
Massey T, Derry S Moore RA, McQuay HJ. Topical NSAID's for acute pain in adults.
Cochrane Database of Systematic Reviews 2010, Issue 6. Art. No.: CD007402. DOI:
10.1002/14651858.CD007402.pub2.
Rédaction Prescrire. Kétoprofène gel: photosensibilisations graves. Rev Prescr
2010;30:114.
Dost M, Hartman T. ‘Dokter, ik heb het niet zo op pillen’. Topische NSAID’s bij artrose,
een klinische les. Huisarts Wet 2005;48:236-9.
Therapeutics Initiative. Should we be using NSAID's for the treatment of osteoarthritis
and “rheumatism”. Therapeutics Letter 1995; n° 4. http://www.ti.ubc.ca/sites/ti.ubc.ca
/files/4.PDF.
Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen
for osteoarthritis. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.:
CD004257. DOI: 10.1002/14651858.CD004257.pub2
Bjordal J, Ljunggren A, Klovning A. Non-steroidal anti-inflammatory drugs, including
cyclooxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised
placebo controlled trials. BMJ 2004;329:1317
Lee C, Straus W, Balshaw R et al. A comparison of the efficacy and safety of
nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of
osteoarthritis: a meta-analysis. Arthritis Rheum 2004;51:746-54.
Hur C, Chan A, Tramontano A, Gazelle G. Coxibs versus combination NSAID and PPI
for chronic pain: an exploration of the risk, benefits and costs. Ann Pharmacother
2006;40:1052-63
Arroll B, Goodyear-Smith F. Corticosteroid injections for osteoarthritis of the knee:
meta-analysis. BMJ 2004;328:869-74.
Poelman T. Zijn corticoïdinfiltraties effectief bij gonartrose Minerva 2006;5:42-4.
http://www.minerva-ebm.be/nl/article.aspid=1097.
Rédaction Prescrire. Gonarthrose et corticoïdes intra articulaires. Rev Prescrire
2006;26:521-2.
Bellamy N, Campbell J, Robinson V et al. Intra-articular corticosteroid for treatment
of osteoarthritis of the knee. Cochrane Database of Systematic Reviews 2006, Issue
2. Art. No.: CD005328. DOI: 10.1002/14651858.CD005328.pub2.
Van der Plas C. Intra-articulaire corticosteroïden bij gonartrose. Huisarts Wet
2005;48:528-9.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
van de Weg F. et al. Wel of geen injectietherapie bij schouderaandoeningen Een
systematisch literatuuronderzoek. Huisarts Wet 2004;47:178-83.
Mitchell C, Adabajo A, Hay E. et al. Shoulder pain: diagnosis and management in
primary care. BMJ 2005;331:1124-8.
Murphy RJ, Carr AJ. Shoulder pain. BMJ Clinical Evidence 2010;07:1107. Search date
August 2009. http://clinicalevidence.bmj.com.
McColl G. Glucosamine for osteoarthritis of the knee. Aust Prescr 2004;27:61-3.
Rédaction Prescrire. Glucosamine dans l’arthrose. Pas de miracle. Rev Prescrire
2004;24:612-4
Scott D, Kowalczyk A. Osteoarthritis of the knee. BMJ Clinical Evidence 2007;12:1121.
Search Date October 2006. http://clinicalevidence.bmj.com.
Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, Hochberg
MC, Wells G. Glucosamine therapy for treating osteoarthritis. Cochrane Database of
Systematic Reviews 2005, Issue 2. Art. No.: CD002946. DOI: 10.1002/
14651858.CD002946.pub2
Anonymous. Glukosamin (Dona 200-S) bei Artrhrose: Nutzen weiterhin zweifelhaft.
Arznei-Telegramm 2006;37:28-9.
Belgisch Centrum voor Farmacotherapeutische Informatie. Flash: glucosamine bij
artrose. Folia Pharmacotherapeutica 2011;38:30. http://www.bcfi.be/PDF/Folia/2011
/P38N04C.pdf.
Kerst A. Chondroïtine bij pijn door artrose. GeBu 2007;41:113. http://gebu.artsen
net.nl/Archief/Tijdschriftartikel/Chondroitine-bij-pijn-door-artrose.htm.
Wandel S, Jüni P, Tendal B et al. Effects of glucosamine, chondroitin, or placebo in
patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010;34:c4675
Hochberg M. Nutritional supplements for knee osteoarthritis - Still no resolution. N
Engl J Med 2006;354:858-60.
Lems W, Bijlsma J. Effectiviteit van voedingssupplementen bij artrose: de twijfel blijft.
Ned Tijdschr Geneeskd 2006;150:1105-7.
Chevalier P. Glucosamine en/of chondroïtine voor gonartrose Minerva 2006;5:148-50.
http://www.minerva-ebm.be/nl/article.aspid=1184.
Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation
for the treatment of osteoarthritis of the knee. Cochrane Database of Systematic
Reviews 2006, Issue 2. Art. No.: CD005321. DOI: 10.1002/14651858.CD005321.pub2
Arrich J, Piribauer F, Mad P et al. Intra-articular hyaluronic acid for the treatment of
osteoarthritis of the knee: systematic review and meta-analysis. CMAJ
2005;172:1039-43.
Van Driel M. Intra-articulair hyaluronzuur bij gonartrose (duiding). Minerva 2006;5:44-6.
http://www.minerva-ebm.be/nl/article.aspid=1098.
Urquhart DM, Hoving JL, Assendelft WJJ, Roland M, van Tulder MW. Antidepressants
for non-specific low back pain. Cochrane Database of Systematic Reviews 2008, Issue
1. Art. No.: CD001703. DOI: 10.1002/14651858.CD001703.pub3.
United States Food and Drug Administration. FDA clears Cymbalta to treat chronic
musculoskeletal pain. FDA News Release Nov. 4, 2010.http://www.fda.gov/NewsEvents
/Newsroom/PressAnnouncements/2010/ucm232708.htm.

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
Underwood M. Gout. BMJ Clinical Evidence 2011;05:1120. Search Date September
2010. http://clinicalevidence.bmj.com
Choi HK, Willett W, Curhan G. Fructose-rich beverages and risk of gout in women.
JAMA 2010;304:2270-8.
Rédaction Prescrire. Traitement de la crise de goutte. Rev Prescrire 2007;27:848.
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van jicht.
Transparantiefiche Juni 2010. http://www.bcfi.be/pdf/tft/TN_Gout.pdf.
Zhang W, Doherty M, Bardin T et al. EULAR Evidence based recommendations for
gout – Part II: Management: report of a task force of the EULAR Standing Committee
for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis
2006;65:1312-24
Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment
of acute and prevention of recurrent gout – a systematic review. Rheumatology
2006;45:1422-31.
Janssens HJEM, Lagro HAHM, Van Peet PG et al. NHG-standaard Arthritis. Huisarts
Wet 2009;52:439-53. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstan
daarden/NHGStandaard/Artritis-3.htm.
Terkeltaub RA, Furst DE, Bennett K et al. High versus low-dosing of oral colchicine for
early acute gout flare: twenty-four hour outcome results of the first multicenter
randomized, double-blind placebo-controlled, parallel-group, dose comparison
colchicine study. Arthritis Rheum 2010;62:1060-8.
Rédaction Prescrire. Colchicine: interactions graves. Rev Prescrire 2008;28:267-70.
Richette P, Bardin T. Should prednisolone be first-line therapy for acute gout Lancet
2008;372:1301-2
Winzenberg T, Buchbinder R. Cochrane Musculoskeletal Group review : Acute gout.
J Fam Pract 2009;58:E1-4
Janssens HJEM, Janssen M, van de Lisdonk EH et al. Use of oral prednisolone or
naproxen for the treatment of gout arthritis: a double blind, randomised equivalence
trial. Lancet 2008;371:1854-60.
Belgisch Centrum voor Farmacotherapeutische Informatie. Geneesmiddelen bij
osteoporose. Transparantiefiche juli 2008 en updates tot en met april 2011. http://
www.bcfi.be/pdf/tft/TN_Osteop.pdf.
Chevalier P. Prévention des chutes chez les personnes âgées. Société Scientifique de
Médecine Générale. Recommendations de Bonne Pratique. Mise à jour mars
2008.http://www.ssmg.be/new/files/RBP_ChutesPA_maj03.08.pdf.
Expertisecentrum Valpreventie Vlaanderen. Valpreventie in woonzorgcentra.
Praktijkrichtlijn voor Vlaanderen. http://www.valpreventie.be
Franken AAM, van Blijderveen NJC Witjes MJH, Netelenbos CJC.
Bisfosfonaatgerelateerde osteonecrose van de kaak. Ned Tijdschr Geneeskd
2011;155:704-9
Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures
of the femoral shaft. N Engl J Med 2011;364:1728-37

53
54
55
56
57
58
59
60
61
Boonen S, Luyten F, Borghs H, Vanderschueren D. Zoledronaatinfusie ter preventie
van osteoporotische fracturen en fractuurrecidieven in de behandeling van patiënten
met ouderdomsgebonden osteoporose. Tijdschr Geneeskd 2011;67:215-22.
Belgisch Centrum voor Farmacotherapeutische Informatie. Bisfosfonaten en bot-, spieren
gewrichtspijn. Folia Pharmacotherapeutica 2009;36:9. http://www.bcfi.be/PDF/Fo
lia/2009/P36N01I.pdf.
Rédaction Prescrire. Diphosphonates et fibrillation auriculaire : les résultats de quelques
essais incitent à la prudence. Rev Prescr 2010;30:908-10
Green J, Czanner G, Reeves G et al. Oral bisphosphonates and risk of cancer of
oesophagus, stomach, and colorectum: case-conctrol analysis within a UK primary
care cohort. BMJ 2010;341:c4444
Kuehn BM. Prolonged bisphophonate use linked to rare fractures, esophageal cancer.
JAMA 2010;304:2114-5
Belgisch Centrum voor Farmacotherapeutische Informatie. Bisfosfonaten: risico van
oesofaguskanker Folia Pharmacothérapeutica 2011;38:18. http://www.bcfi.be/PDF/
Folia/2011/P38N02I.pdf.
World Health Organization Collaborating Centre for Metabolic Bone Diseases, University
of Sheffield, UK. FRAX®: WHO Fracture Risk Assessment Tool. http://www.shef.ac.uk
/FRAX.
National Institute for Health and Clinical Excellence. Alendronate, etidronate,
risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention
of osteoporotic fragility fractures in postmenopausal women (amended). NICE
Technology Appraisal Guidance 161 (amended). Issue date: October 2008 (amended
January 2010 and January 2011). http://guidance.nice.org.uk/TA161/Guidance/pdf/
English.
Belgisch Centrum voor Farmacotherapeutische Informatie. Recente informatie juli
2011. Folia Pharmacotherapeutica 2011;38:80. http://www.bcfi.be/PDF/Folia/2011/
P38N09G.pdf.

Zenuwstelsel
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Centraal
zenuwstelsel (psychische aandoeningen) / Slapeloosheid en hypnotica.
Farmacotherapeutisch Kompas 2011. http://www.fk.cvz.nl
Declercq T, Rogiers R, Habraken H et al. Aanpak van slapeloosheid in de eerste lijn.
Huisarts Nu 2005;34:346-71. http://www.domusmedica.be/images/stories/aanbevelin
gen/H34_7_AB_Slapeloosheid.pdf.
Budur K, Rodriguez K, Foldvary-Schaeffer N. Advances in treating insomnia. Cleve Clin
J Med 2007;74:251-62.
Wolkove N, Elkholy O, Baltzan M et al. Sleep and aging: 1. Sleep disorders commonly
found in older people. CMAJ 2007;176:1299-304.
Neikrug AB, Ancoli-Israel S. Sleep disturbances in nursing homes. J Nutr Health Aging
2010;14(3):207-11.
Wolkove N, Elkholy O, Baltzan M et al. Sleep and aging: 2. Management of sleep
disorders in older people. CMAJ 2007;176(10):1449-54.
Friedman L, Zeitzer JM, Kushida C et al. Scheduled bright light for treatment of
insomnia in older adults. J Am Geriatr Soc 2009 Mar;57(3):441-52.
Dowling GA, Burr RL, Van Someren EJ et al. Melatonin and bright-light treatment for
rest-activity disruption in institutionalized patients with Alzheimer’s disease. J Am
Geriatr Soc 2008;56(2):239-46.
Riemersma-van der Lek RF, Swaab DF, Twisk J et al. Effect of bright light and melatonin
on cognitive and noncognitive function in elderly residents of group care facilities: A
randomized controlled trial JAMA 2008;299:2642-55.
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van slapeloosheid.
Transparantiefiche Oktober 2010. http://www.bcfi.be/pdf/tft/TN_Insomnie_Lng.pdf.
Morin CM, Vallières A, Guay B et al. Cognitive behavioral therapy, singly and combined
with medication, for persistent insomnia. A randomized controlled trial. JAMA
2009;301:2005-15.
Anthierens S, Pasteels I, Habraken H et al. Barriers to nonpharmacologic treatments
for stress, anxiety, and insomnia: Family physicians’ attitudes toward benzodiazepine
prescribing. Can Fam Physician 2010;56:e398-e406.
Vander Stichele RH, Van de Voorde C, Elseviers M et al. Geneesmiddelengebruik in
de Belgische rusthuizen en rust- en verzorgingstehuizen. Federaal Kenniscentrum voor
de Gezondheidszorg (KCE). KCE Reports Vol. 47A, 2006. http://www.kce.fgov.be/si
tes/default/files/page_documents/d20061027361.pdf.
Petrovic M, Spatharakis G, Conroy S et al. Prevalence of sedative drug use in geriatric
in-patients: a multicentre study. Acta Clin Belg 2006;61:119-26.
Glass J, Lanctôt KL, Herrmann N et al. Sedative hypnotics in older people with insomnia:
meta-analysis of risks and benefits. BMJ 2005;331:1169-73.
Habraken H, Declercq T. Sedativa bij bejaarden met insomnia. Minerva 2006,8:114-6.
http://www.minerva-ebm.be/nl/article.aspid=1148.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Bloom HG, Ahmed I, Alessi CA et al. Evidence-Based recommendations for the
assessment and management of sleep disorders in older persons. J Am Geriatr Soc
2009;57:761-89.
Woolcott JC, Richardson KJ, Wiens MO et al. Meta-analysis of the impact of 9
medication classes on falls in elderly persons. Arch Intern Med 2009;169:1952-60.
Boudreau RM, Hanlon JT, Roumani YF et al. Central nervous system medication use
and incident mobility limitation in community elders: the health, aging, and body
composition study. Pharmacoepidemiol Drug Saf 2009;18:916–922.
Anthierens S, Habraken H, Petrovic M et al. Benzodiazepinen opstarten in de
huisartsenpraktijk. Kwalitatieve studie van patiëntenperspectieven. Huisarts Nu
2008;37:379-85.
National Institute for Clinical Excellence. Guidance on the use of zaleplon, zolpidem
and zopiclone for the short-term management of insomnia. NICE Technology Appraisal
77, April 2004. http://guidance.nice.org.uk/TA77/Guidance/pdf/English.
Gehrman PR, Connor DJ, Martin JL et al. Melatonin fails to improve sleep or agitation
in double-blind randomized placebo-controlled trial of institutionalized patients with
Alzheimer disease. Am J Geriatr Psychiatry 2009;17(2):166-9.
Buscemi N, Vandermeer B, Hooton N et al. Efficacy and safety of exogenous melatonin
for secondary sleep disorders and sleep disorders accompanying sleep restriction:
meta-analysis. BMJ 2006;332:385-93.
Buscemi N, Vandermeer B, Hooton N et al. The efficacy and safety of exogenous
melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med
2005;20:1151-8.
Bijl D. Melatonine (Circadin®), primaire insomnia bij patiënten van 55 jaar en ouder.
Gebu 2009;43:80-1. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Melatonine-
Circadin-primaire-insomnia-bij-patienten-van-55-jaar-en-ouder.htm.
Rédaction Prescrire. Plainte d'insomnie. Une place pour la phytothérapie traditionnelle.
Rev Prescrire 2005;25:110-4.
Haute Authorité de Santé. Modalités d’arrêt des benzodiazépines et médicaments
apparentés chez le patient âgé. Octobre 2007. http://www.has-sante.fr/portail/upload
/docs/application/pdf/synthese_bzd_-_version_finale_2008.pdf.
Denis C, Fatséas M, Lavie E, Auriacombe M. Pharmacological interventions for
benzodiazepine mono-dependence management in outpatient settings. Cochrane
Database of Systematic Reviews 2006, Issue 3. Art. No.: CD005194. DOI: 10.1002/
14651858.CD005194.pub2.
PRODIGY. Benzodiazepine and Z drug withdrawal. PRODIGY 2006. http://prodigy.cla
rity.co.uk/benzodiazepine_and_z_drug_withdrawal.
Smalbrugge M, Pot AM, Jongenelis K et al. Prevalence and correlates of anxiety among
nursing home patients. J Affect Disord 2005;88:145-53.
National Institute for Health and Clinical Excellence. Generalised Anxiety disorder (with
or without agoraphobia) in adults. NICE Clinical Guideline 113. January 2011. http://
guidance.nice.org.uk/CG113.

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
Kwaliteitsinstituut voor de Gezondheidszorg (CBO). Update angststoornissen (eerste
revisie). CBO Multidisciplinaire richtlijn 2009. http://www.cbo.nl/thema/Richtlijnen/
Overzicht-richtlijnen/Gedragsstoornissen/p=403.
Ayers CR, Sorrell JT,Thorp SR,Wetherell JL. Evidence-based psychological treatments
for late-life anxiety. Psychol Aging 2007;22:8-17.
Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling. Richtlijnherziening van
de Multidisciplinaire richtlijn Angststoornissen (tweede revisie). Richtlijn voor
diagnostiek, behandeling en begeleiding van volwassen patiënten met een
angststoornis. GGZ-Richtlijnen 2011. http://www.ggzrichtlijnen.nl.
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van
angststoornissen. Transparantiefiche Juli 2008. http://www.bcfi.be/pdf/tft/TN_ANX.pdf.
Forbes D, Creamer MC, Phelps AJ et al. Treating adults with acute stress disorder and
post-traumatic stress disorder in general practice: a clinical update. Med J Aust
2007;187:120-3.
Gale CK, Millichamp J. Generalised anxiety disorder. BMJ Clinical Evidence
2011;10:1002. Search Date May 2011. http://clinicalevidence.bmj.com.
Hunot V, Churchill R, Teixeira V, Silva de Lima M. Psychological therapies for generalised
anxiety disorder. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.:
CD001848. DOI: 10.1002/14651858.CD001848.pub4.
Stanley MA, Wilson NL, Novy DM et al. Cognitive behavioural therapy works for anxiety
in older adults in primary care JAMA 2009;301:1460-7.
van Boeijen Ch, van Oppen P, Boeke J et al. Angststoornissen in de eerste lijn vaak
goed te behandelen. Een gerandomiseerd gecontroleerd onderzoek. Huisarts Wet
2007;50:315-20.
Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake
inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane
Database of Systematic Reviews 2008, Issue 1. Art. No.:CD001765.DOI:10.1002/
14651858.CD001765.pub3.
Soomro GM. Obsessive compulsive disorder. BMJ Clinical Evidence 2009;09:1004.
Search Date August 2007. http://clinicalevidence.bmj.com.
Lauderdale SA, Sheikh JI. Anxiety disorders in older adults. Clin Geriatr Med
2003;19:721-41.
Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised
anxiety disorder: systematic review and meta-analysis. BMJ 2011;342:d1199.
Terluin B, van Heest FB, Van der Meer K et al. NHG-Standaard. Angststoornissen.
Huisarts Wet 2004;47:26-37. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nh
gstandaarden/Samenvattingskaartje-NHGStandaard/M62_svk.htm.
Blank S, Lenze EJ, Mulsant BH et al. Outcomes of late-life anxiety disorders during 32
weeks of citalopram treatment. J Clin Psychiatry 2006;67:468-72.
Taylor CB. Panic disorder [Clinical review]. BMJ 2006;332:951-5.
Licht-Strunk E, Van Marwijk HWJ, Hoekstra T et al. Outcome of depression in later life
in primary care: longitudinal cohort study with three years’ follow-up. BMJ
2009;338:a3079.

49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Loh A, Leonhart R, Wills CE et al. The impact of patient participation on adherence
and clinical outcome in primary care of depression. Patient Educ Couns 2007;65:69-78.
Saver BG, Van-Nguyen V, Keppel G, Doescher MP. A qualitative study of depression
in primary care: missed opportunities for diagnosis and education. J Am Board Fam
Med 2007;20:28-35.
Clever SL, Ford DE, Rubenstein LV et al. Primary care patients' involvement in
decision-making is associated with improvement in depression. Med Care
2006;44:398-405.
Heyrman J, Declercq T, Rogiers R et al. Depressie bij volwassenen; aanpak door de
huisarts. Huisarts Nu 2008;37:284-317. http://www.domusmedica.be/images/stories
/aanbevelingen/h37_6_1_ab_depressie.pdf.
Hermens M, van Hout H, Terluin B et al. Helpen antidepressiva bij depressieve klachten
of lichte depressieve stoornissen Huisarts Wet 2008;51:361-9.
van ’t Veer-Tazelaar N, van Marwijk H, van Oppen P et al. Stapsgewijze preventie van
angst en depressie bij ouderen. Uitkomsten van een gerandomiseerd onderzoek.
Huisarts Wet 2009;52:668-73.
Declercq T, Poelman T. Een stapsgewijs zorgmodel voor preventie van angst en
depressie op oudere leeftijd. Minerva 2009;8(9):132-3. http://www.minerva-ebm.be/
nl/article.aspid=1780.
PRODIGY. Depression. PRODIGY 2010. http://prodigy.clarity.co.uk/depression.
Wilson KCM, Mottram PG, Vassilas CA. Psychotherapeutic treatments for older
depressed people. Cochrane Database of Systematic Reviews 2008, Issue 1. Art.
No.:CD004853. DOI:10.1002/14651858.CD004853.pub2.
Butler R, Hatcher S, Price J, Von Korff M. Depression in adults: psychological treatments
and care pathways. BMJ Clinical Evidence 2007;08:1016. Search Date April 2006.
http://clinicalevidence.bmj.com.
Wilson KCM, Mottram PG, Vassilas CA. Psychotherapeutic treatments for older
depressed people. Cochrane Database of Systematic Reviews 2008, Issue 1. Art.
No.:CD004853. DOI:10.1002/14651858.CD004853.pub2.
Mead GE, Morley W, Campbell P, Greig CA, McMurdo M, Lawlor DA. Exercise for
depression. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.:
CD004366. DOI: 10.1002/14651858.CD004366.pub3.
Jorm AF, Morgan AJ, Hetrick SE. Relaxation for depression. Cochrane Database of
Systematic Reviews 2008, Issue 4. Art. No.: CD007142. DOI: 10.1002/
14651858.CD007142.pub2.
Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for
depression using measurement-based care in STAR*D: Implications for clinical practice.
Am J Psychiatry 2006;163:28-40.
Mulsant BH, Houck PR, Gildengers AG et al. What is the optimal duration of a
short-term antidepressant trial when treating geriatric depression J Clin
Psychopharmacol 2006;26:113-20.
Rédaction Prescrire. Traitement de la maladie de Parkinson: Première partie. Rev
Prescrire 2011;31:200-5.
Timonen M, Liukkonen T. Management of depression in adults. BMJ 2008;336:435-9.

66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Bollen J, Constant E et al. Streven naar remissie van depressie door een betere en
bredere aanpak van de symptomen. Tijdschr voor Geneeskd 2006;62:1339-53.
National Institute for Health and Clinical Excellence. Depression: management of
depression in primary and secondary care. NICE Clinical Guideline 23, 2004. http://
guidance.nice.org.uk/CG23.
Reid S, Barbui C. Long term treatment of depression with selective serotonin reuptake
inhibitors and newer antidepressants. BMJ 2010;340:752-6.
Deshauer D, Moher D, Fergusson D et al. Selective serotonin reuptake inhibitors for
unipolar depression: a systematic review of classic long-term randomized controlled
trials. CMAJ 2008;178:1293-301.
De Meyere M. Majeure depressie bij ouderen twee jaar behandelen Minerva
2007;6:7-9 http://www.minerva-ebm.be/nl/article.aspid=1219.
Kirsch I, Deazcon Bj, Huedo-Medina TB et al. Initial severity and antidepressant benefits:
a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med
2008:5(2):e45.
De Meyere M. Verband tussen ernst van depressie en werkzaamheid van nieuwere
antidepressiva. Minerva 2008;7:118-9. http://www.minerva-ebm.be/nl/arti
cle.aspid=1539.
Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, Kerse N,
MacGillivray S. Antidepressants versus placebo for depression in primary care. Cochrane
Database of Systematic Reviews 2009, Issue 3. Art. No.: CD007954. DOI: 10.1002/
14651858.CD007954.
De Fruyt J, Sienaert P, Demyttenaere K. Doeltreffendheid van antidepressiva in vraag
gesteld: (on)terecht Tijdschr voor Geneeskd 2009;65(17):768-75.
Fournier JC, DeRubeis RJ, Hollon SD et al. Antidepressant drug effects and depression
severity. A patient-level meta-analysis. JAMA 2010;303(1):47-53.
Barbui C, Cipriani A, Patel V et al. Efficacy of antidepressants and benzodiazepines in
minor depression: systematic review and meta-analysis. Br J Psychiatry 2011;198:11-16.
Turner EH, Matthews M, Linardatos E et al. Selective publication of antidepressant
trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
Cipriani A, Barbui C, Butler R, et al. Depression in adults (drug and other physical
treatments). BMJ Clinical Evidence 2011;05:1003. Search Date June 2009. http://clini
calevidence.bmj.com.
Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane
Database of Systematic Reviews 2006, Issue 1. Art. No.: CD003491. DOI: 10.1002/
14651858.CD003491.pub2.
Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake
inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis.
Int J Geriatr psychiatry 2004;19:754-62.
MacGillivray S, Arroll B, Hatcher S et al. Efficacy and tolerability of selective serotonin
reuptake inhibitors compared with tricyclic antidepressants in depression treated in
primary care: systematic review and meta-analysis. BMJ 2003;326:1014-9.
Uher R, Farmer A, Henigsberg N et al. Adverse reactions to antidepressants. Br J
Psychiatry 2009;195:202-10.

83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Centraal
zenuwstelsel (psychische aandoeningen) / Depressie en antidepressiva.
Farmacotherapeutisch Kompas 2011. http://www.fk.cvz.nl.
Diem SJ, Blackwell TL, Stone KL et al. Use of antidepressants and rates of hip bone
loss in older women: the study of osteoporotic fractures. Arch Intern Med
2007;167(12):1240-5.
Medicines and Healthcare products Regulatory Agency. Antidepressants: risk of
fractures. Drug Safety Update 2010;3:3-4. http://www.mhra.gov.uk/home/groups/plp/documents/publication/con081866.pdf.
Price J, Cole V and Goodwin GM. Emotional side-effects of selective serotonin reuptake
inhibitors: qualitative study. Br J Psychiatry 2009;195:211-7.
Anonymous. Hyponatraemia with SSRIs. Australian Adverse Drug Reactions Bulletin
2003;22:10. http://www.tga.gov.au/pdf/aadrb-0306.pdf.
Wijnen H, Van Schendel F, Olde Rikkert M et al. Hyponatriëmie bij gebruik van selectieve
serotonineheropnameremmers: meldingen in 1992-2002. Ned Tijdschr Geneeskd
2004;148:1921-4.
Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective
serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008;66:76-81.
de Abajo FJ, Garcia-Rodriguez LA Risk of upper gastrointestinal tract bleeding associated
with selective serotonin reuptake inhibitors and venlafaxine therapy. Arch Gen
Psychiatry 2008;65(7):795-803.
Healy D, Herxheimer A, Menkes DB. Antidepressants and violence: problems at the
interface of medicine and law. PLoS Med 2006;3:e372.
Rédaction Préscrire. Antidépresseurs IRS et venlafaxine: bruxisme. Rev Prescrire
2007;27:434-5.
Rédaction Préscrire. Antidépresseurs sérotoninergiques: glaucomes aigus par fermeture
de l’angle. Rev Prescrire 2009:29:829.
Boyer, Edward W, Shannon M. The Serotonin Syndrome. N Engl J Med
2005;352:1112-20.
Belgisch Centrum voor Farmacotherapeutische Informatie. Het serotoninesyndroom
en het maligne neurolepticasyndroom. Folia pharmacotherapeutica 2008;35:10-1.
http://www.bcfi.be/PDF/Folia/2008/P35N02B.pdf.
Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of
suicide: a systematic review of observational studies. CMAJ 2009;180:291-7.
Livingston MG, Livingston HM. New antidepressants for old people The evidence
that newer drugs are much better than old is thin. BMJ 1999;318:1640-1.
Cipriani A, La Ferla T, Furukawa TA et al. Sertraline versus other antidepressive agents
for depression. Cochrane Database of Systematic Reviews 2009, Issue 2. Art.
No.:CD006117.DOI: 10.1002/14651858.CD006117.pub2.
Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill
R, Barbui C. Escitalopram versus other antidepressive agents for depression. Cochrane
Database of Systematic Reviews 2009, Issue 2. Art. No.: CD006532. DOI: 10.1002/
1465858.CD006532.pub2.

100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive
disorder: a meta-analysis. Curr Med Res Opin 2009;25(1):161-75.
Chevalier P. De plaats van duloxetine en venlafaxine bij majeure depressie. Minerva
Online 2011-02-28. http://www.minerva-ebm.be/nl/review.aspid=92.
Kallenbach LE, Rigler SK. Identification and management of depression in nursing
facility residents. J Am Med Dir Assoc 2006;7:448-55.
Rédaction Prescrire. Duloxétine: bilan après 3 ans. Rev Prescrire 2009;29:22.
Hansen R, Gartlehner G et al. Efficacy and safety of second-generation antidepressants
in the treatment of major depressive disorder. Ann Intern Med 2005;143:415-26.
Scottish Intercollegiate Guidelines Network. Non-pharmaceutical management of
depression in adults. SIGN Publication 114, January 2010. http://www.sign.ac.uk/pdf
/sign114.pdf.
Bijl D. Agomelatine. Gebu 2010;44:42-4. http://gebu.artsennet.nl/Archief/Tijdschrift
artikel/Agomelatine.htm.
Birkenhager TK, Moleman P, Nolen WA. Benzodiazepines for depression A review
of the literature. Int Clin Psychopharmacol 1995;10:181-95.
Furukawa TA, Streiner DL, Young LT. Antidepressants and benzodiazepine for major
depression. Cochrane Database of Systematic Reviews 2001, Issue 3. Art. No.:
CD001026. DOI: 10.1002/14651858.CD001026.
van Marwijk HWJ, Grundmeijer HGLM, Bijl D et al. NHG-Standaard Depressieve stoornis
(depressie) (eerste herziening). Huisarts Wet 2003;46:614-33. http://nhg.artsennet.nl
/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard
/M44_svk.htm.
Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP, Geddes JR,
Hardy R, Lewis G, Mason JM. Treatment discontinuation with selective serotonin
reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). [Withdrawn]. Cochrane
Database of Systematic Reviews 2006, Issue 3. Art. No.: CD002791. DOI: 10.1002/
14651858.CD002791.pub2.
Anonymous. Do SSRIs cause gastrointestinal bleeding Drug Ther Bull 2004;42:17-8.
British Geriatrics Society, Royal College of Physicians. Guidelines for the prevention,
diagnosis and management of delirium in older people. 2006. http://www.bgs.org.uk
/index.phpoption=com_content&view=article&id=170:clinguidedeliriumtreatment&ca
tid=42:catclinguidelines&Itemid=107.
Mellick EJM, de Vries OJ. Geneesmiddelen en ouderen: het delirium. Gebu
2002;36:73-8. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Geneesmiddelen-enouderen-het-delirium.htm.
Wanrooij B, Koelewijn M. De aanpak van het delier in de palliatieve fase. Huisarts Wet
2005;48:362-7.
Young J, Inouye SK. Clinical Review: Delirium in older people. BMJ 2007;334:842-6.
National Institute for Health and Clinical Excellence. Delirium: diagnosis, prevention
and management. NICE clinical guideline 103. July 2010. http://guidance.nice.org.uk
/CG103.

117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
Van der Weele GM, Van Dijk A, Eekhof JA. NHG-Standaard: Delier bij ouderen. Huisarts
Wet 2003;46:141-6. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstan
daarden/Samenvattingskaartje-NHGStandaard/M77_svk.htm.
Marcantonio E. In the Clinic: Delirium. Annals of Internal Medicine
2011;154:ITC6-1-ITC6-16.
Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. Cochrane
Database of Systematic Reviews 2007, Issue 2. Art. No.: CD005594. DOI: 10.1002/
14651858.CD005594.pub2.
Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician
2010;81(5):617-22.
Rédaction Prescrire. Neuroleptiques: entérocolites nécrosantes. Rev Prescrire
2008;28(300):751.
Lonergan E, Luxenberg J, Areosa Sastre A, Wyller TB. Benzodiazepines for delirium.
Cochrane Database of Systematic Reviews 2009, Issue
1.Art.No.:CD006379.DOI:10.1002/14651858.CD006379.pub2.
Overschott R, Karim S, Burns A. Cholinesterase inhibitors for delirium. Cochrane
Database of Systematic Reviews 2008, Issue 1, Art. No.:CD005317. DOI:10.1002/
14651858.CD005317.pub2.
Ancelin ML, Artero S, Portet F et al. Non-degenerative mild cognitive impairment in
elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ
2006;332:455-9.
Wind AW, Gussekloo J, Vernooij-Dassen MJ. NHG-Standaard Dementie, tweede
herziening. Huisarts Wet 2003;46:754-67. http://nhg.artsennet.nl/kenniscentrum/
k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M21_svk.htm.
Kroes M, Garcia-Stewart S, Allen F et al. Dementie: welke niet-pharmacologische
interventies Federaal Kenniscentrum voor de Gezondheidszorg (KCE). 2011. KCE
Reports Vol. 160A. http://www.kce.fgov.be/sites/default/files/page_documents/
kce_160a_dementie.pdf.
Schoenmakers B. Persoonsgeoriënteerde zorg en ‘dementia care mapping’: is er winst
op het vlak van gedragsproblematiek en levenskwaliteit Minerva 2011;10:34-5.
http://www.minerva-ebm.be/nl/article.aspid=2023.
Kolanowski A, Litaker M, Buettner L et al. A randomized clinical trial of theory-based
activities for the behavioral symptoms of dementia in nursing home residents. J Am
Geriatr Soc 2011;59:1032-41.
Hulstaert F, Thiry N, Eyssen M, Vrijens F. Medicamenteuze en niet-medicamenteuze
interventies voor de ziekte van Alzheimer, een rapid assessment. Federaal
Kenniscentrum voor de Gezondheidszorg (KCE). KCE reports Vol. 111A, 2009. http:/
/www.kce.fgov.be/sites/default/files/page_documents/d20091027327.pdf.
Loveman E, Green C, Kirby J et al. The clinical and cost-effectiveness of donepezil,
galantamine, and memantine for Alzheimer ’s disease. Health Technol Assess
2006;10:1-176.
Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer ’s disease. Cochrane
Database of Systematic Reviews 2006, Issue 1. Art. No.: CD001190. DOI: 10.1002/
14651858.CD001190.pub2.

132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer
’s disease. Cochrane Database of Systematic Reviews 2009, Issue 2.
Art.No.:CD001191.DOI: 10.1002/14651858.CD001191.pub2.
Loy C, Schneider L. Galantamine for Alzheimer ’s disease and mild cognitive impairment.
Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD001747. DOI:
10.1002/14651858.CD001747.pub3.
Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of
Systematic Reviews 2006, Issue 1. Art. No.: CD005593. DOI: 10.1002/
14651858.CD005593.
Belgisch Centrum voor Farmacotherapeutische Informatie. Cardiale ongewenste
effecten van cholinesterase-inhibitoren. Folia Pharmacotherapeutica 2006;33 :54.
http://www.bcfi.be/PDF/Folia/2006/P33N06F.pdf.
Rédaction Prescrire. Anticholinestérasiques: tremblements et aggravation de symptômes
parkinsoniens. Rev Prescrire 2006;26:824-6.
Gill SS, Anderson GM, Fisher HD et al. Syncope and its consequences in patients with
dementia receiving cholinesterase inhibitors. A population-based cohort study. Arch
Intern Med 2009;169(9):867-73.
Fisher AA, Davis MW. Prolonged QT interval, syncope, and delirium with galantamine.
Ann Pharmacother 2008;42:278-83.
Hernandez RK, Farwell W, Cantor MD et al. Cholinesterase inhibitors and incidence
of bradycardia in patients with dementia in the veterans affairs new England healthcare
system. J Am Geriatr Soc 2009;57:1997-2003.
Rédaction Prescrire. Bradycardies sous anticholinestérasique: reconnaître l’effet
indésirable et le prendre en compte. Rev Prescrire 2010;30:675-6.
Kim DH, Brown RT, Ding EL et al. Dementia medications and risk of falls, syncope,
and related adverse events : Meta-analysis of Randomized Controlled Trials. J Am
Geriatr Soc 2011;29:1019-31.
Rédaction Prescrire. Mémantine: forme « modérée » de la maladie d’Alzheimer: pas
d’intérêt clinique établi. Rev Prescrire 2007;27:655.
Kwaliteitsinstituut voor de Gezondheidszorg (CBO). Diagnostiek en medicamenteuze
behandeling van dementie. CBO 2005. http://www.diliguide.nl/document/969/demen
tie.html.
National Institute for Health and Clinical Excellence. Donepezil, galantamine,
rivastigmine (review) and memantine for the treatment of Alzheimer’s disease. NICE
Technology Appraisal 217. http://guidance.nice.org.uk/TA217/Guidance/pdf/English.
Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy
of memantine in mild Alzheimer disease. Arch Neurol 2011;68:991-8.
Birks J, Grimley Evans J. Ginkgo Biloba for cognitive impairment and dementia.
Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD003120. DOI:
10.1002/14651858.CD003120.pub3.
Weinmann S, Roll S, Schwarzbach C et al. Effects of Ginkgo biloba in dementia:
systematic review and meta-analysis. BMC Geriatrics 2010,10:14.
Harms SL, Garrard J, Schwinghammer P et al. Ginkgo biloba use in nursing home
elderly with epilepsy or seizure disorder. Epilepsia 2006;47:323-9.

149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
Rédaction Prescrire. Hémorragies liées au Ginkgo biloba Rev Prescrire 2007;27:618-9.
Rands G, Orrell M, Spector AE. Aspirin for vascular dementia. Cochrane Database of
Systematic Reviews 2000, Issue 4. Art. No.: CD001296. DOI: 10.1002/
14651858.CD001296.
Michiels B. Aspirine voor de ziekte van Alzheimer (AD-2000-studie). Minerva
2008;7:110. http://www.minerva-ebm.be/nl/article.aspid=1521.
Husebo BS, Ballard C, Sandvik R et al. Efficacy of treating pain to reduce behavioural
disturbances in residents of nursing homes with dementia: cluster randomised clinical
trial. BMJ 2011;343:d4065.
Vereniging van specialisten ouderengeneeskunde en sociaal geriaters. Multidisciplinair
werken aan probleemgedrag. Een multidisciplinaire handreiking bij de NVVA richtlijn
Probleemgedrag 2008. http://www.verenso.nl/wat-doen-wij/vakinhoudelijke-produc
ten/handreikingen/probleemgedrag.
Ayalon L, Gum AM, Feliciano L et al. Effectiveness of nonpharmacological interventions
for the management of neuropsychiatric symptoms in patients with dementia. a
systematic review. Arch Intern Med 2006;166:2182-8.
Ryden MB, Feldt KS. Goal-directed care: Caring for agressive nursing home residents
with dementia. J Gerontol Nurs 1992;18:35-42.
American Psychiatric Association. Practice Guideline for the treatment of patients with
Alzheimer’s Disease and Other Dementias. APA Practice Guideline, October 2007
http://psychiatryonline.org/content.aspxbookid=28&sectionid=1679489#152139.
Belgisch Centrum voor Farmacotherapeutische Informatie. Geneesmiddelen bij
dementie. Transparantiefiche Juli 2008. http://www.bcfi.be/pdf/tft/TN_Dem.pdf.
Doody RS, Stevens JC, Beck C et al. Practice parameter: Management of dementia (an
evidence-based review): Report of the Quality Standards Subcommittee of the American
Academy of Neurology. Neurology 2001;56;1154-66.
Burgio LD, Stevens A, Burgio KL et al. Teaching and maintaining behavior management
skills in the nursing home. Gerontologist 2002;42:487-96.
Fossey J, Ballard C et al. Effect of enhanced psychosocial care on antipsychotic use in
nursing home residents with severe dementia: cluster randomised trial. BMJ
2006;332:756-61.
Redactie WZC-Formularium. Psychosociale zorg vermindert gebruik van neuroleptica
bij rusthuisbewoners met ernstige dementie. Geneesmiddelenbrief 2006;13:35.
http://www.farmaka.be/nl/geneesmiddelenbrief/2006_06_geneesmiddelenbrief.pdf.
Lonergan E, Luxenberg J, Colford J, Birks J. Haloperidol for agitation in dementia.
Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD002852. DOI:
10.1002/14651858.CD002852.
Sink K, Holden K, Yaffe. Pharmacological treatment of neuropsychiatric symptoms of
dementia: A review of the evidence. JAMA 2005;293:596-608.
De Paepe P, Petrovic M. Medicamenteuze behandeling van neuropsychiatrische
symptomen bij dementie. Minerva 2006;5:7-10. http://www.minerva-ebm.be/nl/arti
cle.aspid=1070.

165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
Zuidema S, van Iersel M et al. Werkzaamheid en bijwerkingen van antipsychotica voor
neuropsychiatrische symptomen bij dementie; een systematische review. Ned Tijdschr
Geneeskd 2006;150:1565-73.
Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical antipsychotic
drugs in patients with alzheimer's disease. N Engl J Med 2006;355:1525-38.
Muench J, Hamer AN. Adverse effects of antipsychotic medications. Am Fam Physician
2010;81(5):617-22.
Streim JE, Beier MT, Jeste DV et al. Atypical antipsychotics and the geriatric patient:
balancing safety and efficacy. A supplement to Geriatrics, July 2007:3-18.
Rédaction Prescrire. Neuroleptiques: troubles de la déglutition. Rev Prescrire
2010;30:746-8.
Trifiro G, Gambassi G, Sen EF et al. Association of community-acquired pneumonia
with antipsychotic drug use in elderly patients. Ann Intern Med 2010;152:418-25.
Gill S, Rochon P, Herrmann N, Lee P et al. Atypical antipsychotic drugs and risk of
ischaemic stroke: population based retrospective cohort study. BMJ 2005;330:445.
Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled
case series study. BMJ 2008;337:616-8.
Seider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug
treatment for dementia : analysis of randomized placebo-contolled trials. JAMA
2005:294:1934-43.
Kales HC, Valenstein M, Kim HM et al. Mortality risk in patients with dementia treated
with antipsychotics versus other psychiatric medications. Am J Psychiatry
2007;164:1568-76.
Schneeweiss S, Setoguchi S et al. Comparative safety of conventional and atypical
antipsychotic medications: risk of death in British Columbia seniors. Effective Health
Care Research Report No. 2 August 2007. http://www.effectivehealthcare.ahrq.gov/
ehc/products/26/75/DEcIDE_Atypical_Antipsychotics_Seniors.pdf.
Ballard C, Hanney ML, Theodoulou M et al. The dementia antipsychotic withdrawal
trial (DART_AD) Long-term follow-up of a randomised placebo-controlled trial. Lancet
Neurol 2009;8:151-7.
Ray WA, Chung CP, Murray KT et al. Atypical antipsychotic drugs and the risk of
sudden cardiac death. N Engl J Med 2009;360:225-35.
Ballard C, Lana MM, Theodoulou M et al. A randomised, blinded, placebo-controlled
trial in dementia patients continuing or stopping neuroleptics (the DART_AD trial).
PLoS Med 2008;5:0001-13.
Warner J, Butler R , Gupta S. Dementia. BMJ Clinical Evidence 2010;04:1001. Search
Date April 2008. http://clinicalevidence.bmj.com.
Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the
treatment of neuropsychiatric symptoms and functional impairment in Alzheimer’s
disease: a meta-analysis. JAMA 2003;289:210-6.
Howard RJ, Juszczak E, Ballard CG et al. Donepezil for the treatment of agitation in
Alzheimer ’s disease. N Engl J Med 2007;357:1382-92.

182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
Seitz DP, Adunuri N, Gill SS et al. Antidepressants for agitation and psychosis in
dementia. Cochrane Database of Systematic Reviews 2011, Issue 2. Art. No.:
CD008191.DOI: 10.1002/14651858.CD008191.pub2.
Banerjee S, Hellier J, Dewey M et al. Sertraline or mirtazapine for depression in dementia
(HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet
2011;378:403-11.
Martinón-Torres G, Fioravanti M, Grmley Evans J. Trazodone for agitation in dementia.
Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD004990. DOI:
10.1002/14651858.CD004990.
Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane
Database of Systematic Reviews 2009, Issue 3.Art. No.:CD003945. DOI: 10.1002/
14651858.CD003945.pub3.
Clarke CE. Clinical review: Parkinson’s disease. BMJ 2007;335:441-5.
Bloem BR, van Laar T, Keus SHJ et al. Multidisciplinaire richtlijn ziekte van Parkinson.
Alphen a/d Rijn, Van Zuiden Communications, 2010. http://www.cbo.nl/thema/Richt
lijnen/Overzicht-richtlijnen/Neurologische-aandoeningen/p=368.
Draijer W, Eizenga W, Sluiter A. NHG-Standaard Ziekte van Parkinson. Huisarts Wet
2011;54:380-92. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaar
den/Samenvattingskaartje-NHGStandaard/M98_svk.htm.
PRODIGY. Parkinson’s disease. PRODIGY 2007. http://prodigy.clarity.co.uk/parkin
sons_disease.
Deane KHO, Whurr R, Clarke CE et al. Non-pharmacological therapies for dysphagia
in Parkinson's disease. Cochrane Database of Systematic Reviews 2001, Issue 1. Art.
No.: CD002816. DOI:10.1002/14651858.CD002816.
Deane KHO, Ellis-Hill C, Playford ED et al. Occupational therapy for Parkinson's disease.
Cochrane Database of Systematic Reviews 2001, Issue 2. Art. No.: CD002813.
DOI:10.1002/14651858.CD002813.
Deane KHO, Jones D, Playford ED et al. Physiotherapy versus placebo or no intervention
in Parkinson's disease. Cochrane Database of Systematic Reviews 2001, Issue 3. Art.
No.: CD002817. DOI:10.1002/14651858.CD002817.
Mehrholz J, Friis R, Kugler J, Twork S, Storch A, Pohl M. Treadmill training for patients
with Parkinson’s disease. Cochrane Database of Systematic Reviews 2010, Issue 1.Art.
No.:CD007830.DOI:10.1002/14651858.CD007830.pub2.
Suchowersky O, Gronseth G et al. Practice parameter: neuroprotective strategies and
alternative therapies for Parkinson disease (an evidence-based review) Report of the
Quality Standards Subcommittee of the American Academy of Neurology. Neurology
2006;66:976–82.
National Health Service. Initial bromocriptine therapy of no long-term advantage in
Parkinson’s disease NeLM news Service, 01/09/2008. http://www.nelm.nhs.uk/en/
NeLM-Area/News/2008---September/01/Initial-bromocriptine-therapy-of-no-long-termadvantage-in-Parkinsons-disease-/.
Rédaction Prescrire. Traitement de la maladie de Parkinson: Première partie. Rev
Prescrire 2011;31:200-5.

197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
Clarke CE, Moore PA. Parkinson’s disease. BMJ Clinical Evidence 2007;12:1203. Search
Date November 2006. http://clinicalevidence.bmj.com.
LeWitt PA. Levodopa for the treatment of Parkinson’s Disease. N Engl J Med
2008;359:2468-76.
Rédaction Prescrire. Agonistes dopaminergiques: jeu pathologiques et hypersexualité
(suite). Rev Prescrire 2008;28:187-9.
Weber WE, Nijssen PC. Impulscontrolestoornis door gebruik van dopamineagonisten.
Ned Tijdschr Geneeskd 2009;153:80-1.
National Institute for Health and Clinical Excellence. Parkinson’s disease: diagnosis and
management in primary and secondary care. NICE Clinical Guideline 35, June 2006.
http://guidance.nice.org.uk/CG35.
Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, Shah L, Wheatley K,
Gray R. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database of
Systematic Reviews 2008, Issue 2. Art. No.:CD006564. DOI: 10.1002/
14651858.CD006564.pub2.
Van Camp G, Flamez A, Cosyns B et al. Treatment of Parkinson's disease with pergolide
and relation to restrictive valvular heart disease. Lancet 2004;10:1179-83.
Schade R, Andersohn F et al. Dopamine agonists and the risk of cardiac-valve
regurgitation. N Engl J Med 2007;356:29-38.
Zanettini RR, Antonini A, Gatto G et al. Valvular heart disease and the use of dopamine
agonists for parkinson’s disease. N Engl J Med 2007;356:39-46.
Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors
versus other dopaminergic agents in early Parkinson's disease. Cochrane Database of
Systematic Reviews 2009, Issue 4. Art. No.: CD006661. DOI:10.1002/
14651858.CD006661.pub2.
Ives NJ, Stowe RL et al. Monoamine oxidase type B inhibitors in early Parkinson's
disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ
2004;329:593-9.
Scottish Intercollegiate Guidelines Network. Diagnosis and pharmacological
management of Parkinson’s disease. SIGN Clinical Guideline 113, January 2010.
http://www.sign.ac.uk/pdf/sign113.pdf.
Rédaction Prescrire. Traitement de la maladie de Parkinson: Réduire les fluctuations
motrices sous lévodopa. Rev Prescrire 2011;31:273-9.
Glare J. Pramipexole may help depression in Parkinson’s disease, as well as motor
symptoms. Lancet Neurol 2010;9(6):573-80.
Friedman JH. Treating depression in Parkinson disease. Journal Watch Neurology
January 27, 2009.
Nomura T, Inoue Y, Mitani H et al. Visual hallucinations as REM sleep behavior disorders
in patients with Parkinson's disease. Mov Disord 2003;18:812-7.
Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder:
demographic, clinical and laboratory findings in 93 cases. Brain 2000;123:331-9.
Gagnon JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep
behavior disorder. Neurology 2006;67:742–7.

Infecties
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Belgian Antibiotic Policy Coordination Committee (BAPCOC). Belgische gids voor
anti-infectieuze behandeling in de ambulante praktijk. Editie 2008. http://www.he
alth.belgium.be/eportal/Myhealth/Care/Properuse/Antibiotics/index.htm.
Costelloe C, Metcalfe C, Lovering A et al. Effect of antibiotic prescribing in primary
care on antimicrobial resistance in individual patiënts: systematic review and
meta-analysis. BMJ 2010;340:c2096.
Vergidis P, Hamer DH, Meydani SN et al. Patterns of antimicrobial use for respiratory
tract infections in older residents of long-term care facilities. J Am Geriatr Soc
2011;59:1093-8.
Hessen MT. In the Clinic: Clostridium difficile Infection. Ann Intern Med
2010;153:ITC4-1-ITC4-16.
Velghe A, Vogelaers D. Multiresistente micro-organismen in thuisvervangende
instellingen. Tijdschr Geneeskd 2007;63:169-73.
Simor AE. Diagnosis, management, and prevention of clostridium difficile infection in
long-term care facilities : a review. J Am Geriatr Soc 2010;58:1556-64.
Belgian Antibiotic Policy Coordination Committee (BAPCOC). Analyse van de
activiteitenrapporten voor 2009 van de antibioticatherapiebeleidsgroepen in de
Belgische ziekenhuizen. http://www.health.belgium.be/internet2Prd/groups/public/
@public/@dg1/@acutecare/documents/ie2faq/19069259.pdf.
European Surveillance of Antimicrobial Consumption. Report on point prevalence
survey of antimicrobial prescription in European nursing homes, 2009. ESAC-3: Nursing
Home Subproject Group. http://www.esac.ua.ac.be/main.aspxc=*ESAC2&n=50297.
Rédaction Prescrire. Les otites moyennes aiguës de l’adulte. Rev Prescrire
2003;23:127-8.
PRODIGY. Otitis media – acute. PRODIGY 2007.http://prodigy.clarity.co.uk/otitis_me
dia_acute .
Rédaction Prescrire. Ototoxicité des solutions auriculaires contenant un aminoside.
Rev Prescrire 1998;18:37.
Flynn CA, Griffin GH, Schultz JK. Decongestants and antihistamines for acute otitis
media in children. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.:
CD001727.pub2. DOI:10.1002/14651858.CD001727.pub2.
Acuin J. Chronic suppurative otitis media. BMJ Clinical Evidence 2007;02:507. Search
Date January 2007. http://clinicalevidence.bmj.com..
Rédaction Prescrire. Auricularum®: désormais avec solvant, mais toujours à éviter. Rev
Prescrire 2006;26:745.
Bjerre LM, Verheij TJM, Kochen MM. Antibiotics for community acquired pneumonia
in adult outpatiënts. Cochrane Database of Systematic Reviews 2009, Issue 4. Art.
No.: CD002109. DOI: 10.1002/14651858.CD002109.pub3.

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
Vardakas KZ, Siempos II, Grammatikos A et al. Respiratory fluoroquinolones for the
treatment of community-acquired pneumonia: a meta-analysis of randomized controlled
trials. CMAJ 2008;179:1269-77.
Depuydt P, Vogelaers D. Nosocomiale pneumonie buiten het ziekenhuis: ‚health-care
associated pneumonia‛ en rusthuispneumonie. Tijdschr Geneeskd 2007;63:174-81.
Redactie WZC-Formularium. Klinisch pad: acute lage luchtweginfectie in een RVT.
Geneesmiddelenbrief 2008;15:21-32. http://www.farmaka.be/nl/geneesmiddelenbrief
/2008_06_geneesmiddelenbrief.pdf.
Elinck C, Vints A, Sibille Y, Gérard B. Aanpak van acute exacerbaties van COPD in de
ambulante praktijk. Belgian Antibiotic Policy Coordination Committee (BAPCOC),
februari 2009. http://www.health.belgium.be/eportal/Myhealth/Care/Properuse/Anti
biotics/Humanmedicine/Recommendations/7468570.
Jefferson T, Jones M, Doshi P, Del Mar C, Dooley L, Foxlee R. Neuraminidase inhibitors
for preventing and treating influenza in healthy adults. Cochrane Database of
Systematic Reviews 2010, Issue 2. Art. No.: CD001265. DOI: 10.1002/
14651858.CD001265.pub3.
Falagas ME, Koletsi PK, Vouloumanou EK et al. Effectiveness and safety of
neuraminidase inhibitors in reducing influenza complications : a meta-analysis of
randomized controlled trials. J Antimicrob Chemo 2010;65:1330-46
Rédaction Prescrire. Oseltamivir: gare aux effets neuropsychiques chez les jeunes. Rev
Prescr 2010;30:23.
Rédaction Prescrire. Oseltamivir: troubles visuels et cardiaques. Rev Prescr 2009;29:107.
Canadian Agency for Drugs and Technologies in Health. Antivirals for pandemic
influenza: a review of the clinical effectiveness. CADTH Rapid Response Report, 17
dec 2010.http://www.cadth.ca/media/pdf/htis/dec_2010/L0236_Antivirals_Pandemic_In
fluenza.pdf.
Pappas P, Rex J, Sobel J et al. Guidelines for treatment of candidiasis. Clin Infect Dis
2004;38:161-89.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Middelen
bij orofaryngeale mycosen. Farmacotherapeutisch Kompas 2011 http://www.fk.cvz.nl
PRODIGY. Candida – oral. PRODIGY 2009. http://prodigy.clarity.co.uk/candida_oral.
Centers for Disease Control. Updated Norovirus outbreak management and disease
prevention guidelines. MMWR 2011;60 (No. RR 3):1-16. http://www.cdc.gov/mmwr/
pdf/rr/rr6003.pdf.
Gottlieb T, Heather CS. Diarrhoea in adults (acute). BMJ Clinical Evidence 2011;02:901.
Search date January 2010. http://clinicalevidence.bmj.com.
Redactie WZC-Formularium. Infecties in WZC. Geneesmiddelenbrief 2011;18:21-32.
http://www.farmaka.be/nl/geneesmiddelenbrief/2011_09_geneesmiddelenbrief.pdf.
Sen A. Recurrent cystitis in non-pregnant women. BMJ Clinical Evidence 2008;07:801.
Search date April 2007. http://clinicalevidence.bmj.com.
Barbosa-Cesnik C, Brown MB et al. Cranberry juice fails to prevent recurrent urinary
tract infection: results from a randomized placebo-controlled trial. Clin Infect Dis
2011;52:23-30.

33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Rodhe N, Mölstad S, Englund L, Svärdsudd K. Asymptomatic bacteriuria in a population
of elderly residents living in a community setting: prevalence, characteristics and
associated factors. Fam Pract 2006;23:303-7.
Nicolle LE, Bradley S, Colgan R et al. Infectious diseases society of America guidelines
for the diagnosis and treatment of asymptomatic bacteriura in adults. Clin Infect Dis
2005;40:643-54.
Van Haaren KAM, Visser HS, Van Vliet S et al. NHG-Standaard Urineweginfectie
(Tweede herziening). Huisarts Wet 2005;8:341-52 http://nhg.artsennet.nl/kenniscen
trum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/
M05_svk.htm.
Nicolle L. Catheter-related urinary tract infection. Drugs Aging 2005;22:627-39.
Dekker JH, Boeke AJP, Gercama AJ et al. NHG-standaard Fluor vaginalis. Huisarts Wet
2005;48:459-66. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaar
den/Samenvattingskaartje-NHGStandaard/M38_svk.htm.
Spence D. Candidiasis (vulvovaginal). BMJ Clinical Evidence 2010;01:815. Search date
March 2009. http://clinicalevidence.bmj.com.
Jefferson T, Di Pietrantonj C, Al-Ansary et al. Vaccines for preventing influenza in the
elderly. Cochrane Database of Systematic Reviews 2010, Issue 2. Art. No.: CD004876.
DOI: 10.1002/14651858.CD004876.pub3.
Belgisch Centrum voor Farmacotherapeutische Informatie. Influenza 2010-2011. Folia
Pharmacotherapeutica 2005;32:69-70. http://www.bcfi.be/PDF/Folia/2010/
P37N08C.pdf.
Belgisch centrum voor Farmacotherapeutische Informatie. Influenzavaccinatie bij
ouderen. BCFI Goed om weten 02.12.10. http://www.bcfi.be/nieuws/index.cfm.
Rédaction Prescrire. Vaccination des personnes âgées contre la grippe saisonnière. Rev
Prescr 2011 ;31 :205-8.
Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers
who work with the elderly. Cochrane Database of Systematic Reviews 2010, Issue 2.
Art. No.: CD005187. DOI: 10.1002/14651858.CD005187.pub3.
Anonymous. Seasonal flu vaccination for healthcare workers Drug Ther Bull
2010;48:122-5.
Nuorti J, Butler J, Farley M et al. Cigarette smoking and invasive pneumococcal disease.
Active Bacterial Core Surveillance Team. N Engl J Med 2000;342:681-9.
Hoge Gezondheidsraad Vaccinatiegids februari 2009. http://www.health.belgium.be
/eportal/Aboutus/relatedinstitutions/SuperiorHealthCouncil/publications/factsheetsvac
cination/index.htm.
Belgisch centrum voor Farmacotherapeutische Informatie. Gecommentarieerd
Geneesmiddelenrepertorium 2011. http://www.bcfi.be.
Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing
pneumococcal infection in adults. Cochrane Database of Systematic Reviews 2008,
Issue 1. Art. No.: CD000422. DOI: 10.1002/14651858.CD000422.pub2.
Huss A, Scott P, Stuck AE et al. Efficacy of pneumococcal vaccination in adults: a
meta-analysis. CMAJ 2009;180:48-58. Erratum in: CMAJ 2009;180(10):1038

50
51
52
53
54
55
56
57
58
59
60
61
62
63
Walters JAE, Smith S, Poole PJ et al. Injectable vaccines for preventing pneumococcal
infection in patiënts with chronic obstructive pulmonary disease. Cochrane Database
of Systematic Reviews 2010, Issue 11. Art. No.: CD001390. DOI: 10.1002/
14651858.CD001390.pub3.
Maruyama T, Taguchi O, Niederman MS et al. Efficacy of 23-valent pneumococcal
vaccine in preventing pneumonia and improving survival in nursing home residents:
double blind, randomised and placebo controlled trial. BMJ 2010:340:c1004.
Loeb M. The 23-valent polysaccharide vaccine prevents pneumococcal pneumonia
and reduces associated mortality in nursing home residents in Japan EBM 2010;15:117.
Joint Committee on Vaccination and Immunisation. JCVI statement on discontinuation
of the routine pneumococcal vaccination programme for adults aged 65 years and
older. UK Department of Health, 16 March 2011. http://www.dh.gov.uk/dr_consum_dh
/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_125122.pdf.
Van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing
Staphylococcus aureus infections in nasal carriers. Cochrane Database of Systematic
Reviews 2008, Issue 4. Art. No.: CD006216. DOI: 10.1002/14651858.CD006216.pub2.
Belgisch Centrum voor Farmacotherapeutische Informatie. Meticilline-resistente
Staphylococcus aureus. Folia Pharmacotherapeutica 2007;34:19-22. http://www.bc
fi.be/PDF/Folia/2007/P34N03B.pdf.
GOSPIZ-GDEPIH. Richtlijnen ter preventie van overdracht van MRSA in woon- en
zorgcentra. Juli 2005. http://www.belgianinfectioncontrolsociety.be.
Rebmann T, Areden K. Preventing methicillin-resistant Staphylococcus aureus
transmission in long-term care facilities : an executive summary of the APIC elimination
guide. Am J Infect Control 2011;39:235-8.
Schmitz GR, Bruner D, Pitotti R, et al. Randomized controlled trial of
trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patiënts at risk
for community-associated methicillin-resistant Staphylococcus aureus infection. Ann
Emerg Med 2010;56:283-7.
Hoge Gezondheidsraad. Belgische aanbevelingen voor de beheersing en preventie
van infecties met Clostridium difficile in acute ziekenhuizen en in woon- en zorgcentra.
HGR nr. 8365, mei 2008. http://www.health.belgium.be/eportal/Aboutus/relatedinsti
tutions/SuperiorHealthCouncil/publications/booklets/index.htm&fodnlang=nl.
Wetenschappelijk Instituut Volksgezondheid. Clostridium difficile-infecties in Belgische
ziekenhuizen: resultaten van de nationale surveillance. Juli 2006-decembre 2008.
ISP-WIV Juli 2009. https://www.wiv-isp.be/nsih/download/CDIF/CDIF-report-Ju
ly%202009-NL.pdf.
Linsky A, Gupta K, Lawler EV et al. Proton pump inhibitors and increased risk for
recurrent Clostridium difficile infection. Arch Intern Med 2010;170:772-8.
Shannon-Lowe J, Matheson NJ, Cooke FJ, et al. Prevention and medical management
of Clostridium difficile infection. BMJ 2010;12;340:c1296.
Jefferson T, Del Mar C, Dooley L et al. Physical interventions to interrupt or reduce the
spread of respiratory viruses: a Cochrane review. Health Technol Assess
2010;14:347-476.

64
65
Cowling BJ, Leung GM. Simple physical interventions such as hand washing and
wearing masks can reduce spread of respiratory viruses. Evid Based Med 2010;15:3.
Hoge Gezondheidsraad. Aanbevelingen inzake handhygiëne tijdens de zorgverlening.
HGR nr. 8349. Januari 2009. http://www.health.belgium.be/eportal/Aboutus/related
institutions/SuperiorHealthCouncil/publications/booklets/index.htm.

Vitaminen en mineralen
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Hoge Gezondheidsraad. Voedingsaanbevelingen voor België. Herziening 2009. HGR
nr. 8309. http://www.health.belgium.be/internet2Prd/groups/public/@public/@shc/do
cuments/ie2form/19066661.pdf.
Commissie Farmaceutische Hulp van het College voor zorgverzekeringen.
Farmacotherapeutisch Kompas. “Vitamines en mineralen”. Farmacotherapeutisch
Kompas 2011. http://www.fk.cvz.nl .
Belgische Centrum voor Farmacotherapeutische Informatie. BCFI - Gecommentarieerd
Geneesmiddelen Repertorium 2011. http://www.bcfi.be.
Evans JR. Antioxidant vitamin and mineral supplements for slowing the progression
of age-related macular degeneration. Cochrane Database of Systematic Reviews 2006,
Issue 2. Art. No.: CD000254. DOI: 10.1002/14651858.CD000254.pub2.
Vivekananthan DP, Penn MS, Sapp SK et al. Use of antioxidant vitamins for the
prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet
2003;361:2017-23.
Cook NR, Albert CM, Gaziano JM. A randomized factorial trial of vitamins C and E
and Beta Carotene in the secondary prevention of cardiovascular events in women:
results from the women’s antioxidant cardiovascular study. Arch Intern Med
2007;167:1610-8.
Hercberg S, Galan P, Preziosi P et al. The SU.VI.MAX Study: a randomized,
placebo-controlled trial of the health effects of antioxidant vitamins and minerals.
Arch Intern Med 2004;164:2335-42.
Hennekens CH, Buring JE, Manson JE et al. Lack of effect of long-term supplementation
with beta carotene on the incidence of malignant neoplasms and cardiovascular
disease. N Engl J Med 1996; 334:1145-9.
Lee IM, Cook NR, Manson JE et al. Beta-carotene supplementation and incidence of
cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 1999;
91:2102-6.
Lin J, Cook NR, Albert C et al. Vitamins C and E and beta carotene supplementation
and cancer risk: a randomized controlled trial. J Natl Cancer Inst 2009; 101:14-23.
Bjelakovic G, Nikolova D, Simonetti RG et al. Antioxidant supplements for preventing
gastrointestinal cancers. Cochrane Database of Systematic Reviews 2008, Issue 3. Art.
No.: CD004183. DOI: 10.1002/14651858.CD004183.pub3.
ATBC (The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group). The
effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers
in male smokers. N Engl J Med 1994; 330:1029-35.
Omenn GS, Goodman GE, Thornquist MD et al. Effects of combination of beta carotene
and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;
334:1150-5.
Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements
for prevention of mortality in healthy participants and patients with various diseases.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD007176. DOI:
10.1002/14651858.CD007176.
Penniston KL, Tanumihardjo SA. The acute and chronic toxic effects of vitamin A. Am
J Clin Nutr 2006; 83(2):191-201.
Martindale: the complete drug reference. 36th edition, 2009 The Pharmaceutical Press.
Gezondheidsraad. Naar een toereikende inname van vitamine D. Den Haag:
Gezondheidsraad, 2008; publicatie nr 2008//15. http://www.gezondheidsraad.nl/sites
/default/files/200815c.pdf.
Medical Advisory Secretariat. Clinical utility of vitamin D testing: an evidence-based
analysis. Ont Health Technol Assess Ser ]. 2010 ; 10; 1-95. http://www.health.gov.on.ca
/english/providers/program/mas/tech/reviews/pdf/rev_vitamin d_201002.pdf.
Holick MF, Binkley NC, Bischoff-ferrari HA, et al. Evaluation, treatment, and prevention
of vitamin D deficiency : an Endocrine Society clinical practice guideline. J Clin
Endocrinol Metab 2011;96:1911-30.
Ross AC, Taylor CL, Yaktine AL, et al. Dietary reference intakes for calcium and vitamin
D. The National Academies Press, Washington DC, 2010. http://www.ncbi.nlm.nih.gov
/books/NBK56070/pdf/TOC.pdf.
Avenell A, Gillespie WJ, Gillespie LD, O’Connell D. Vitamin D and vitamin D-analogues
for preventing fractures associated with involutional and post-menopausal osteoporosis.
Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD000227.DOI:
10.1002/14651858.CD000227.pub3.
Simon JA. Review: evidence for the efectiveness of vitamin D and calcium for reducing
CV outcomes, cancer and death is limited. ACP Journal Club 2009;151:JC5-5.
Bespreking van Chung M, Balk EM, Brendel M et al. Vitamin D and calcium: a systematic
review of health outcomes. Evid Rep Technol Assess 2009;183:1-420.
Chung M, Balk EM, Brendel M et al. Vitamin D and Calcium: Systematic Review of
Health Outcomes. Evid Rep Technol Assess 2009;183:1-420.
Grey A, Bolland M. Vitamin D supplementation and fracture risk. Arch Intern Med
2011;171:265-6.
Lee IM, Cook NR, Gaziano JM et al. Vitamin E in the primary prevention of
cardiovascular disease and cancer: the Women’s Health Study. JAMA 2005;294:56-65.
Sesso HD, Buring JE, Christen WG et al. Vitamins E and C in the prevention of
cardiovascular disease in men: the Physicians’ Health Study II randomized controlled
trial. JAMA 2008;300:2123-33.
Lonn E, Bosch J, Yusuf S et al. Effects of long-term vitamin E supplementation on
cardiovascular events and cancer. JAMA 2005;293:1338-47.
Lippman SM, Klein EA, Goodman PJ et al. Effect of selenium and vitamin E on risk of
prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention
Trial (SELECT). JAMA 2009;301:39-51.
Gaziano JM, Glynn RJ, Christen WG et al. Vitamins E and C in the prevention of
prostate and total cancer in men: the Physicians' Health Study II randomized controlled
trial. JAMA 2009;301:52-62.

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol,
or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative
Study. N Engl J Med 1997;336:1216-22.
Yaffe K, Clemons TE, McBee WL et al. Impact of antioxidants, zinc, and copper on
cognition in the elderly: a randomized, controlled trial. Neurology 2004;63:1705-7.
Kang JH, Cook N, Manson J et al. A randomized trial of vitamin E supplementation
and cognitive function in women. Arch Intern Med 2006;166:2462-8.
Kang JH, Cook NR, Manson JE et al. Vitamin E, vitamin C, beta carotene, and cognitive
function among women with or at risk of cardiovascular disease: The Women's
Antioxidant and Cardiovascular Study. Circulation 2009;119:2772-80.
Meydani SN, Leka LS, Fine BC et al. Vitamin E and respiratory tract infections in elderly
nursing home residents: a randomized controlled trial. JAMA 2004;292:828-36.
Graat JM, Schouten EG, Kok FJ. Effect of daily vitamin E and multivitamin-mineral
supplementation on acute respiratory tract infections in elderly persons: a randomized
controlled trial. JAMA 2002;288:715-21.
Agler AH, Kurth T, Gaziano JM, et al. Randomised vitamin E supplementation and risk
of chronic lung disease in the Women's Health Study. Thorax 2011;66:320-5.
Christen WG, Glynn RJ, Sesso HD, et al. Age-related cataract in a randomized trial of
vitamins E and C in men. Arch ophtalmol 2010;128(11):1397-1405.
Cockayne S, Adamson J, Lanham-New S. Vitamin K and the prevention of fractures:
systematic review and meta-analysis of randomized controlled trials. Arch Intern Med
2006;166:1256-61.
Meerkerk GJ, Aarns T, Dijkstra RH et al. NHG-standaard Problematisch alcoholgebruik
(Tweede herziening). Huisarts Wet 2005;48(6);284-85. http://nhg.artsennet.nl/kennis
centrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/
M10_svk.htm.
Raistrick D, Heather N, Godfrey C. Review of the effectiveness of treatment for alcohol
problems. National Treatment Agency for Substance Misuse. November 2006.http://
www.nta.nhs.uk/uploads/nta_review_of_the_effectiveness_of_treatment_for_alco
hol_problems_fullreport_2006_alcohol2.pdf .
Charness ME, So YT. Wernicke's encephalopathy. UpToDate 2010. http://www.upto
dateonline.com. .
Scottish Intercollegiate Guidelines Network. The management of harmful drinking
and alcohol dependence in primary care. SIGN Publication 74, September
2003.http://www.sign.ac.uk/pdf/sign74.pdf.
PRODIGY. Alcohol – problem drinking. PRODIGY 2007http://prodigy.clarity.co.uk/alco
hol_problem_drinking.
Charness ME. Overview of the chronic neurologic complications of alcohol. UpToDate
2010. http://www.uptodateonline.com. .
Ang CD, Alviar MJ, Dans AL et al. Vitamin B for treating peripheral neuropathy.
Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD004573. DOI:
10.1002/14651858.CD004573.pub3.

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
Gezondheidsraad. Voedingsnormen: calcium, vitamine D, thiamine, riboflavine, niacine,
pantotheenzuur en biotine. Den Haag: Gezondheidsraad, 2000; publicatie nr 2000/12.
http://www.gezondheidsraad.nl/sites/default/files/00@12Nr2.pdf.
Pazirandeh S, Lo CW, Burns D. Overview of water-soluble vitamins. UpToDate
2009.http://www.uptodateonline.com.
Gezondheidsraad. Voedingsnormen: vitamine B6, foliumzuur en vitamine B12. Den
Haag: Gezondheidsraad, 2003; publicatie nr 2003/04.http://www.gezondheidsraad.nl
/sites/default/files/03@04nr.pdf.
Malouf R, Grimley Evans J. Vitamin B6 for cognition. Cochrane Database of Systematic
Reviews 2003, Issue 4. Art. No.:CD004393. DOI: 10.1002/14651858.CD004393.
Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G. Homocysteine lowering interventions
for preventing cardiovascular events. Cochrane Database of Systematic Reviews 2009,
Issue 4. Art. No.: CD006612. DOI: 10.1002/14651858.CD006612.pub2.
Heinz J, Kropf S, Domröse U et al. B vitamins and the risk of total mortality and
cardiovascular disease in end-stage renal disease. Circulation 2010;121:1432-8.
Ebbing M, Bleie O, Ueland PM et al. Mortality and cardiovascular events in patients
treated with homocysteine-lowering B vitamins after coronary angiography. JAMA
2008;300:795-804.
Zhang SM, Cook NR, Albert CM et al. Effect of combined folic acid, vitamin B6, and
vitamin B12 on cancer risk in women: a randomized trial. JAMA 2008;300:2012-21.
Christen WG, Glynn RJ, Chew EY et al. Folic acid, pyridoxine, and cyanocobalamin
combination treatment and age-related macular degeneration in women: the Women's
Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med 2009;169:335-41.
Katan M. Hoeveel vitamine B6 is toxisch Ned Tijdschr Geneeskd 2005;149:2545.
Gezondheidsraad. Voedingsnormen: Naar een optimaal gebruik van foliumzuur. Den
Haag: Gezondheidsraad, 2008; publicatie nr 2008/02. http://www.gezondheidsraad.nl
/sites/default/files/200802N.pdf.
PRODIGY. Dementia. PRODIGY 2010. http://prodigy.clarity.co.uk/dementia .
Scottish Intercollegiate Guidelines Network. Management of patients with dementia.
SIGN Publication 86, February 2006. http://www.sign.ac.uk/pdf/sign86.pdf.
British Geriatrics Society. Guidelines for the prevention, diagnosis and management
of delirium in older people in hospital. Published January 2006.http://www.bgs.org.uk.
Malouf R, Grimley Evans J. Folic acid with or without vitamin B12 for the prevention
and treatment of healthy elderly and demented people. Cochrane Database of
Systematic Reviews 2008, Issue 4. Art. No.: CD004514. DOI:10.1002/
14651858.CD004514.pub2.
Armitage JM, Bowman L, Clarke RJ et al. Effects of homocysteine-lowering with folic
acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial
infarction survivors. JAMA 2010;303:2486-94.
Cole BF, Baron JA, Sandler RS et al. Folic acid for the prevention of colorectal adenomas:
a randomized clinical trial. JAMA 2007;297:2351-9.
Logan RF, Grainge MJ, Shepherd VC et al. Aspirin and folic acid for the prevention of
recurrent colorectal adenomas. Gastroenterology 2008;134:29-38.

64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
Wu K, Platz EA, Willett WC et al. A randomized trial on folic acid supplementation
and risk of recurrent colorectal adenoma. Am J Clin Nutr 2009;90:1623-31.
Figueiredo JC, Grau MV, Haile RW et al. Folic acid and risk of prostate cancer: results
from a randomized clinical trial. J Natl Cancer Inst 2009;101:432-5.
Ebbing M, Bønaa KH, Nygård O et al. Cancer incidence and mortality after treatment
with folic acid and vitamin B12. JAMA 2009;302:2119-26.
Van Vlierberghe H, Bogaert M. Vitaminen en mineralen: wetgeving en toxiciteit. Tijdschr
voor Geneeskd 2003;58:1455-9.
Carmel R. Cobalamin, the stomach and aging. Am J Clin Nutr 1997;66:750-9.
Dali-Youcef N, Andrès E. An update on cobalamin deficiency in adults. QJM
2009;102:17-28.
Joosten E, Fabri R. Is er plaats voor perorale therapie bij vitamine-B12-tekort Tijdschr
voor Geneeskd 2000;56:451-6.
Alaball V, Butter CC. Editorial. Reduced serum vitamin B-12 in patients taking
metformin. BMJ 2010;340:1147-8.
De Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients
with type 2 diabetes and risk of vitamin B-12 deficiency: randomized placebo controlled
trial. BMJ 2010;340:c2181.
Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency. Arch Intern Med
1999;159:1289-98.
Wiersinga WJ, De Rooij SEJA, Huijmans JGM et al. De diagnostiek van
vitamine-B12-deficiëntie herzien. Ned Tijdschr Geneeskd 2005;149:2789-94.
Titeca K, Van Heeringen C. Een delirium ten gevolge van een vitamine-B12-deficiëntie.
Tijdschr voor Geneeskd 2001;57:379-81.
Malouf R, Areosa Sastre A. Vitamin B12 for cognition. Cochrane Database of Systematic
Reviews 2003, Issue 3. Art. No.:CD004394. DOI: 10.1002/14651858.CD004394.
Duyvendak M, Veldhuis GJ. Vitamine B12-suppletie liever oraal dan parenteraal. Ned
Tijdschr Geneeskd 2009;153:2107-11.
Vidal-Alaball J, Butler C, Cannings-John R et al. Oral vitamin B12 versus intramuscular
vitamin B12 for vitamin B12 deficiency. Cochrane Database of Systematic Reviews
2005, Issue 3. Art. No.: CD004655. DOI: 10.1002/14651858.CD004655.pub2.
Anonymous. Oral or intramuscular vitamin B12. Drug Ther Bull 2009;47:19-21.
Hemilä H, Chalker E, Douglas B. Vitamin C for preventing and treating the common
cold. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD000980.
DOI: 10.1002/14651858.CD000980.pub3.
Hemilä H, Louhiala P. Vitamin C for preventing and treating pneumonia. Cochrane
Database of Systematic Reviews 2007, Issue 1. Art. No.: CD005532. DOI: 10.1002/
14651858.CD005532.pub2.
El-Kadiki A, Sutton A. Role of multivitamins and mineral supplements in preventing
infections in elderly people: systematic review and meta-analysis of randomized
controlled trials. BMJ 2005;330:871.
Avenell A, Campbell MK, Cook JA et al. Effect of multivitamin and multimineral
supplements on morbidity from infections in older people (MAVIS trial): pragmatic,
randomized, double blind, placebo controlled trial. BMJ 2005;324-9.

84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
Neuhouser ML, Wassertheil-Smoller S, Thomson C et al. Multivitamin use and risk of
cancer and cardiovascular disease in the Women’s Health Initiative Cohorts. Arch
Intern Med 2009;169:294-304.
Park SY, Murphy SP, Wilkens LR, et al. Multivitamin Use and the Risk of Mortality and
Cancer Incidence. The Multiethnic Cohort Study. Am. J. Epidemiol 2011;173:906-14.
Stratton J, Godwin M. The effect of supplemental vitamins and minerals on the
development of prostate cancer: a systematic review and meta-analysis. Family Practice
2011;8(3):243-52.
Clarke R, Halsey J, Lewington S, et al, Vitamin Treatment Trialists' Collaboration. Effects
of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer,
and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485
individuals. Arch Intern Med 2010;170:1622-31.
Lee M, Hong KS, Chang SC, et al. Efficacy of homocysteine-lowering therapy with
folic Acid in stroke prevention: a meta-analysis. Stroke 2010;41:1205-12.
House AA, Eliasziw M, Cattran DC, et al. Effect of B-vitamin therapy on progression
of diabetic nephropathy: a randomized controlled trial. JAMA 2010;303:1603-9.
Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega3 fatty
acids on cardiovascular diseases: a randomized placebo controlled trial. BMJ
2010;341:c6273.
Pittas A, Chung M, Trikalinos T, et al. Systematic Review: Vitamin D and
Cardiometabolic Outcomes. Ann Intern Med 2010;152:307-14.
Hackam DG. Review: antioxidant supplements for primary and secondary prevention
do not decrease mortality. ACP J Club 2007;147:4. Bespreking van: Bjelakovic G,
Nikolova D, Gluud LL et al. Mortality in randomized trials of antioxidant supplements
for primary and secondary prevention: systematic review and meta-analysis. JAMA
2007;297:842-57
PRODIGY. Age related macular degeneration. PRODIGY 2010http://prodigy.clarity.co.uk
/macular_degeneration_age_related.
Laekeman G, Chevalier P. Maculadegeneratie bij de vrouw: zijn antioxidantia effectief
Minerva 2009;8:108-9. http://www.minerva-ebm.be/nl/article.aspid=1752. Bespreking
van : Christen WG, Glynn RJ, Chew EY et al. Vitamin E and age-related cataract in a
randomized trial of women. Ophthalmology 2008;115:822-9.
Canadian Agency for Drugs and Technologies in Health. Vitalux for the prevention
and treatment of age-related macular degeneration: clinical effectiveness. CADTH
Rapid Response 12 January 2011. http://www.cadth.ca/media/pdf//htis/jan-2011/
K0301_Vitalux_AMD.pdf.
Anonymous. Vitamins for cataract prevention. The Medical Letter 2008;50:46-7.
Christen WG, Glynn RJ, Chew EY et al. Vitamin E and age-related cataract in a
randomized trial of women. Ophthalmology 2008;115:822-9.
Huysman F, Mathieu C. Behandeling van pijnlijke diabetische neuropathie: overzicht.
Tijdschr voor Geneeskd 2009;7:275-81.
Grodstein F, Kang JH, Glynn RJ et al. A randomized trial of beta carotene
supplementation and cognitive function in men: the Physicians' Health Study II. Arch
Intern Med 2007;167:2184-90.

100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
Belgisch Centrum voor Farmacotherapeutische Informatie. Geneesmiddelen bij
dementie. Transparantiefiche Juli 2008 (met jaarlijkse updates tot en met September
2010). http://www.bcfi.be/pdf/tft/TN_Dem.pdf.
Balk E, Raman G, Tatsioni A et al. Vitamin B6, B12 and folic acid supplementation and
cognitive function. Arch Intern Med 2007;167:21-30.
Aisen PS, Schneider LS, Sano M et al. High-dose B vitamin supplementation and
cognitive decline in Alzheimer disease. JAMA 2008;300:1774-83.
Laekeman G. Invloed van vitamine B6, B12 of foliumzuur op cognitief functioneren:
meer rook dan vuur. Minerva 2007;6:114-5. http://www.minerva-ebm.be/nl/arti
cle.aspid=1317 Bespreking van Balk E, Raman G, Tatsioni A et al. Vitamin B6, B12
and folic acid supplementation and cognitive function. Arch Intern Med
2007;167:21-30.
Ford AH, Flicker L, Alfonso H, et al. Vitamins B(12), B(6), and folic acid for cognition
in older men. Neurology 2010;75:1540-7.
The DIPART (vitamin D Individual Patient Analysis of Randomized Trials) Group. Patient
level pooled analysis of 68.500 patients from seven major vitamin D fracture trials in
US and Europe. BMJ 2010;340:b5463.
Bischoff-Ferrari HA, Dawson-Hughes B, Stahelin HB et al. Fall prevention with
supplemental and active forms of vitamin D: a meta-analysis of randomised controlled
trials. BMJ 2009;339:b3692.
Michael YL, Whitlock EP, Lin JS, et al. Primary care-relevant interventions to prevent
falling in older adults: a systematic evidence review for the US Preventive Services Task
Force. Ann Intern Med 2010;153:815-25.
Sanders KM, Stuart AL, Williamson EJ, et al. Annual High-Dose Oral Vitamin D and
Falls and Fractures in Older Women: A Randomized Controlled Trial. JAMA
2010;303:1815-182.
Elders PJM, Leusink GL, Graafmans WC et al. NHG-standaard osteoporose (eerste
herziening). Huisarts Wet 2005;48(11):559-570. http://nhg.artsennet.nl/kenniscentrum
/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M69_svk.htm
.
Sato Y, Honda Y, Iwamoto J et al. Effect of folate and mecobalamin on hip fractures
in patients with stroke. JAMA 2005;293:1082-88.
Sawka, AM, Ray, JG, Yi, Q, et al. Randomized clinical trial of homocysteine level
lowering therapy and fractures. Arch Intern Med 2007;167:2136.
Belgisch Centrum voor Farmacotherapeutische Informatie. Preventie en behandeling
van postmenopauzale osteoporose. Folia Pharmacotherapeutica 2004;31:64-70.
http://www.bcfi.be/PDF/Folia/2004/P31N08B.pdf .
Topal C, Algun E, Sayarlioglu H, et al. Diurnal rhythm of urinary calcium excretion in
adults. Renal Failure 2008;30: 499-501.
Bolland MJ, Avenell A, Baron JA et al. Effect of calcium supplements on risk of
myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691.
Singh S, Furberg CD. Systematic review: Calcium supplements increase risk of
myocardial infarction. EBM 2010;15:181.

116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
Lewis JR, Calver J, Zhu K, et al. Calcium supplementation and the risks of atherosclerotic
vascular disease in older women: results of a 5-year RCT and a 4.5 year follow-up. J
Bone Miner Res 2011;26:35-41.
van der Sijs IH,Ho-Dac-Pannekeet MM.The treatment of hypomagnesemia. Ned Tijdschr
Geneeskd 2002;146:934-8.
Young G. Leg cramps. BMJ Clinical Evidence2009;03:1113. Search Date September
2008http://www.clinicalevidence.bmj.com. .
Semla T, Beizer J, Higbee M. Geriatric dosage Handbook. 8th Edition. Lexi-Comp Inc.
2004.
Commissie Farmaceutische Hulp van het College voor zorgverzekeringen. Anemie
door ijzergebrek, ijzerpreparaten.Farmacotherapeutisch Kompas 2011. http://
www.fk.cvz.nl .
Van Wijk MAM, Mel M, Muller PA et al. NHG-Standaard Anemie. Huisarts Wet
2003;46(1):21-9. Rectificatie algoritme Huisarts Wet 2003;46(3):147. http://nhg.art
sennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHG
Standaard/M76_svk.htm.
PRODIGY. Anaemia – Iron deficiency. PRODIGY 2008. http://prodigy.clarity.co.uk/anae
mia_iron_deficiency .
van der Linden MW. Ijzerpreparaten bij ijzergebreksanemie. GeBu2009;43:13-8.
http://gebu.artsennet.nl/Archief/Tijdschriftartikel/IJzerpreparaten-bij-ijzergebreksane
mie.htm.
Rimon E, Kagansky N, Kagansky M et al. Are we giving too much iron Low-dose iron
therapy is effective in octogenarians. Am J Med 2005;118:1142-7.
Ioannou G, Debley C. Low dose iron supplementation was effective in older patients
with iron deficincy anaemia. Evid Based Med 2006;11:89. Discussion of: Rimon E,
Kagansky N, Kaansky M et al. Are we giving too much iron Low-dose iron therapy
is effective in octogenarians. Am J Med 2005;118:1142-7.
Joosten E. Diagnostiek en therapie van niet-oncologische anemie bij ouderen. Tijdschr
voor Geneeskd 2010;66:611-7.
Wilkinson EAJ, Hawke CC. Oral zinc for arterial and venous leg ulcers. Cochrane
Database of Systematic Reviews 1998, Issue 4. Art. No.: CD001273. DOI: 10.1002/
14651858.CD001273.
Arrol B. Common cold. BMJ Clinical Evidence 2011;03:1510. Search Date January
2010.http://www.clinicalevidence.bmj.com .
Singh M, Das RR. Zinc fot the common cold. Cochrane Database Syst Rev
2011:issue2CD0012364.DOI 10.1002/14651858.CD001364.pub3.
Stranges S, Marshall JR, Natarajan R et al. Effects of long-term selenium
supplementation on the incidence of type 2 diabetes. Ann Intern Med
2007;147:217-23.

Dermatologie
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Mulder WM, Meinardi MM, Bruynzeel DP. Huidreacties door geneesmiddelen. Ned
Tijdschr Geneeskd 2004;148:415-20.
Gielen K, Goossens A. Contactallergische reacties bij medisch personeel door
geneesmiddelen. Tijdschr voor Geneeskd 2004;60:1776-84.
Hodgkinson B, Nay R, Wilson J. A systematic review of topical skin care in aged care
facilities. J Clin Nurs 2007;16,129-36.
Belgische Farmacopeecommissie. Therapeutische Magistraal Formularium. Uitgave
2010. Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten. http://
www.fagg-afmps.be/nl/binaries/TMF_Apothekers_Uitgave_2010_tcm290-121400.pdf.
National Institute for Health and Clinical Excellence. Frequency of application of topical
corticosteroids for atopic eczema. NICE Technology Appraisal 81, August 2004.
http://guidance.nice.org.uk/TA81/Guidance/pdf/English.
PRODIGY. Dermatitis – contact. PRODIGY 2005. http://prodigy.clarity.co.uk/dermati
tis_contact.
Bath-Hextall F, Delamere FM, Williams HC. Dietary exclusions for established atopic
eczema. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD005203.
DOI:10.1002/14651858.CD005203.pub2.
Williams H, Bigby M, Diepgen T et al. Evidence Based Dermatology. BMJ Books. April
2003.
National Prescribing Centre. Atopic eczema in primary care. MeReC Bulletin
2004;14:1-4. http://www.npc.nhs.uk/merec/therap/skin/resources/
merec_bulletin_vol14_no1.pdf.
Schmitt J, Apfelbacher CJ, Flohr C. Eczema. BMJ Clinical Evidence 2011;05:1716.
Search Date May 2009. http://clinicalevidence.bmj.com.
Anonymous. Bath emollients for atopic eczema: why use them Drug Ther Bull
2007;45:73.
Saary J, Qureshi R, Palda V et al. A systematic review of contact dermatitis treatment
and prevention. J Am Acad Dermatol 2005;53:845-55.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen.
Dermatocorticosteroïden. Farmacotherapeutisch Kompas 2011.http://www.fk.cvz.nl.
Anonymous. Topical steroids for atopic dermatitis in primary care. Drug Ther Bull
2003;41:5-8.
Green C, Colquitt JL, Kirby J et al. Clinical and cost-effectiveness of once-daily versus
more frequent use of same potency topical corticosteroids for atopic eczema: a
systematic review and economic evaluation. Health Technology Assessment
2004;8(47):1-134. http://www.hta.ac.uk/1372..
Williams HC. Established corticosteroid creams should be applied only once daily in
patients with atopic eczema. BMJ 2007;334:1272.
Rédaction Prescrire. Tacrolimus dermique: trop d’inconnues pour utiliser cet
immunosuppresseur par voie cutanée. Rev Prescrire 2003;23:805-9.

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Ashcroft D, Dimmock P, Garside R et al. Efficacy and tolerability of topical pimecrolimus
and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised
controlled trials. BMJ 2005;330:516-22.
Garside R, Stein K, Castelnuovo E et al. The effectiveness and cost-effectiveness of
pimecrolimus and tacrolimus for topic eczema: a systematic review and economic
evaluation. Health Technology Assessment 2005;9(29); 1-246. http://www.hta.ac.uk
/1379.
Rédaction Prescrire. Pimécrolimus ou tacrolimus dermique et cancer. Rev Prescrire
2005;25:592.
European Medicines Agency. Questions and answers on Protopic/Protopy and Elidel.
http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Eli
del_31/WC500012303.pdf.
Anonymous. Pimecrolimus. Aust Prescr 2003;26:149-50.
National Institute for Health and Clinical Excellence. Tacrolimus and pimecrolimus for
atopic eczema. NICE Technology Appraisal 82, August 2004. http://guidance.nice.org.uk
/TA82.
Naldi L. Seborrhoeic dermatitis. BMJ Clinical Evidence 2010;12:1713. Search date April
2010. http://clinicalevidence.bmj.com.
Lareb (Nederlands Bijwerkingen Centrum). Seleniumsulfide en huidirritatie. GeBu
2009;43:81. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Seleniumsulfide-Selsunen-huidirritatie.htm.
Van Zuuren EJ, Graber MA, Hollis S et al. Interventions for rosacea. Cochrane Database
of Systematic Reviews 2005, Issue 3. Art. No.: CD003262. DOI:10.1002/
14651858.CD003262.pub3.
Van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S. Systematic review of rosacea
treatments. J Am Acad Dermatol 2007; 56:107-15.
Korting HC, Schöllmann C. Current topical and systemical approaches to treatment
of rosacea. J Eur Acad Dermatol Venereol 2009;23:876-82.
Anonymous. De behandeling van rosacea. Geneesmiddelenbulletin 1998;32:101-5.
http://gebu.artsennet.nl/Archief/Tijdschriftartikel/De-behandeling-van-rosacea.htm.
Finnish Medical Society Duodecim. Psoriasis. In: EBM Guidelines. Evidence-Based
Medicine Helsinki Finland.
Naldi L, Rzany B. Psoriasis (chronic plaque). BMJ Clinical Evidence 2009;01:1706. Search
Date August 2007. http://clinicalevidence.bmj.com.
Belgisch Centrum voor Farmacotherapeutische Informatie. Vitamine D-analogen bij
psoriasis. Folia Pharmacotherapeutica 2003;30:7-8. http://www.bcfi.be/PDF/Folia/2003
/P30N01D.pdf.
Van Hecke E. Calcipotriol voor chronische plaque psoriasis. Minerva (Huisarts Nu)
2002;32:378-80. http://www.minerva-ebm.be/nl/article.aspid=575.
Lantinga H, Ek JW, Nijman FC et al. NHG-Standaard Psoriasis (tweede herziening).
http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattings
kaartje-NHGStandaard/M39_svk.htm.
Bruner CR, Feldman SR, Ventrapragada M et al. A systematic review of adverse effects
associated with topical treatments for psoriasis. Dermatol Online J 2003;9:2.

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
Afifi T, de Gannes G, Huang C et al. Topical therapies for psoriasis: evidence-based
review. Can Fam Physician 2005;51:519-25.
National Health Service Scotland. Re-submission: Calcipotriol and betamethasone
dipropionate ointment. Scottisch Medicines Consortium Advice, 12 December 2005.
http://www.scottishmedicines.org.uk/files/Calcipotriol_betamethasone__Dovobet_-
Resubmission_09-02.pdf.
Rédaction Prescrire. Cancers cutanés après puvathérapie. Rev Prescrire 2005;261:353.
Rédaction Prescrire. Antibiotiques locaux (suite): retraits et restrictions bienvenus dans
les infections cutanées. Rev Prescrire 2009;29(305):181.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Middelen
bij wondbehandeling en desinfectie van de huid. Farmacotherapeutisch Kompas 2011.
http://www.fk.cvz.nl.
George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo.
Br J Gen Pract 2003;53:480-7.
Koning S, Verhagen AP, van Suijlekom-Smit LWA, Morris AD, Butler C, van der Wouden
JC. Interventions for impetigo. Cochrane Database of Systematic Reviews 2003, Issue
2. Art. No.: CD003261. DOI: 10.1002/14651858.CD003261.pub2.
Health Protection Agency. Management of infection guidance for primary care for
consultation & local adaptation. Health Protection Agency Latest review March-July
2010. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1279888711402.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Bacteriële
huidinfecties. Farmacotherapeutisch Kompas 2011. http://www.fk.cvz.nl.
Belgian Antibiotic Policy Coordination Committee (BAPCOC). Belgische gids voor
anti-infectieuze behandeling in de ambulante praktijk. Editie 2008.http://www.he
alth.belgium.be/eportal/Myhealth/Care/Properuse/Antibiotics/index.htm.
Boukes FS, Van der Burgh JJ, Nijman FC et al. NHG-Standaard Bacteriële Huidinfecties.
Huisarts Wet 1998;41:427-37. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/
k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M68_svk.htm
Laube S, Farrell AM. Bacterial skin infections in the elderly: diagnosis and treatment.
Drugs Aging 2002;19:331-42.
Morris AD. Cellulitis and erysipelas. BMJ Clinical Evidence 2008;01:1708. Search Date
May 2007. . http://clinicalevidence.bmj.com.
PRODIGY. Cellulitis. PRODIGY 2006. http://prodigy.clarity.co.uk/cellulitis_acute.
Von den Driesch P. Candidiasis. Evidence Based Dermatology. BMJ Books. April 2003,
p. 490-500.
Belgisch Centrum voor Farmacotherapeutische Informatie. Gecommentarieerd
Geneesmiddelen Repertorium 2009. www.bcfi.be
Van Puijenbroek EP, Duyvendak RJP, De Kock CA et al. NHG-Standaard
Dermatomycosen, eerste herziening. Huisarts Wet 2008;51(2):76-84 http://nhg.artsen
net.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStan
daard/M64_svk.htm.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen.
Dermatomycosen. Farmacotherapeutisch Kompas 2011. http://www.fk.cvz.nl.

54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
Crawford F. Athlete’s foot. BMJ Clinical Evidence 2009;07:1712. Search Date July
2008. http://clinicalevidence.bmj.com.
PRODIGY. Fungal (dermatophyte) skin infections. PRODIGY 2006. http://prodigy.clari
ty.co.uk/fungal_skin_infection_body_and_groin.
PRODIGY. Fungal and candidal nail infection. PRODIGY 2006. http://prodigy.clari
ty.co.uk/fungal_nail_infection.
Rédaction Prescrire. Mycoses ungéales. Rev Prescrire 2008;28:205-11.
Szepietowski JC, Reich A, Garlowska E, et al. Factors Influencing Coexistence of Toenail
Onychomycosis With Tinea Pedis and Other Dermatomycosis: A Survey of 2761 Patients.
Arch Dermatol 2006;142:279-84.
Ferrari J. Fungal nail infections. BMJ Clinical Evidence 2011;08:1715. Search Date
March 2011. . http://clinicalevidence.bmj.com.
Amabile CM, Spencer AP. Keeping your patient with heart failure safe: a review of
potentially dangerous medications. Arch Intern Med 2004;164:709-20.
Rédaction Prescrire. Syndrome de Lyell et terbinafine. Rev Prescr 2010;30:832.
PRODIGY. Warts (including verrucas). PRODIGY 2007. http://prodigy.clarity.co.uk/
warts_and_verrucae.
Loo SK, Tang YM. Warts (non-genital). BMJ Clinical Evidence 2009;09:1710.Search
Date June 2008. http://clinicalevidence.bmj.com.
Bruggink SC, Gussekloo J, Berger MY et al. Stikstoftherapie is de effectiefste
behandeling voor handwratten in de huisartsenpraktijk. Ned Tijdschr Geneeskd
2011;155:A3134.
Rédaction Prescire. Varicelle ou zona et anti-inflammatoires non stéroïdiens:
complications cutanées graves. Rev Prescrire 2009;29:906-7.
Mikaeloff Y, Kezouh A, Suissa S. Nonsteroidal anti-inflammatory drug use and the risk
of severe skin and soft tissue complications in patients with varicella or zoster disease.
Br J Clin Pharmacol 2008;65:203-209.
Belgisch Centrum voor Farmacotherapeutische Informatie. Aanpak van zona.
Transparantiefiche Juni 2010. http://www.bcfi.be/pdf/tft/TN_Zona_Lng.pdf.
Oxman MN, Levin MJ et al. A vaccine to prevent Herpes Zoster and Postherpetic
Neuralgia in older adults. N Engl J Med 2005;352:2271-84.
Fekete T. A varicella-zoster virus vaccine reduced the burden of illness of herpes zoster
in older adults. Evid Based Med 2005;10:177.
Chen N, Li Q, Zhang Y et al. Vaccination for preventing postherpetic neuralgia.
Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No.:CD007795. DOI:
10.1002/14651858.CD007795.pub2.
Bilcke J, Marais C, Benson O et al. Kosteneffectiviteit van vaccinatie tegen windpokken
bij kinderen en tegen zona bij ouderen in België. Federaal Kenniscentrum voor de
Gezondheidszorg. KCE Reports vol. 151A, 2010. http://www.kce.fgov.be/sites/default
/files/page_documents/kce_151a_vaccinatie_tegen_windpokken_en_zona.pdf.
Lapeere H. Aanpak van schurft in rust- en verzorgingstehuizen. Tijdschr voor Geneeskd
2007;63:235-7.
Johnstone P, Strong M. Scabies. BMJ Clinical Evidence 2008;08:1707. Search Date
October 2007. http://clinicalevidence.bmj.com.

74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
PRODIGY. Scabies. PRODIGY 2007. http://prodigy.clarity.co.uk/scabies.
Redactie WZC-Formularium. Chronische wonden bij ouderen: oorzaken en preventie.
Geneesmiddelenbrief 2007;14:33-42. http://www.farmaka.be/nl/geneesmiddelenbrief
/2007_09_geneesmiddelenbrief.pdf.
Fernandez R, Griffiths R. Water for wound cleansing. Cochrane Database of Systematic
Reviews 2002, Issue 4. Art. No.: CD003861. DOI: 10.1002/14651858.CD003861.pub2.
Vanderwee K, Grypdonck M, Defloor T. Non-blanchable erythema as an indicator for
the need for pressure ulcer prevention: a randomized-controlled trial. J Clin Nurs
2007;16,325-35.
Nixon J, Cranny G, Iglesias C et al. Randomised, controlled trial of alternating pressure
mattresses compared with alternating pressure overlays for the prevention of pressure
ulcers: PRESSURE (pressure relieving support surfaces) trial. BMJ 2006;332:1413-5.
Reddy M. Pressure ulcers. BMJ Clinical Evidence 2011;05:1901. Search Date June
2010. http://clinicalevidence.bmj.com.
National Institute for Health and Clinical Excellence, Royal College of Nursing. The
management of pressure ulcers in primary and secondary care. A clinical practice
guideline. NICE Clinical Guideline 29, 2005. http://guidance.nice.org.uk/CG29.
Chel VGM, Germs PH, Van der Wal J et al. NHG-Standaard decubitus.. Huisarts Wet
1999;42:165-72. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaar
den/Samenvattingskaartje-NHGStandaard/M70_svk.htm.
Moore ZEH, Cowman S. Wound cleansing for pressure ulcers. Cochrane Database of
Systematic Reviews 2005, Issue 4. Art No.: CD004983.pub2. DOI:10.1002/14651858.
CD04983.pub2.
Bergin SM, Wraight P. Silver based wound dressings and topical agents for treating
diabetic foot ulcers. Cochrane Database of Systematic Reviews 2006, Issue 1. Art.No.:
CD005082.pub2.DOI: 10.1002/14651858.CD005082.pub2.
Nelson EA, Jones J. Venous leg ulcers. BMJ Clinical Evidence 2008;09:1902. Search
Date September 2007. http://clinicalevidence.bmj.com.
Van Hof N, Balak FSR, Apeldoorn L et al. NHG-Standaard Ulcus cruris venosum. Huisarts
Wet 2010;53:321-33. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstan
daarden/Samenvattingskaartje-NHGStandaard/M16_svk.htm.
Nederlandse Vereniging voor Dermatologie en Venerologie. Richtlijn: Diagnostiek en
behandeling van het ulcus cruris venosum. NVDV, 2005. http://www.huidarts.info/do
cuments/v=2&id=75.
Palfreyman SJ, Nelson EA, Lochiel R, Michaels JA. Dressings for healing venous leg
ulcers. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD001103.
DOI: 10.1002/14651858.CD001103.pub2.
Nelson EA, Bradley MD. Dressings and topical agents for arterial leg ulcers. Cochrane
Database of Systematic Reviews 2007, Issue 1. Art. No.: CD001836. DOI:10.1002/
14651858.CD001836.pub2.
Hunt D. Diabetes : foot ulcers and amputations. BMJ Clinical Evidence 2011;08:602.
Search Date September 2010. http://clinicalevidence.bmj.com.

90
91
92
93
94
95
Jeffcoate WJ, Price PE, Phillips CJ et al. Randomised controlled trial of the use of three
dressing preparations in the management of chronic ulceration of the foot in diabetes.
Health Technol Assess 2009 ;13 :1-86.
Hailey D, Jacobs P, Perry DC et al. Adjunctive Hyperbaric Oxygen Therapy for Diabetic
Foot Ulcer: An Economic Analysis . Canadian Agency for Drugs and Technology in
Health, Technology overview no 75, 2007. http://www.cadth.ca/en/publication/688.
Vlayen J, Camberlin C, Ramaekers D. Vacuümgeassisteerde Wondbehandeling: een
Rapid Assessment Fedraal Kenniscentrum voor de Gezondheidszorg, KCE Reports vol.
61A, 2007. http://www.kce.fgov.be/sites/default/files/page_documents/
d20071027330.pdf.
Rédaction Prescrire. Brûlures cutanées sans gravité d’origine thermique. Rev Prescr
2011;31:116-23.
Wasiak J, Cleland H. Burns (minor thermal). BMJ Clinical Evidence 2009;10:1903.
Search Date October 2008. http://clinicalevidence.bmj.com.
PRODIGY. Itch – widespread. PRODIGY 2010. http://prodigy.clarity.co.uk/itch_wi
despread.

Oftalmologie
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
Rietveld RP, Cleveringa JP et al. NHG-Standaard Het rode oog. Huisarts Wet
2006;49:78-91. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaar
den/Samenvattingskaartje-NHGStandaard/M57_svk.htm.
Rietveld R, Ter Riet G et al. Met drie vragen naar de diagnose bacteriële infectieuze
conjunctivitis; cohortonderzoek naar de waarde van combinaties van klachten en
symptomen. Huisarts Wet 2005;48:53-8.
Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis. Cochrane
Systematic review and meta-analysis update. Br J Gen Practice 2005;55:962-4.
PRODIGY. Conjunctivitis - Infective. PRODIGY 2007. http://prodigy.clarity.co.uk/con
junctivitis_infective.
Anonymous. New topical drugs for open-angle glaucoma. Drug Ther Bull 2003;41:12-6.
Rose PW, Harnden A, et al. Chloramphenicol treatment for acute infective conjunctivitis
in children in primary care: a randomised double-blind placebo-controlled trial. Lancet
2005;366:37-43.
Rietveld R, ter Riet G et al. The treatment of acute infectious conjunctivitis with fusidic
acid: a randomised controlled trial. Br J Gen Pract 2005;55:924-30.
Chevalier P. Fusidinezuur bij acute conjunctivitis. Minerva 2006;5:133-5. http://www.mi
nerva-ebm.be/nl/article.aspid=1164.
Epling J. Bacterial conjunctivitis. BMJ Clinical Evidence 2010;03:704. Search Date July
2009. http://clinicalevidence.bmj.com.
Everitt HA, Little PS et al. A randomized controlled trial of management strategies for
acute infective conjunctivitis in general practice. BMJ 2006;333:321-6.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Middelen
bij ooginfecties. Farmacotherapeutisch Kompas 2011.http://www.fk.cvz.nl.
Belgisch Centrum voor Farmacotherapeutische Informatie.. Aanpak van zona.
Transparantiefiche. Juni 2010: p. 9. http://www.bcfi.be/pdf/tft/TN_Zona_Lng.pdf.
Anonymous. Herpes zoster und postherpetische neuralgie. Arznei-telegramm
2003;34:13-4.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Middelen
in allergische conjunctivitis. Farmacotherapeutisch Kompas 2011.http://www.fk.cvz.nl.
Rédaction Prescrire. Collyres à visée antiallergique. Rev Prescrire 2007;27:182.
Owen CG, Shah A et al. Topical treatments for seasonal allergic conjunctivitis:
systematic review and meta-analysis of efficacy and effectiveness. Br J Gen Pract
2004;54:451-6.
PRODIGY. Conjunctivitis - Allergic. PRODIGY 2007. http://prodigy.clarity.co.uk/conjunc
tivitis_allergic.
Rédaction Prescrire. Collyres anti-inflammatoire + antibiotique. Aucun intérêt clinique
après chirurgie de la cataracte. Rev Prescrire 2003;21:94-6.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Middelen
bij droge ogen. Farmacotherapeutisch Kompas 2011.http://www.fk.cvz.nl.

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
PRODIGY. Dry eye syndrome. PRODIGY 2008. http://prodigy.clarity.co.uk/dry_eye_syn
drome.
Belgisch Centrum voor Farmacotherapeutische Informatie. Gels op basis van timolol
bij glaucoom. Folia Pharmacotherapeutica 2004;31:44. http://www.bcfi.be/PDF/Folia
/2004/P31N05G.pdf.
Shah R, Wormald R. Glaucoma. BMJ Clinical Evidence 2011;06:703. Search Date May
2010. http://clinicalevidence.bmj.com.
Maier PC, Funk J, et al. Treatment of ocular hypertension and open angle glaucoma:
meta-analysis of randomised controlled trials. BMJ 2005;331:134-6.
Chevalier P. Behandeling van oculaire hypertensie en glaucoom. Minerva 2006;5:46-48.
http://www.minerva-ebm.be/nl/article.aspid=1099.
Rédaction Prescrire. Glaucomes chroniques à angle ouvert. Idées-forces tirées de la
revue Prescrire jusqu’au n° 269 (février 2006).http://www.prescrire.org
www.pxe.nl/amsler_grid.htm
Wiggins M, Uwaydat SH. Age-related macular degeneration: options for earlier
detection and improved treatment. J Fam Practice 2006;55:22-7.
Anonymous. Nutritional supplements for macular degeneration. Drug Ther Bull
2006;44:9-11.
Augood C, Vingerling JR et al. Prevalence of age-related maculopathy in older
europeans. The European Eye Study (EUREYE). Arch Ophtalmol 2006;124:529-35.
Van Leeuwen R, Boekhoorn S et al. Dietary intake of antioxidants and risk of age-related
macular degeneration. JAMA 2005;24:3101-7.
Evans JR. Primary prevention of age related macular degeneration. BMJ 2007;335:729.
Evans JR, Henshaw K. Antioxidant vitamin and mineral supplements for preventing
age-related macular degeneration. Cochrane Database of Systematic Reviews 2008,
Issue 1. Art. No.: CD000253. DOI: 10.1002/14651858.CD000253.pub2.
Cugati S, Mitchell Pet al. Cataract surgery and the 10-year incidence of age-related
maculopathy: the Blue Mountains Eye Study. Ophtalmology. 2006;113:2020-5.
Evans JR. Antioxidant vitamin and mineral supplements for slowing the progression
of age-related macular degeneration. Cochrane Database of Systematic Reviews 2006,
Issue 2. Art. No.: CD000254. DOI: 10.1002/14651858.CD000254.pub2.
Rédaction Prescrire. Pegaptanib dans la dégénérescence maculaire: trop de risques
pour trop peu de bénéfices. Rev Prescrire 2006;26:333.

Neus-keel-oren
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
DeGuzman DA, Bettcher CM, Harrison RV et al. Guidelines for Clincal Care: Allergic
rhinitis. University of Michigan Health System; October 2007http://www.med.umich.edu
/1info/fhp/practiceguides/allergic/allergic.pdf.
Harvey R, Hannan SA, Badia L, Scadding G. Nasal saline irrigations for the symptoms
of chronic rhinosinusitis. Cochrane Database of Systematic Reviews 2007, Issue 3. Art.
No.: CD006394. DOI: 10.1002/14651858.CD006394.pub2
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Middelen
bij allergische rhinitis. Farmacotherapeutisch Kompas 2011.http://www.fk.cvz.nl.
Sheikh A, Panesar SS, Salvilla S. Hay fever in adolescents and adults. BMJ Clinical
Evidence 2009;11:509. Search Date April 2008. http://clinicalevidence.bmj.com.
Rédaction Prescrire. Bromure d'ipratropium: nouvelle indication. Rev Prescrire
1987;7:114.
PRODIGY. Allergic rhinitis. PRODIGY 2008. http://prodigy.clarity.co.uk/allergic_rhinitis.
Grainer J, Drake-Lee A. Montelukast in allergic rhinitis: a systematic review and
meta-analysis. Clin Otolaryngol 2006;31:360-7.
Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic
rhinitis. Cochrane Database of Systematic Reviews 2010, Issue 12. Art. No.: CD 002893.
DOI: 10.1002/14651858.CD002893.pub2.
Rédaction Prescrire. Grazax® lyophilisants oraux: Commercialisation effective. Rev
Prescr 2011;31:99.
Sachs AP, Berger MY, Lucassen PL et al. NHG-Standaard Allergische en niet-allergische
rhinitis, eerste herziening. Huisarts Wet 2006;49:254-65. http://nhg.artsennet.nl/ken
niscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/
M48_svk.htm
Vissink A, Spiskervet F, Stegenga B. Geneesmiddelen bij aandoeningen van mond,
gebit en kaak. GeBu 2001;35:119-26. http://gebu.artsennet.nl/Archief/Tijdschriftarti
kel/Geneesmiddelen-bij-aandoeningen-van-mond-gebit-en-kaak.htm.
Porter S, Scully C. Aphthous ulcers (recurrent). BMJ Clinical Evidence 2007;06:1303.
Search Date August 2006. http://clinicalevidence.bmj.com.
Barrons RW. Treatment strategy for recurrent oral aphtous ulcers. Am J Health Syst
Pharm 2001;58:41-50.
Rédaction Prescrire. Mucites orales dues aux traitements anticancéreux. Hygiène
buccodentaire et glaçons à sucer. Rev Prescrire 2007;27:286-8.
Scully C, Porter S. Halitosis. BMJ Clinical Evidence 2008;07:1305. Search Date July
2008. http://clinicalevidence.bmj.com.
Outhouse TL, Al-Alawi R, Fedorowicz Z, Keenan JV. Tongue scraping for treating
halitosis. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD005519.
DOI:10.1002/14651858.CD005519.pub2.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Overige
mond- en keelmiddelen. Farmacotherapeutisch Kompas 2011.http://www.fk.cvz.nl.

18
19
20
21
22
23
24
25
26
27
28
Darby I. Drugs and gingival bleeding. Austr Prescr 2006;29:154-5.
Belgisch Centrum voor Farmacotherapeutische Informatie. Droge mond: oorzaken en
aanpak. Folia Pharmacotherapeutica 2010;37:3-4. http://www.bcfi.be/PDF/Folia/2010
/P37N01C.pdf.
Anonymous. Zur Erinnering – Geschmacksverlust durch terbinafin. Arznei-telegramm
2010;41:98.
Browning G. Ear wax. BMJ Clinical Evidence 2008;01:504. Search Date June 2007.
http://clinicalevidence.bmj.com.
Roland PS, Eaton DA, Gross RD et al. Randomized, placebo-controlled evaluation of
cerumenex and murine earwax removal products. Arch Otolaryngol Head Neck Surg
2004;130:1175-7.
Eekhof J, Neven AK. Cerumen. Huisarts Wet 2009;52:251-3.
Chevalier P. Lokale behandeling van otitis externa. Minerva 2004;3:83-4. http://www.mi
nerva-ebm.be/nl/article.aspid=818.
Hajioff D, Mackeith S. Otitis externa. BMJ Clinical Evidence 2010;08:510. Search Date
October 2007. http://clinicalevidence.bmj.com.
Van Balen FA, Smit WM, Zuithoff NP, Verheij TJ. Clinical efficacy of three common
treatments in acute otitis externa in primary care: a randomised controlled trial. BMJ
2003;327:1201-5.
Rooijackers-Lemmens E, van Wijngaarden JJ, Opstelten W et al. NHG Standaard Otitis
Externa. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samen
vattingskaartje-NHGStandaard/M49_svk.htm.
Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen. Middelen
bij ooraandoeningen. Middelen bij oorinfecties. Farmacotherapeutisch Kompas 2011.
http://www.fk.cvz.nl.

Urgentietrousse
1
2
3
4
5
6
7
8
9
10
11
Philips H, De Sutter A, Buylaert W et al. Aanbeveling voor goede medische
praktijkvoering. Gebruik van medicatie bij urgenties. Huisarts Nu 2008;37:472-504.
http://www.domusmedica.be/images/stories/aanbevelingen/ab_medicatie_bij_urgen
ties.pdf
Budnitz DS, Shehab N, Kegler S et al. Medication use leading to emergency department
visits for adverse drug events in older adults. Ann Intern Med 2007;147:755-65.
Eskenasi R, Lheureux P. Manuel de Médecine d’urgence. Editions de l’Université de
Bruxelles - Maloine, 4th edition, 1997.
Vandenhaute M. Urgences au domicile. Editions De Boeck, 2000.
Ball C, Phillips R. Evidence-Based on call. Acute Medicine. Elsevier Health Sciences,
2001.
Haist S, Robbins J. Internal Medicine on call. Lange Medical Books/McGraw-Hill, 2002.
Drajer LW, Kolnaar BG, Nouma M et al. NHG-Farmacotherapeutische Richtlijn:
Geneesmiddelen in spoedeisende situaties. Huisarts Wet 2005;48:295-303.
Philips H, De Sutter A, Buylaert W et al. Aanbeveling voor goede medische
praktijkvoering. Gebruik van medicatie bij urgenties: checklist per stofnaam. Huisarts
Nu 2008;37:490. http://www.domusmedica.be/images/stories/aanbevelingen/ab_ur
genties_checklist_per_stofnaam.pdf
Philips H, De Sutter A, Buylaert W et al. Aanbeveling voor goede medische
praktijkvoering. Gebruik van medicatie bij urgenties: checklist per ziektebeeld. Huisarts
Nu 2008;37:491-494. http://www.domusmedica.be/images/stories/aanbevelingen/
ab_urgenties_checklist_per_ziektebeeld.pdf.
SOS-KANTO study group. Cardiopulmonary resuscitation by bystanders with chest
compression only (SOS-KANTO): an observational study. Lancet 2007;369:920-26
Rea TD, Fahrenbruch C, Culley L. CPR with chest compression alone or with rescue
breathing. N Engl J Med 2010 363:423-433.